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Abstract
Stereotactic ablative radiotherapy (SABR) is a guideline-specified treatment option for
patients with early stage non-small cell lung cancer. This high-precision treatment delivers a
high dose of radiation to the tumour while avoiding surrounding normal tissue. After
treatment, patients are followed up regularly with computed tomography (CT) imaging to
determine treatment response. However, benign radiographic changes to the lung known as
radiation-induced lung injury (RILI) frequently occur. Due to the large doses delivered with
SABR, these changes can mimic the appearance of a recurring tumour and confound
response assessment. The objective of this work was to evaluate the accuracy of radiomics,
for prediction of eventual local recurrence based on CT images acquired within 6 months of
treatment. We calculated quantitative image features within manually delineated regions of
common post-SABR changes (consolidation and ground-glass opacity (GGO)). Second-order
texture features could predict recurrence in individual patients with an area under the receiver
operating characteristic curve (AUC) of 0.8. To eliminate the need for time-consuming
manual delineations, a semi-automated graph cuts based segmentation algorithm was adapted
for the consolidative regions. A peri-consolidative region, intended to subsample regions of
GGO surrounding the consolidative region, was automatically derived and demonstrated
consistent classification performance, with non-inferiority to manual delineations. Physician
ability to detect timely local recurrence was also measured on CT imaging, and compared
with that of the radiomics tool. Within 6 months post-SABR, physicians assessed the
majority of images as no recurrence whereas our radiomics system produced an AUC of 0.85
on the same images. These results suggest that radiomics can detect early changes associated
with local recurrence that are not typically considered by physicians. Patients with recurrence
tend to have increased presence of ground-glass opacity surrounding consolidative changes
compared to patients with benign injury at the early follow-up time point. These appearances
detected by radiomics may be early indicators of the promotion and progression to local
recurrence. This has the potential to lead to a clinically useful computer aided decision
support tool based on routinely acquired CT imaging, which could lead to earlier life-saving
salvage opportunities for patients with recurrence and fewer unnecessary invasive
investigations of patients with only benign injury.
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Introduction

1.1

Lung Cancer Epidemiology
Lung cancer remains the leading cause of cancer death in Canada. It is estimated

that 26,600 Canadians will be diagnosed and 20,900 Canadians will die from lung cancer
in 2015 [1]. On average, 1 in 12 Canadian men and 1 in 15 Canadian women are
expected to develop lung cancer in his or her lifetime, and 1 in 13 men and 1 in 17
women are expected to die from it [1]. Five-year survival rates for lung cancer are
typically poor, around 15%, as the majority of patients are diagnosed with advanced stage
disease [2]. Smoking cigarettes, as well as second-hand or passive smoking, are the
predominant risk factors for developing lung cancer [3]. Environmental and occupational
factors including air pollution and asbestos have been shown to increase the risk of
developing a primary lung cancer [3].
Non-small cell lung cancer (NSCLC) arises in the epithelial cells of the lung from
the central bronchi to the alveoli. NSCLC accounts for around 80% of all lung cancers
and includes adenocarcinoma, squamous cell carcinoma (SCC), and large cell carcinoma
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[4]. The majority of peripheral tumours are adenocarcinomas, whereas squamous cell
tumours tend to be located centrally [5]. The majority of patients with NSCLC present
with advanced stage III or IV disease [6]. The remaining 20% of lung cancers are small
cell lung carcinoma (SCLC), which is typically found in smokers and has a very poor
prognosis [4].

1.2

Lung Cancer Presentation
Patients with clinical signs and symptoms of lung cancer typically present with

cough, hemoptysis, dyspnea, or chest pain [7]. However, these symptoms can be nonspecific and detection of new symptoms can be more difficult in patients with co-existing
lung diseases including chronic obstructive pulmonary disease. Physicians should be alert
to possible lung cancers when patients present with these symptoms, especially if they are
smokers, ex-smokers, or over the age of 50 [8]. When lung cancer is suspected, initial
imaging with chest radiography and computed tomography (CT) imaging are typically
performed. Once a lung nodule is determined, work-up for a suspected lung cancer will
include both diagnostic and staging tests.

1.2.1

Lung Cancer Screening
In patients with a high risk of developing lung cancer, including those between

the ages of 55 and 74 who have a history of cigarette smoking of at least 30 pack-years,
screening has the potential to find lung cancers early. A recent study by the National
Lung Screening Trial (NLST) demonstrated that low-dose CT for screening showed a
20% relative reduction in lung cancer mortality compared with chest radiography [9].
However, approximately 98% of all positive CT screening exams are benign and do not
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result in a diagnosis of lung cancer, which may result in unnecessary invasive procedures.
The Canadian Task Force on Preventive Health Care now recommends low-dose CT lung
cancer screening annually for up to 3 years, for Canadians aged 55 to 74 with at least a 30
pack-year smoking history, who currently smoke or have quit within 15 years. [10]. The
introduction of low-dose CT screening will result in an increase in detection of stage I
NSCLC.

1.3

Lung Cancer Diagnosis
A physical examination and medical history will assist a physician in determining

any signs, symptoms and risk factors associated with a primary lung cancer. Medical
imaging, including chest radiography, CT, and positron emission tomography (PET) is
also used to diagnose a lung cancer. CT can be used to determine the size, shape, and
location of the suspicious lung nodule. On CT imaging, a suspicious lung nodule is
typically a rounded or irregular region of increased attenuation. The size of the tumour is
measured based on the longest axial diameter and is important for staging. Lung nodules
can be classified as solid, sub-solid, or ground-glass [11]. Cavitation of a lesion is a
frequent finding in SCC. A contrast-enhanced CT is typically performed to determine if
the tumour is invading the mediastinum and to differentiate mediastinal lymph nodes
from vascular structures. Suspicious lymph nodes in the mediastinum are typically larger
than 10 mm in diameter [12].
Once a lung cancer has been suspected on imaging, a biopsy must be performed
to confirm a diagnosis of cancer. Flexible bronchoscopy is a standard procedure to obtain
tissue samples for diagnosis of central lesions with high sensitivity [13]. A transthoracic
image guided biopsy can be performed for peripheral lesions not accessible by
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bronchoscopy [14]. The use of CT-guided transthoracic core needle biopsies has risen
over the past decade and is currently recommended for peripheral lung nodules [15].
Pathologic assessment of the tissue will distinguish a NSCLC from a SCLC as well as
determine the histological subtype. The histological grade of the tumour is also classified,
from well differentiated (grade 1) to undifferentiated (grade 4).

1.4

Lung Cancer Staging
After a diagnosis of NSCLC is made, tumour node metastasis (TNM)

classification is critical for determining the appropriate treatment. The TNM
classification characterizes a lesion according to the primary tumour (T), nodal status (N),
and distant metastasis (M). Staging is determined based on TNM data and in NSCLC
there are four primary stages (I, II, III and IV) [16]. Early stage lung cancer is considered
stage I disease with small tumours (less than 5 cm) contained within the lung that have
not spread to the nearby lymph nodes. Cancers which have spread to bronchial or hilar
lymph nodes are considered stage II. Stage III disease, or locally advance disease, has
spread to mediastinal lymph nodes. Tumours which have metastasized outside of the lung
are considered stage IV disease.
Standard CT imaging has the ability to classify the primary tumour. For
mediastinal lymph node staging, CT imaging has a sensitivity and specificity of 83% and
82% respectively [12]. For suspicious lymph nodes adjacent to the mediastinum, a
mediastinoscopy is the standard approach for obtaining tissue samples. In this approach a
mediastinoscope is inserted through a small incision in the throat to sample a lymph node
of interest. Significant advances in staging have developed from the introduction of
endoscopic ultrasound and endobroncial ultrasound. These techniques are less invasive
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than a standard mediastinoscpy and allow for efficient sampling of regional lymph node
stations.18-fluorodeoxyglucose (FDG) PET imaging also has an increasing role in lung
cancer staging and for regional nodal staging the detection of distant metastases [17, 18].
FDG-PET images the metabolic uptake of glucose in tissue and allows for the
differentiation of normal and malignant tissue [19].

1.5

Lung Cancer Treatment
The treatment of NSCLC is dependent on the stage and patient’s overall health

and lung function [20]. Treatment options can include surgery, radiation therapy (RT),
and/or chemotherapy. The role of personalized medicine in lung cancer treatment is also
emerging where targeted therapies have the potential to improve outcomes in patients
with a known gene mutation [17]. For stage I disease, patients are typically treated with
surgery or radiation therapy alone. In stage II disease, surgery may be performed
followed by adjuvant chemotherapy and radiation therapy. A combination of surgery,
chemotherapy, and/or radiation therapy is typically considered for stage III disease [20].
Patients with stage IV disease are generally considered palliative, but may benefit from a
combination of the chemotherapy, radiation therapy, and/or targeted agents [17].

1.5.1

Early Stage NSCLC

1.5.1.1 Surgery
Surgery remains the standard treatment option for patients with early-stage
(T1/T2 N0) NSCLC. To determine if a patient is eligible for surgery, pulmonary function
or lung function tests are completed to measure lung capacity and function. For patients
who are then considered medically operable, a lobectomy is the guideline-recommended
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treatment option [21, 22]. Wedge or sublobar resection is recommended for patients with
small tumours who are at higher risk with a lobectomy. However, several studies have
demonstrated sublobar resection has inferior clinical outcomes compared to standard
lobectomy [22, 23]. Minimally invasive surgery through video-assisted thoracic surgery
has been shown to have fewer post-operative complications with comparable outcomes to
traditional thoracotomy [24].
The most common cause of death following surgical resection of early stage
disease is tumour recurrence. Therefore long term survival is moderate, with five-year
survival rates in stage I NSCLC following surgery ranging between 55-80% [25-27].
Rates of recurrence following surgical resection range from 30-55%, with most patients
failing at distant sites [28]. Local control rates following surgical resection are quite
favorable; greater than 90% in many studies [29].

1.5.1.2

Stereotactic Ablative Radiotherapy

Stereotactic ablative radiotherapy (SABR) has become a standard treatment
option for patients with early-stage (T1/T2 N0) NSCLC who refuse surgery or are
considered medically inoperable [21, 30]. The use of SABR, which is also known as
stereotactic body radiation therapy (SBRT), for curative-intent treatment of NSCLC has
been rapidly increasing over the last decade [31]. SABR differs from conventional
radiotherapy techniques in that it delivers high doses per fraction (approximately 7.5–18
Gy per fraction versus 2 Gy per fraction) over a shorter treatment time (typically 3–8
fractions over 1–2 weeks versus 20–30 fractions over 4–6 weeks). Evidence suggests that
a biologically effective dose (BED) in excess of 100 Gy10 is required for optimal local
control [32]. These high doses are achievable with the use of highly conformal treatment
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plans, which include precise planning, targeting, and treatment delivery. SABR is
arguably one of the largest medical breakthroughs in the curative treatment of early stage
NSCLC in the last two decades, with improved population-based survival rates
demonstrated after the implementation of SABR [33-35].
In addition to treatment of primary lung cancer, the use of SABR has also been
rapidly increasing for oligometastatic disease [36, 37]. Several single-institution studies
have demonstrated high rates of local control, with favorable comparisons to surgery in
overall survival outcomes [38, 39]. However, for colorectal cancer, rates of local control
after SABR may be lower than other histologies, approximately 70–80% [39]. The
impact of SABR on overall survival in patients with oligometastatic disease is currently
being evaluated in a randomized trial [40].

1.5.1.2.1

Comparison to Surgery

The effectiveness of SABR for local tumour control has been well established.
Reported three-year local control rates often exceed 90% [29, 41]. SABR outcomes
appear not only superior to more fractionated regimens [42] (e.g. 55 Gy in 20 fractions
[43]), but are comparable to standard surgical resection, as supported by retrospective,
single- or multi-institution, and modeling studies, with the largest single-institution
retrospective study reporting a 5-year local control rate of 89.5% [29, 44, 45]. Three
randomized trials comparing resection vs. SABR have closed due to poor accrual. A
pooled analysis of the accrued patients from two trials has been completed, and although
the sample size was small, results showed the two treatment options to be comparable
[41]. SABR was better tolerated (10% grade 3 toxicity with SABR vs. 44% grade 3–4
toxicity with surgery), with better post-treatment quality of life [46]. SABR achieved
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better overall survival than surgery (3-year OS 95% vs. 79%, p=0.037); however, larger
studies are needed to confirm these findings.
In high-risk patients with severe pulmonary comorbidities, SABR offers
comparable rates of local control without the attendant short-term mortality risks of
surgery [47]. In the operable patient population, promising outcomes are reported by two
prospective clinical trials: RTOG 0618, reporting a primary tumour failure rate of 7.7%
[48], and JCOG 0403, reporting a preliminary 3-year tumour control rate of 86% [49].
For institutions without the capability to deliver SABR, other hypofractionated regimens
can also achieve reasonable local control at early time-points: a recent Canadian
multicenter study of hypofractionated RT delivering 60 Gy in 15 fractions (BED of 75
Gy10) achieved a two-year local control rate of 88% [50].

1.5.1.2.2

Recurrence Following SABR

Outcomes following SABR are favourable, with recent studies demonstrating 5year local and regional control rates of 90% and 87% respectively. Local recurrences,
typically defined as failure within the treated area, typically manifest at a median time of
15 months post-SABR, but they may present up to 5 years following treatment [51].
Despite high rates of local control, patients still remain at risk of lobar recurrence: the
multicenter RTOG 0236 trial demonstrated a 5-year primary tumour recurrence rate of
7%, but an involved lobar recurrence rate of 20% [45, 52]. However, lobar recurrence
after SABR may be difficult to distinguish from development of second primary lung
cancers (SPLC). Regardless of the classification as recurrence or SPLC, many patients
with lobar recurrence can be salvaged with surgical resection [41, 53-55].
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Many factors have been identified in the literature as predictive of local control
based on Cox multivariable analysis. These include both dose factors, including the
biologically effective dose (BED) and minimum planning target volume (PTV) dose, as
well as tumour factors including T-stage and gross tumour volume (GTV) size [56-58].

1.6

Lung Cancer Follow-up
After SABR treatment, patients are typically followed with physical examination

and CT imaging every 3–6 months for the first 3 years following treatment [51].
Although FDG-PET scans are recommended in lung cancer diagnosis and re-staging,
functional imaging currently has a limited role in the evaluation of tumour response [19].

1.6.1

Computed Tomography Imaging
CT imaging plays an important role in lung cancer diagnosis, treatment, and

follow-up. Current recommendations for imaging follow-up after SABR are generally
based on retrospective evidence and expert opinion, rather than randomized data. Such
follow-up serves 3 major goals: detection of local recurrence, detection of regional
recurrence that may be amenable to salvage, and detection of new primary lung tumours,
which occur at a rate of 2-10% per person-year [51, 59]. Based on the results of the
National Lung Screening Trial [60], the American Association for Thoracic Surgery
guidelines recommends 4 years of CT follow-up for patients who have undergone
treatment for lung cancer and are eligible for additional treatment [61].

1.6.1.1

Radiation-Induced Lung Injury

Following radiotherapy to the lungs, the development of radiographic radiationinduced lung injury (RILI) on CT imaging can occur. Radiation delivered to the tumour
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and surrounding lung parenchyma results in radiologic lung injury (pneumonitis and
fibrosis) appearing as increased density on CT. The amount of radiation damage to
normal tissue varies according to delivered dose, fractionation, dose rate, irradiated
volume, and beam arrangement [62]. The appearance and patterns of RILI can also vary
across follow-up time intervals. Radiation pneumonitis is typically seen in the acute
setting within 6 months of treatment, following which it is classified as fibrosis [63].
From histopathological studies obtained after resection for false-positive imaging studies,
these areas of lung injury are made up of a benign mixture of inflammatory cells,
fibrocytes and other benign features [64]. Lung injury following traditional 3Dconformal radiation therapy (CRT) is often characterized by straight edges that conform
to treatment portals [65], as shown in Figure 1-1.
(a)

(b)

Figure 1-1: Radiation induced lung injury following a traditional anterior/posterior
parallel opposed pair (treatment plan shown in (a)); (b) The resulting benign injury
conforms to the treatment portals and is easily distinguished by a straight line.
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1.6.1.2

Common Appearances after SABR

Following SABR, benign RILI is nearly always present on follow-up CT imaging.
Ablative doses of radiation result in radiographic changes appearing as an increased
density and opacity on CT in the area of the high-dose region [66, 67]. Such CT changes
correlate closely with local delivered dose [68]. The total dose, fractionation, treatment
delivery technology, and tumour size are all factors which may affect the degree of
radiographic lung injury [68, 69]. Such findings are not unique to lung SABR; they have
also been described in other organs treated with stereotactic radiotherapy including brain
and liver [70, 71].
The appearance of fibrosis is very common, occurring in 62% of patients within 6
months of treatment (acute) and 91% thereafter (late), as classified by a common
classification scheme (Figure 1-2) [66, 67]. This scheme classifies acute radiation
pneumonitis into consolidative or ground-glass opacity changes, which can further be
subdivided into diffuse (> 5cm) or patchy (≤ 5cm). Late radiation fibrosis can be
categorized into modified conventional, mass-like, or scar-like patterns [66, 72]. A
modified conventional pattern has been described, defining a fibrosis pattern that is larger
than the original tumour size, may be associated with ground-glass opacity, and may
include consolidation, volume loss, and bronchiectasis that is similar to or less extensive
than conventional radiation fibrosis [66, 73]. These radiographic changes can persist and
continue to evolve even after 2 years following treatment.
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Acute: ≤ 6 months
Diffuse Consolidation (>5cm)

Patchy Consolidation (≤5cm)

Diffuse GGO (>5cm)

Mass-like

Modified Conventional

Patchy GGO (≤5cm)

Late: > 6 months
Scar-like

Figure 1-2: Classification of post-SABR radiological changes. Adapted from Dahele et
al. [66]

Morphologic patterns of fibrosis can also vary with treatment type; patients who
underwent arc-based SABR had a predicted probability of a modified conventional
pattern of 96.3% versus 68.9% for those who underwent fixed-beam treatment [69].
Although such radiologic lung injury occurs in nearly all patients by 2-years [66], only a
small minority of patients develop clinical symptoms.
Several studies have examined simple dose-response relationships of HU changes
following SABR. Increasing densities on CT post-SABR are seen with larger planning
target volumes and longer time post-SABR, and these are most evident in regions
receiving doses greater than 20 Gy [68]. Density changes post-SABR have also been
shown to linearly increase to doses of 35-40 Gy and then plateau thereafter [68, 74]. The
spatial location of fibrosis following SABR is on average 2.6 cm from the GTV position,
although displacement of the fibrotic changes of >5 cm can also be observed [75].
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1.6.1.2.1

Radiation-Induced Lung Injury versus Recurrence

As a direct result of the highly ablative and conformal doses delivered with
SABR, these benign radiographic changes can appear similar to a recurring tumour
(Figure 1-3). Against the background of asymptomatic radiation-induced lung injury,
accurate assessment of local recurrence is of paramount importance. These changes on
CT can result in a major clinical dilemma with respect to accurately distinguishing
patients with local recurrence from benign RILI, especially in cases with mass-like
changes [76]. Although the classification scheme previously described is used to
categorize radiological changes following SABR, it is not used to distinguish recurrence
from fibrosis.
+3 m

+6 m

+16 m

+10 m

+2 y

+3 y

+4 y

Figure 1-3: Planning CT image for SABR treatment and subsequent follow-up imaging
after radical treatment for early-stage primary lung cancer.

Distinguishing a recurrent tumour from fibrotic lung changes on CT can be
challenging for several reasons, as demonstrated in Figure 1-4. Both radiation-induced
lung injury and recurrent disease follow a similar temporal course, with lung fibrosis
continuing to evolve two years after treatment, during which time, the majority of local
recurrences occur [51, 66]. In contrast to lung injury following traditional 3D-CRT,
which was often characterized by straight edges that conform to treatment portals (Figure
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1-1), the pattern of lung injury on CT following SABR can be mass-like, due to the
conformal nature of SABR [66, 76, 77]. Fibrosis may even appear on CT as an enlarging
density and therefore can the mimic the growth of a local recurrence [77].
Misclassification of a recurrence as “benign fibrosis” can result in a missed
window of opportunity for curative-intent salvage treatment. Conversely,
misclassification of fibrosis as a recurrence may lead to unnecessary interventions, such
as biopsy, imaging, chemotherapy, and even surgery, exposing patients to unnecessary
risks and morbidity [64, 77-80]. The ability to accurately assess response is particularly
important in light of the changing practice patterns for early stage NSCLC. As a growing
number of patients are being treated by SABR [81], this clinical scenario will become
more common. The treatment of a fitter patient population may result in a larger
proportion of patients who are candidates for salvage treatment in the case of recurrence.
Finally, since recent data on potentially operable SABR patients suggest that failure may
be higher than in the inoperable SABR cohort (with two-year lobar failure rates in one
recent multicenter study [defined as recurrence anywhere in the irradiated lobe] as high
as 19.2% [48]), accurate distinction between recurrence and fibrosis to permit early
salvage is pressing clinical problem.
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(a)

(b)

0m

Absolute
60 Gy
56.7 Gy
54 Gy
52.9 Gy
51.3 Gy
48.6 Gy
43.2 Gy
27 Gy
20 Gy
10 Gy

+3m

+18m

+6m

+3y

Figure 1-4: Radiological changes following SABR for an 85-year-old gentleman with
biopsy proven adenocarcinoma. This patient received 54 Gy in 3 fractions with the
treatment plan shown in (a). Radiological changes are seen (b) where 0m indicates the
pre-treatment lesion measuring 2.0 cm. At 3 months post-SABR, there is presence of an
enlarged ground-glass and semi-solid opacity measuring 4.3 cm. At 6 months there is
interval reduction in size and a decrease in ground-glass opacity, with ongoing reduction
in size at 18 months and 3 years post-treatment.

Several groups have reported patients with suspicious findings on CT and/or
FDG-PET imaging who underwent salvage lung resection to have pathology show no
viable tumour cells [77, 80, 82]. Takeda and colleagues demonstrated an enlarging solid
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mass on CT follow-up for a patient treated with SABR (as shown in Figure 1-5) [77].
This was suspicious for recurrence and the patient underwent surgical resection, which
demonstrated only a benign fibrotic scar. In most cases, persistent CT findings do not
indicate recurrence: a recent study determining the fate of residual masses after SABR
found that in 50 patients with masses present greater than 1 year following treatment,
only 8 developed local recurrence [83].

Figure 1-5: (a) Pre-treatment CT image of a 79 year old gentlemen treated with
stereotactic radiotherapy and (b-d) post-treatment follow-up CT images at 3, 6, and 9
months respectively. Enlargement of the nodule at 6 and 9 months raised suspicion of
local recurrence and the patient was sent for surgical resection. (e) A 7 mm diameter
tumour-like fibrous scar was observed on pathology, with sharply defined regions of
fibrosis surrounding the scar and mild pleural thickening. Adapted from Takeda et al.
[77]

1.7

Response Assessment Following SABR
With the increase in number of patients receiving SABR for primary lung cancer

or metastatic disease, determining the appropriate follow-up and management of patients
is critical [84]. With a shift toward the use of SABR for patients declining surgery, or
borderline operative candidates, modern cohorts receiving SABR are fit with longer life
expectancies. As a result, surgical or nonsurgical salvage opportunities are available if
failure occurs [53, 54, 85].
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1.7.1

Response Evaluation Criteria in Solid Tumours
Response Evaluation Criteria in Solid Tumours (RECIST) is the standard measure

of imaging response in oncology. RECIST, first published in 2000, have been widely
adopted by many institutions and provide a clear set of guidelines to perform
unidimensional measurements for overall evaluation of tumour response. In 2009, the
RECIST guidelines were updated to version 1.1 [86] and specific criteria are used to
determine tumour response for a target lesion based on measurement of the sum of
longest diameters of all target lesions. The baseline sum of longest diameters is used as
the reference to characterize response. A complete response denotes the disappearance of
all target lesions. A partial response is at least a 30% decrease in sum of longest diameter
of the target lesions (reference being the baseline sum of longest diameters). Progressive
disease is at least 20% increase in sum of longest diameter of the target lesions (reference
being the smallest sum of longest diameter since treatment has started), or the appearance
of one or more new lesions. Lastly, stable disease does not have sufficient shrinkage to be
considered partial response or sufficient increase in size to be considered progressive
disease (less than 20% increase or less than 30% decrease in diameter of the target
lesion), again taking as reference the smallest sum of longest diameters since treatment
has started.
Response is determined through measurement of the longest diameter of the target
lesion within the imaging plane (axial for CT imaging). In the event of isotropic
reconstructions, measurements can be made on the reconstructed images in the nonimaging planes. However, since not all radiology sites are capable of producing isotropic
reconstructions, caution must be taken to avoid the undesirable situation in which
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measurements are taken on different imaging planes at subsequent assessments. It is
worth noting that for CT scans of the chest, in which typical slice thicknesses of 5 mm
are used; target lesions should have a minimum size of 10 mm to be considered
measurable. There are also several other CT image acquisition parameters which should
be taken into account for consistency when evaluating lesions using RECIST. These
include anatomic coverage, contrast administration, slice thickness, and reconstruction
interval which can all impact the evaluation of lesion response [86].

1.7.1.1

Limitations of RECIST

Although RECIST provides a clear set of guidelines for response assessment, they
have several limitations [87, 88]. Response assessment based on RECIST relies on
physician measurement of lesion diameter. It was been well-described that variability in
target lesion diameter exists and this can have an impact on accurately assessing response
[89-91]. Inter-observer variability is greater than intra-observer variability, and
measurement differences are greatest when there is an irregular edge or spiculated lesion
[91]. For consistent measurements, one should consider having a single observer measure
the target lesion response across the course of follow-up. The limitation of nonmeasureable disease in which the lesion diameter is less than 10 mm can be a major
limitation after SABR for small lung nodules [87]. The requirement that measurements
be taken in the imaging plane can also be a limitation in the context of post-SABR
response assessment, since cranio-caudal growth may be a major predictor of recurrence
and is measured in the sagittal/coronal plane [92]. Re-evaluation of RECIST 1.1 has been
proposed [93].
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In the context of response assessment following SABR, the presence of benign
fibrotic changes within the high dose region on CT can affect the ability to accurately
assess response [35]. When measuring the longest axial diameter of post-SABR changes,
it can be unknown if these changes represent viable tumour cells or benign fibrotic tissue.
Another limitation of RECIST is in non-spherical lesions which can be difficult to
measure. This is specifically important in patients treated with SABR as the appearance
and morphology of post-SABR changes can be quite irregular with pleural attachment (as
seen in Figure 1-3).This makes accurately determining local lesion response very difficult
in the light of significant fibrotic changes following SABR. An example of RECIST
failure in a patient treated with SABR is shown in Figure 1-6.
A

B

C

D

Figure 1-6: Demonstration of RECIST failure in a patient who received stereotactic
radiotherapy for stage I NSCLC. Radiation planning scan (A) shows the prescribed dose
(red; 54 Gy in 3 fractions), 50% of prescribed dose (orange) and 25% of prescribed dose
(yellow). 3 month scan (B) showed a large area of consolidation meeting RECIST criteria
for progressive disease, but the patient was observed. Ongoing observation at 6 months
(C) and 40 months (D) showed development of fibrosis with no progression.
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1.7.2

High-Risk CT Features (HRFs)
A series of HRFs on CT imaging have been identified for detection of local

recurrence following SABR. These include the presence of an enlarging opacity,
enlargement after one year, sequential enlargement from one scan to the next, bulging
margin, linear margin disappearance, and air bronchogram loss [94]. These HRFs were
identified based on a systematic review of the literature and then validated in a blinded
study of patients with pathologic proof of recurrence [92]. Patients with recurrence were
matched 1:2 to patients without local recurrence according to baseline factors. A new
HRF of cranio-caudal growth was identified in this cohort. All HRFs were significantly
associated with local recurrence and the odds of recurrence increased 4-fold for each
additional HRF [92]. A recent validation of these features was performed on an
independent patient cohort and demonstrated a bulging margin, linear margin
disappearance and craniocaudal growth as the best predictors (Table 1-1) [95].
Combining HRFs was also shown to increase sensitivities and specificities over number
of HRFs.
However, not all studies have found all HRFs to be useful. A study by Halpenny
et al. examined the predictive value of qualitative CT features for predicting local
recurrence following SABR. Eight patients with local recurrence and 83 patients without
local recurrence were evaluated for the following signs of local recurrence on CT: a new
bulging margin, opacification of air bronchograms, a new or enlarging pleural effusion, a
new or enlarging mass, or increased in lung density in the irradiated field. They found
that the only feature significantly associated with local recurrence was a new bulging
margin at the treatment site [96].
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The use of HRFs is subject to limitations. Early detection of local recurrence is
difficult, as many require sequential assessments (i.e. sequential enlargement, loss of air
bronchograms, loss of linear margin) and may vary depending on frequency of scanning.
One HRF cannot be detected until more than a year following treatment. Inter- and intraobserver variability in detecting HRFs is not well-established.
Table 1-1: High-risk features for recurrence prediction on computed tomography (CT)
imaging.
Sensitivity (%)
High-risk feature

Specificity (%)

Huang et al. Peulen et al. Huang et al. Peulen et al.
[92]
[95]
[92]
[95]

Enlarging opacity at
primary site

92

100

67

31

Sequential enlargement

67

62

100

77

Enlargement after 12
months

100

92

83

50

Bulging margin

83

85

83

100

Linear margin
disappearance

42

85

100

100

Loss air bronchogram

67

15

96

100

Cranio-caudal growth of ≥ 5
mm and ≥ 20%

92

100

83

50

1.7.3

Positron Emission Tomography
The increased opacity on CT is occasionally found with a corresponding increase

in metabolic activity on functional imaging in the months following SABR [66, 67]. The
use of FDG-PET in the context of response assessment post-SABR has been well studied;
however, the data are quite heterogeneous [97-100]. Some studies have shown that the
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maximum standardized uptake value (SUVmax) [101-104] and residual SUV uptake 12
weeks post-treatment [105] are strong predictors of local recurrence. Additional work has
found that a pre-treatment SUVmax ≥ 5, post-treatment SUVmax ≥ 2 or a reduction in
SUVmax < 2.55 were associated with a higher risk of distant failure [106]. Although
optimal SUV cutoffs vary across studies, a SUVmax > 5, or greater than the pretreatment value, appears to be most indicative of recurrence [94, 98, 103-105]. However,
many of these studies are subject to type I errors, as multiple SUV cutoffs were assessed
for statistical significance.
A major limitation of PET is that inflammatory reaction in areas of the lung
receiving high doses from SABR can result in elevated uptake on PET imaging, resulting
in false positive findings [107, 108]. These metabolically active FDG-avid lesions may
rise transiently immediately post-SABR and persist after 12 months [107-109]. Falsepositive PET SUVmax readings as high as 7.0 have been reported [64, 110].
Another limitation of the use of FDG-PET imaging is in regard to the
standardization of image acquisition across scanners and institutions, which must be
considered in the context of these studies [111]. PET is also more costly than standard CT
imaging and may not be a routine post-treatment investigation at some institutions. Lack
of PET/CT standardization can be an important confounder: measured SUVs can be
affected by multiple factors, including technical, physical, and biologic [111]. In order to
generalize PET/CT findings, minimum performance or harmonizing standards are needed
for many factors including uptake period, patient motion, inflammation, blood glucose
level correction, as well as scan acquisition and reconstruction parameters.
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A systematic workflow for imaging follow-up post-SABR has been published
based on HRFs and SUVmax on PET imaging [92]. This workflow classifies patients as
having a low, intermediate, or high risk of recurrence. A more rigorous follow-up might
be indicated in patients with a higher likelihood of disease recurrence, including those
patients with larger tumours or sub-optimal radiation doses [112, 113]. As more data
become available in the management of patients following SABR, applicability of this
follow-up recommendation is expected to change.

1.7.4

Other Novel Imaging Methods
Novel imaging modalities may allow for better assessment of treatment responses

following SABR. In addition to standard FDG-PET reporting SUVmax values, functional
imaging with additional metrics such as metabolic tumour burden markers may show
improvement for assessing response. Preliminary studies have investigated using pretreatment measures such as metabolic tumour volume and total lesion glycolysis for
assessing clinical outcomes after SABR, however further studies with larger samples and
follow-up periods are needed [114]. Additional PET tracers such as 18-fluoroazomycinarabinoside (FAZA) and 18F-fluoromisonidazole (F-MISO) are used for imaging
hypoxia in head and neck cancers [115, 116] and could also be investigated for assessing
response following hypofractionated radiotherapy.
Perfusion imaging, such as dynamic-contrast-enhanced (DCE) CT or magnetic
resonance imaging (MRI) characterizes vascular properties of a tissue and can
quantitatively map their spatial distributions. Measures such as blood volume, blood
flow, permeability, and mean transit time can be calculated after administration of a
contrast agent. Both DCE-CT and DCE-MRI have shown promise as prognostic or
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predictive biomarkers in oncology, and their value in assessing response after SABR
warrants investigation [114, 117, 118]. CT perfusion imaging has been investigated for
response assessment in pulmonary metastases treated with SABR [119]. Although
changes in perfusion data were not statistically significant, a qualitative trend consisting
of an early increase followed by a decrease in tumour perfusion was noted. Validation on
a larger data set is required to determine the role of CT perfusion in response assessment
post-SABR. Enhancement patterns have also been investigated following SABR and
have shown that patients with recurrence showed a more rapid wash-in and wash-out
phenomenon, compared to the continuous enhancement observed in RILI [120].

1.7.5

Limitations of Current Studies Assessing Response Post-SABR
Several potential pitfalls must be considered when evaluating novel imaging

modalities for response assessment. First, the gold-standard definition of “recurrence”
varies across studies, and many studies use imaging-based definitions of recurrence,
rather than pathologic confirmation. Such imaging-based definitions of the endpoint may
introduce substantial bias and create a self-fulfilling prophesy: if imaging features are
used to define “recurrence” (e.g. sequential growth of lesion) and then the same features
are assessed to predict these “recurrences”, their performance may be artificially inflated.
The majority of studies include only a small number of biopsy-proven recurrences, and
with remainder of patients defined as recurrence an increase in tumour size on successive
CT scans [98, 102, 105]. Many also use a modified progression criterion of two
consecutive enlargements on CT to define recurrence, therefore suggesting the difficulty
in response assessment at an early time point and that the usefulness of PET is limited.
Since recurrences are uncommon after SABR, large databases are required to have
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sufficient events for analysis, and any new promising markers require robust external
validation, since the chances of type I error are high when multiple features are being
assessed. Variations in standardization of imaging protocols in both CT and PET studies
must assessed for their impact of predictive ability. Finally, post-SABR surgical studies,
including registration of digitized histology to CT, would be valuable for correlating
imaging findings at the voxel level with true pathologic outcome.

1.8

Radiomics
In contrast to qualitative image assessment, quantitative image feature analysis

extracts measurable information from within an image, such as intensities or densities,
shape or morphology, or texture. Radiomics is an emerging area of study which aims to
extract more information from medical images [121, 122]. The use of radiomics and
texture analysis in oncology, and specifically radiation oncology, has been rapidly
expanding over the past decade to quantify tumour heterogeneity and predict response
[123]. The goal of radiomics is to potentially tailor a patient’s radiotherapy treatment
based on predicted response on pre-treatment imaging, or to detect treatment failure at an
earlier time point post-treatment [124]. Radiomics look to quantify tumour phenotypes
based on a large number of quantitative image features [125]. This can involve the
extraction of quantitative image features from regions of interest on either pre- or posttreatment images.
Image feature analysis has emerging roles in general medicine and oncology.
Numerous imaging modalities can be used for quantitative image analysis at different
body sites, including CT, MRI, ultrasound, and mammography [126, 127]. Applications
in oncology include the computer-aided detection or diagnosis of diseases such as breast
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and bladder cancer [126, 127]. Texture analysis of the liver has suggested that texture
parameters may distinguish high-risk from low-risk colorectal cancer patients [128].
Texture analysis on MRI, CT, and PET has been able to diagnose and characterize
tumour heterogeneity for several tumour types and is showing promise in response
assessment and as a predictive biomarker [129, 130]. In the thorax, the use of
quantitative image feature analysis on CT has been widely investigated in many benign
diseases, including characterizing pulmonary infections as well as varying benign lung
disease patterns [131-133]. Texture analysis, specifically the product of tumour
uniformity and gray-level, has also been correlated with tumour response following
chemotherapy in advanced stage NSCLC [134]. The use of CT texture analysis has also
been applied to quantify radiation-induced lung damage. Predictive modelling of
radiation pneumonitis using texture analysis on CT has been studied following definitive
radiation for lung and esophageal cancer [135, 136]. Future work integrating radiomics
and genomics (radiogenomics) could aid in characterizing tumour phenotypes and
genotypes to associate with outcomes [137]. Many studies have demonstrated the
potential of radiomic features to provide additional tumour phenotypic information that
may not be visible to the human eye. This information may augment standard clinical or
genomic information to provide a more comprehensive analysis of the disease as a whole.

1.8.1

Workflow
An overview of a standard radiomic workflow is shown in Figure 1-1. Following

image acquisition, a region of interest (ROI) is defined and within it a series of radiomic
image features can be calculated [125]. Following feature extraction, feature selection
can be performed to obtain the optimal set of radiomic features. Machine learning using
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unsupervised or supervised analysis options, is then performed to summarize information
on the data or to build models to predict outcomes or a response variable [138].
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Figure 1-7: Radiomics involves image acquisition and region of interest delineation. An
example CT image and corresponding region of interest are shown in red. Within the
region of interest several image features can be extracted, including first-order statistics,
second-order texture and size and shape-based features. These features can be used to
predict patient outcomes.
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1.8.1.1

Segmentation

Radiomic analysis can be performed on any ROI, such as tumour, normal lung, or
fibrotic regions; such ROIs can be selected by means of manual, semi-automated, or
fully-automated methods. A manual method involves delineation of an ROI by an
investigator on each individual slice using imaging software. Manual methods do not
require specialized algorithms, but can be tedious and time consuming, and are subject to
intra- and inter-observer variability [139]. A semi-automated method requires a smaller
amount of user input, and may require a user to initialize the segmentation by selecting a
point or region of interest. A fully automated approach requires no user interaction or
input and the image is automatically segmented based on a series of predetermined
parameters. This makes a fully automated approach quick and reproducible; however the
lack of user input or knowledge can be an issue in terms of the reliability. Therefore,
semi-automated approaches to segmentation have become increasingly popular as they
are reproducible, fast, and require minimal user input or knowledge [140].
Several algorithms exist for semi-automated and fully automated segmentations
[141]. In general, segmentation algorithms can be separated into two main categories:
low-level and model-based methods. Low-level methods perform the segmentation
exclusively based on features in the image. Model-based methods allow for high-level
knowledge about the region of interest to be incorporated into the algorithm, including
boundary smoothness, appearance, or shape information. The choice of image
segmentation algorithm relies on the specific imaging modality being used as well as
characteristics of the region to be segmented [142].
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Low-level methods include thresholding, clustering methods, and region-growing
techniques. The simplest method is thresholding which relies on the selection of a
threshold value to convert a grey-scale image into a binary image. Although this is a
simple and fast segmentation technique, in some cases selection of the optimal threshold
is done manually and this technique does not guarantee object coherency, therefore postprocessing may needed. However more advanced thresholding techniques including
Otsu’s method have been developed to select the optimal value by minimizing the
variance between regions [143]. Clustering methods partition an image into a specified
number of clusters according to similar grey-levels. The k-means clustering algorithm is
the most common and allows for image segmentation into multiple classes by computing
a mean intensity for each class [144]. Region-growing methods work by comparing each
pixel with its neighbours and they assume that neighbouring pixels within one region
have similar values [145]. In seeded region growing, initialization of the segmentation
requires the selection of seeds to mark the object to be segmented. This technique is good
for regions with clear edges, however it can be sensitive to image noise, seed point
selection and segmentation parameters [146].
Model-based methods can include parametric deformable models and level set
algorithms. To achieve the desired segmentation result, parametric deformable models
are initialized with a measure of curvature and a contour surrounding the region of
interest that is represented parametrically [147]. The algorithm is evolved to minimize an
energy/objective function according to image (e.g. edges) and internal (e.g. curvature)
terms. These techniques can automatically search for the minimum state and are
advantageous as they can incorporate curvature characteristics; however they do require
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manual interaction to initialize the model and parameters and can be sensitive to the
convergence criteria and local minima [141]. Another limitation of parametric
deformable models is their inability to evolve and split into multiple curves to segment
multiple disjointed regions of interest. Level set methods address this issue by
representing the boundary implicitly. The level set is represented using a signed distance
function where zero is the actual contour [148]. Level sets can account for different
topologies and provide a direct way to estimate the geometric properties of the structure.
Another class of segmentation methods includes graph partitioning methods
[149]. These methods involve having a pixel or group of pixels associated with nodes and
edge weights to define similarity between neighbouring pixels. The graph, or image, is
then segmented according to different criterion to model specific clusters. Graphs are
typically partitioned by finding the minimum cut, by either cutting the minimum number
of edges or so that the sum of the cut edges is as small as possible based on a specified
cost function [150]. Boykov and Jolly introduced an interactive graph cuts based
segmentation for binary image segmentation by minimizing an energy function based on
user defined foreground and background samples [151]. Graph cut segmentations can be
biased towards producing small contours since it aims to find the minimum cut in the
graph. They are also limited to binary segmentations problems: foreground versus
background image segmentation. However, it is computationally fast, can be optimized
for 3D images, and can achieve a globally optimal solution. Several methods exist for
trying to optimize for graph construction, criterion for graph partitioning, and efficient
partitioning [152].
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1.8.1.2

Feature Extraction

Following region of interest segmentation, qualitative or semantic features of the
region of interest can be developed and characterized by expert observers. Such features
could include tumour characteristics such as spiculation or pleural attachment. Radiomic
image features can be also be extracted from the ROI. These features can include firstorder statistics based on the distribution of the intensity histogram. These features include
things such as the mean, median, standard deviation, variance, skewness, and kurtosis.
Intensity refers the brightness of an individual voxel; in CT imaging this can also be
described as density and is quantified in Hounsfield Units (HU). HUs measure the
attenuation of a material relative to water (HU=0).
CT image texture is a set of more complex measurements which describe local
brightness variation or the spatial arrangement of intensities in an image [153, 154].
Second-order texture features take into account the neighbouring relationships of voxels
within the region of interest. Extraction of second and third-order texture features can be
performed in many ways, including statistical methods, structural methods, model-based
methods, and transform-based methods [155]. Statistical texture analysis is the most
frequently cited method of texture analysis. This approach describes texture through
high-order statistics of an image intensity histogram [155]. These features can include
grey-level co-occurrence matrix (GLCM) texture features as well as grey-level run length
matrix (GRLM) texture features [156-159]. GLCM features are analyzed by assessing
neighbouring voxel pairs; however it can be done with multiple spatial directions and
distances. GLRM texture features assess grey-level run lengths in an image which are
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defined as consecutive pixels with a specific grey-level. These features are also
calculated for a specified spatial direction from a pixel of interest.
Structured approaches obtain descriptions of the spatial relationships of textures
through Voronoi tessellation [160]. Model based texture analysis generate an empirical
model of each pixel in the image based on neighbouring pixel intensities, and include
Markov random fields and fractal models [155]. Transform based texture analysis
techniques convert the image into a new form based on the spatial frequency information
regarding pixel intensity variations. A common method in radiomics is the use of wavelet
features, in which the image is transformed into low and high frequency domains, similar
to Fourier analysis, and texture is then calculated on the transformed images [125].
Size and shape based features of the region can also be calculated. Size can be
quantified by measures such as longest axial diameter, 3D volume, and surface area
[161]. The shape or morphology of a region describes the geometry of the external
boundary. Shape-based features can include sphericity, roughness, or spiculation. More
advanced quantitative features to characterize shape complexity can also be developed in
radiomics to correlate with observed qualitative or semantic image features [162].

1.8.1.3

Machine Learning

Optimal features or sets of features for predictive or prognostic biomarkers must
be determined and validated through training and testing on multiple data sets. This can
include analyzing individual features alone or a combination of these features together.
Machine learning refers to algorithms that can learn and make predictions from data and
operate by building models from inputs to make an output based on predictions or
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decisions [163]. There are two main types of machine learning: supervised and
unsupervised machine learning. In unsupervised machine learning, there are no labels on
the training data and the goal is to discover patterns in the data. On the other hand,
supervised machine learning is given a set of labels or outputs, and an algorithm tries to
determine a rule to map the inputs, or features, to the outputs. Machine learning can also
be classified depending on the desired output of the machine learning tool. Classification
has a discrete set of labels for the data, for example cancer or non-cancer. In linear
regression the outputs are continuous, for example likelihood of cancer. Logistic
regression can also be used for predictive analysis and describes the relationship between
one dependent binary label and one or more independent variables.
There are several different classification algorithms which can be used in machine
learning. Linear classifiers use a linear combination of features to obtain a classification
decision [164]. Support vector machine (SVM) classifiers are a maximal margin classifier
which can efficiently perform linear classification. One benefit of SVM classifiers is the
flexibility to perform non-linear classification. When features are not separable by a
linear decision surface, a kernel trick can be performed to achieve non-linear
classification. The kernel trick maps the features into a high-dimensional feature space
such that is separable by a linear hyperplane. [165]. Decisions trees are another method
which can easily visualize and explicitly represent the decision making. Random forests
use multiple decision trees to improve classification performance [166]. Artificial neural
networks are based on biological neural networks and are used to model complex
interactions between inputs and outputs [167].
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An emerging area of machine learning is the use of deep learning. Deep learning
attempts to model high-level abstractions of data based on multiple processing layers
[168]. Many deep learning approaches are based on neural networks with many
variations on network architecture to obtain optimal classification performance. A major
advantage of deep learning is that it can learn the features from the data itself. However, a
major limitation to deep learning is the requirement for extensive amounts of training
examples to learn the data.
Machine learning may also include feature selection in which a subset of relevant
features are chosen for use in model building. This is done to remove redundant or
irrelevant features and to enhance generalizability of the model [169]. There are two main
classes of feature selection algorithms: filter and wrapper methods [170]. Filter methods
analyze the intrinsic properties of the data by ranking and selecting a subset of the
features while ignoring the classifier. These methods are fast and avoid overfitting of the
data. Unlike filter methods, wrapper methods evaluate the interaction between a subset of
features and can risk overfitting on the data with a high computation time. Some
algorithms, including decision trees and random forests, perform feature selection as part
of their overall classification operation [166]. Due to the large number of features
available as well as the large number of possible combinations of these features, the highrisk of type I error must be recognized when comparisons and cross-validations are
performed. As a result, initial exploratory studies in radiomics must be considered
hypothesis-generating, and validation on external datasets is crucial.
There are several approaches to evaluate classification performance. In a binary
classification problem, the true positive, true negative, false positive and false negative
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conditions can all be determined. Based on these values overall accuracy, false positive
rate, false negative rate, positive predictive value (precision), sensitivity (recall or true
positive rate), and specificity (true negative rate) can be calculated. To determine the
trade-off between true and false positive classification, the area under the receiver
operating characteristic curve (AUC) can also be calculated. The F1 score can also be
measured to convey the balance between precision and recall.

1.8.2

Challenges and Limitations
There are several limitations and challenges when performing radiomic studies

[121]. In general, image acquisition should be standardized to minimize any variability
between scanners, imaging parameters, or reconstruction techniques. Standardization
includes the use of the same scan protocol for imaging acquisition, with consistencies in
settings such as kV, mAs, slice collimation, and slice thickness. Breathing instructions
and the use of intravenous contrast should also be consistent across all patients, although
patients with contra-indications to contrast injection must be noted and studies analyzing
the effect of contrast on image feature analysis should be performed. Reconstruction
kernels or filters are used to determine image quality of a CT scan and are chosen based
on the intended clinical application of the scan. Such decisions are a compromise
between spatial resolution and noise, and depending on the organ being scanned, may
require a smoother image with less noise or a sharper image with higher noise.
Reconstruction kernels should also be consistent across all images and a higher sharpness
thorax kernel should be used when available. However, optimal scan parameters and
reconstruction kernels must be investigated for the effect of variations among these
settings on quantitative image feature analysis.
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1.8.3

State of the Art in Lung Cancer Radiomics
The work presented in this thesis was one of the first studies to assess the utility

of quantitative image features for response assessment in lung cancer. A summary of
other studies using radiomics to assess outcomes and response following lung cancer
treatment is shown in Table 1-2. One of the first large scale studies determining the
prognostic power of radiomics was by Aerts et al. [125]. They examined 440 intensity,
shape, and texture features on CT for predicting outcomes in lung and head and neck
cancer patients. They demonstrated the association of radiomic features with clinical
data, including TNM descriptors, stage, and histology. They also showed the association
of a radiomic signature with overall survival and gene-expression, demonstrating the
potential of a radiogenomics analysis to associate quantitative image features with
underlying gene-expression patterns. More recent studies have also evaluated complex
shape and appearance descriptors to predict overall survival (OS) following lung cancer
surgery [162].
Additional studies have determined the potential of radiomics on pre-treatment
CT images to predict outcomes in later stage disease (stage II or III) following
chemotherapy and radiation therapy [171, 172]. Predictive models incorporating texture
features and conventional prognostic factors demonstrated a significant improvement for
predicting overall survival (OS), loco-regional control (LRC) and freedom from distant
metastases (FFDM) compared to conventional prognostic factors alone [171]. Radiomic
features were also found to be associated with distant metastasis (DM), which was
validated in an independent validation set [172]. When combining this radiomic signature
with a clinical model, prediction of DM was significantly improved, demonstrating the
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potential of radiomics to provide additional information regarding tumour phenotype
compared to clinical data alone.
For early stage I lung cancers, several studies have investigated the use of pretreatment CT radiomic features for predicting recurrence after surgery [173, 174].
Emaminejad et al. found that a radiomics and genomic biomarker based classifier could
predict recurrence after surgery with an area under the receiver operating characteristic
curve (AUC) values of 0.78 and 0.68 respectively [173]. Combining these two classifiers
significantly improved performance with an AUC of 0.84. Higher order wavelet features
and CT intensities of solid and GGO tumour components demonstrated the ability to
predict tumour recurrence with an AUC of 0.8 [174]. These studies demonstrate the
potential to assess patients who may be at a higher risk of recurrence pre-treatment to
facilitate individualized patient care.
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Table 1-2: A summary of previous studies using radiomics to assess outcomes and
response following lung cancer treatment.
Authors
Mattonen et al.
2013 [175]
Mattonen et al.
2014 [176]
Mattonen et al.
2015 [177]
Mattonen et al.
2016 [178]
Emaminejad et

Treatment

Outcome

SABR

LR

SABR

LR

SABR

LR

SABR

LR

Surgery

Recurrence

Surgery

Recurrence

SABR

LR

SABR

DM

Aerts et al. 2014

RT &

[125]

ChemoRT

Fried et al. 2014

ChemoRT

[171]
ChemoRT

OS

2015 [162]

CT
(post-tx)
CT
(post-tx)
CT

24

Texture

I

24

Radiomics

I

24

I

45

I

79

Radiomics/Genomics

I

101

Reisz wavelets

I

45

Texture

I

101

Radiomics

I-IV

1019

Radiomics

III

91

Texture

II-III

182

Radiomics

I-IV

108

Tumour shape and

Radiomics with semiautomated system
Physician performance
vs. Radiomics

CT

PET/CT

PET/CT

CT
(pre-tx)

OS, LRC,

CT

FFDM

(pre-tx)

DM

CT
(pre-tx)

2015 [172]
Grove et al.

(post-tx)

I

(pre-tx)

[180]

Coroller et al.

CT

Method

(pre-tx)

[179]
Wu et al. 2016

(post-tx)

N

(pre-tx)

al. 2015 [174]
Pyka et al. 2015

CT

Stage

(pre-tx)

al. 2015 [173]
Depeursinge et

Modality

Surgery

OS

CT
(pre-tx)
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heterogeneity

LR = local recurrence, DM = distant metastases, FFDM = freedom from distant
metastases, OS = overall survival, LRC = loco-regional control, N = number of patients.

The use of radiomics to quantify the appearance of FDG-PET SUV changes can
also be performed [179, 180]. This may be an important area of study to determine
regional variations in SUV uptake pre- or post-treatment. A study by Pyka et al.
evaluated the use of second-order GLCM texture features on pre-treatment FDG-PET
images for predicting local recurrence following SABR for 45 patients with early-stage
lung cancer [179]. They found that the entropy texture feature demonstrated an AUC of
0.87. Wu et al. analyzed 101 patients treated with SABR and found radiomic features on
pre-treatment PET were associated with DM [180]. These techniques may be valuable for
predicting outcomes in this patient population following SABR treatment. However, all
of these studies need to ensure standardization of methodology as discretization of SUV
values can have a major impact on the resultant texture features [181].

1.9

Thesis Hypothesis and Objectives
SABR has been shown to be to surgery for the treatment of patients with early-

stage NSCLC. However, the presence of benign radiographic changes on post-SABR CT
can occur and appear with similar shape and size to a recurring tumour. Being able to
differentiate benign fibrotic changes from local tumour recurrence remains a major
clinical challenge for timely response assessment following SABR. There is currently a
great unmet clinical need to provide timely and accurate assessment of response
following SABR for early stage NSCLC. Therefore, a reliable measure of recurrence on
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CT imaging is critically needed, as the utilization of SABR is rapidly increasing and CT
imaging remains the standard measure of imaging follow-up for these patients.
There are several advantages to the use of CT, rather than routine functional
imaging, in assessment of response post-SABR. In contrast to FDG-PET imaging, CT is
more accessible and inexpensive, does not rely on isotopes with short half-lives, and is
already part of standard-of-care follow-up for patients who have received curative
treatment for early-stage lung cancer, and who are eligible for salvage. Importantly,
standardization of CT across centres is much less complex than standardization of
PET/CT. Standard machine settings and reconstruction algorithms are widely available
for CT imaging of the chest, increasing the generalizability of any follow-up
recommendations. As such, new algorithms for early detection of recurrence based on
standard-of-care CT imaging could be easily integrated into current clinical practice.
However, novel imaging techniques must move beyond qualitative image analysis and
simple RECIST measurements.
Quantitative image analysis allows for maximal information to be obtained from
images already being performed in clinical practice, and can easily be translated into a
useful clinical tool to aid in outcome prediction and treatment response assessment.
Radiomics on pre-treatment imaging has demonstrated the potential to predict outcomes
in all stages of lung cancer. To the best of our knowledge, there has been no previous
work using radiomics to predict response using follow-up CT imaging. Physicians
currently rely on qualitative image analysis to try to distinguish patients with recurrence
from those with only benign injury, and typically rely on features of an enlarging mass.
No prior studies have assessed physician performance or inter-physician variability and
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reliability in detecting recurrence after SABR. We conjecture that post-SABR
radiological changes can be quantified through the use of a radiomic software system to
aid in response assessment after treatment.
To address the unmet clinical need to provide timely and accurate assessment of
response following SABR for early stage NSCLC, the overarching objective of this thesis
is to develop a radiomic software system to aid in treatment response assessment on
follow-up CT after SABR. This objective will be evaluated by testing the following
central hypothesis; a radiomic software system will outperform physicians in the early
assessment of response post-SABR. To test the central hypothesis, this thesis has the
following four aims:
1) To determine group differences in radiomic features between patients with
recurrence and benign injury.
2) To develop a radiomics system to predict recurrence in individual patients.
3) To develop a semi-automated segmentation system to predict recurrence in
individual patients.
4) To compare a radiomics decision support system to physician performance.
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1.10

Thesis Outline

1.10.1

Chapter 2: Distinguishing radiation fibrosis from tumour
recurrence after SABR for lung cancer: a quantitative analysis of
CT density changes
This work was a hypothesis generating study to determine if quantitative image

feature analysis could be used for distinguishing groups of patients with and without local
recurrence following SABR. Quantitative image features were extracted from manually
delineated regions of common post-SABR changes; consolidation and GGO. This will
allow us to assess the potential for quantitative image appearance features to provide
additional information over traditional size measurements. This could allow for
quantitative appearance features to be used in a decision support tool for aiding in
response assessment post-SABR. We hypothesized that there would be quantitative
differences in appearance features between recurrence and benign fibrosis patient groups.

1.10.2

Chapter 3: Early prediction of tumour recurrence based on CT
texture changes after SABR for lung cancer
The objective of this work was to evaluate quantitative image feature analysis and

machine learning techniques for predicting local recurrence in individual patients
following SABR. A more comprehensive set of first- and second-order image features
was extracted from regions of post-SABR changes and machine learning was performed
to evaluate classification performance. We wanted to work towards the goal of
understanding if second-order quantitative image features can predict local recurrence in
individual patients within 6 months of SABR treatment. We also aimed to assess the
impact of variations in manual segmentation boundaries on classification performance
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and compare the quantitative appearance features to traditional measure of response postSABR. We hypothesized that quantitative appearance features can predict recurrence
within 6 months of SABR with accuracies greater than 75%.

1.10.3

Chapter 4: Imaging texture analysis for automated prediction of
lung cancer recurrence after stereotactic radiotherapy
The objective of this work was to develop and evaluate a semi-automated graph

cuts based approach to segment and sample regions of post-SABR radiological changes.
The work in Chapters 2 and 3 relied on manual delineations of post-SABR radiological
changes on CT which are time consuming and subject to operator variability. We look to
determine if semi-automated segmentation methods can decrease segmentation time and
produce consistent segmentations between operators. In addition to developing a semiautomated segmentation approach, we wanted to determine if this system can be used
with the radiomic decision support system to predict local recurrence following SABR.
We hypothesized that a semi-automated segmentation algorithm could demonstrate
consistent segmentations and prediction accuracies between operators, with noninferiority to manual segmentations.

1.10.4

Chapter 5: Detection of local cancer recurrence after SABR for
lung cancer: physician performance versus radiomic assessment
The objective of this work was to perform an observer study to assess how well

physicians can distinguish between benign fibrosis and local recurrence on follow-up CT
after SABR. This would allow for a basis of comparison for our radiomics system and
allow us to move towards the goal of understanding how physicians perform in response
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assessment post-SABR. To the best of our knowledge, there has been no study to date
assessing a physician’s performance in distinguishing fibrosis from recurrence following
SABR for lung cancer. An additional objective of this work was to develop and evaluate
a multi-feature radiomic signature to predict local recurrence following SABR. In this
chapter we compared our radiomic signature to physician performance for the early
prediction of recurrence within 6 months of treatment. We hypothesized that a radiomic
software system will outperform physicians in the early assessment of response postSABR.
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Chapter 2
Towards the goal of understanding the quantitative image features between benign
radiation induced lung injury and local recurrence, we evaluated quantitative image
feature analysis for distinguishing groups of patients with and without local recurrence
following SABR.
The contents of this chapter were previously published in the journal Acta Oncologica:
SA Mattonen, DA Palma, CJ Haasbeek, S Senan, and AD Ward. Distinguishing radiation
fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung
cancer: A quantitative analysis of CT density changes. Acta Oncol 2013; 52:910–918;
http://dx.doi.org/10.3109/0284186X.2012.731525. Permission to reproduce this article
was granted by Taylor & Francis Group and is provided in Appendix A.3.

2

DISTINGUISHING RADIATION FIBROSIS FROM
TUMOUR RECURRENCE AFTER SABR FOR LUNG
CANCER: A QUANTITATIVE ANALYSIS OF CT
DENSITY CHANGES

2.1

Introduction
Stereotactic ablative radiotherapy (SABR), also known as stereotactic body

radiotherapy (SBRT), employs image guidance and precise treatment delivery to deliver a
high dose of radiation to tumours while sparing surrounding normal tissue [1].
Treatments are typically delivered with high doses per fraction, over 3-8 fractions [2].
SABR is becoming a standard treatment option for stage I non-small cell lung cancer
(NSCLC) patients who are medically inoperable or refuse surgery [2, 3]. Following lung
radiotherapy, radiation-induced lung injury (RILI) can occur in the acute phase (within 6
months) as radiation pneumonitis and in the late phase (after 6 months) as fibrosis [4].
With SABR, the incidence of acute- and late-onset RILI is high: 54-79% of patients
develop acute benign CT changes, and 80-100% of patients develop late changes [5].
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With older radiotherapy techniques, benign computed tomography (CT) changes
typically follow the edges of the treatment fields, consisting of straight borders and
allowing for easier diagnosis of RILI [4]. Due to the high doses delivered and steep dose
gradients with SABR, as well as the 3D conformity of the treated region to the
morphology of the target, benign CT changes are common and can mimic tumour
recurrence, especially when they develop as mass-like patterns [5, 6]. Therefore,
distinguishing between benign fibrosis and recurrence becomes of major importance in
identifying patients who are candidates for salvage treatment [7]. Misclassification of
injury as recurrence can cause patients to undergo unnecessary investigations and
interventions for no oncologic benefit. Conversely, misclassification of recurrence as
injury can result in a missed opportunity for salvage [6].
18

F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging has

been investigated to detect recurrence, but has several limitations: hypermetabolic
activity has been observed in benign SABR-treated lesions [8], optimal SUV cut-offs
have not been defined, and repeated PET scanning of all SABR patients would be costly.
A biopsy can be considered for a definite diagnosis of recurrence; however, high risks of
complications such as pneumonthorax (~20%) and hemoptysis (5-10%) prevent it from
being a first line tool for differentiating fibrosis from recurrence [9]. As a result, better
methods are needed to aid in distinguishing RILI from recurrence. A reliable measure of
recurrence on CT imaging would be a valuable clinical tool, as the utilization of SABR
for early stage lung cancer is increasing [10], and CT scanning is the standard measure of
imaging follow-up for SABR patients [11].
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The goal of this study is to measure the utility of CT image feature analysis in
differentiating RILI from recurrence, when compared to Response Evaluation Criteria in
Solid Tumours (RECIST) measurements, which is the standard method used for response
assessment in trials of oncology [12]. Specifically, this study compares the imaging
characteristics of CT density, texture and 3D volume of contoured regions of interest:
consolidative regions (increased density with no visibility of vessels) and ground-glass
opacity (GGO: an increase in normal lung parenchyma density but with visibility of
vessels). Analysis was completed on planning and follow-up CT images, and determines
which measures may provide the earliest differentiation of local recurrence from injury.

2.2
2.2.1

Methods and Materials
Patient Selection and Treatment
A total of 22 patients with 24 tumours treated with SABR for Stage I NSCLC at

the VU University Medical Center between February 2004 and February 2010 were
selected for this study. Patients without recurrence were selected from a previous study
[13] based on presence of CT findings of moderate/severe fibrosis that were ultimately
found to be benign. Of the 24 lesions, 13 developed only benign RILI, and 11 developed
recurrence. Of the latter, pathological evidence of recurrence was available in 8 of 11
lesions; the other 3 were deemed to be recurrences based on sequential imaging findings
and multidisciplinary group consensus, as biopsy was not feasible. One patient had 2
treated lesions in close proximity; these were considered as a single lesion for analysis as
the post-SABR CT changes spanned the location of both lesions.
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All patients were treated with SABR using a risk-adapted fractionation scheme as
previously described [13-15]. Briefly, patients were treated with one of three
fractionation regimens: 60 Gy in 3 fractions for T1 tumours surrounded by lung
parenchyma; 60 Gy in 5 fractions for T2 tumours or those in broad contact with the chest
wall; and 60 Gy in 8 fractions for tumours within 2 cm of the mediastinum or close to the
brachial plexus. For 3D-conformal treatments, done using 9-11 fixed beams, planning
was completed using BrainLab software (Brainscan version 5.2; BrainLab Inc.,
Feldkirchen, Germany) and a pencil beam dose calculation algorithm. For those patients
treated with volumetric modulated arc therapy (VMAT) using RapidArc (Varian Medical
Systems, Palo Alto, USA), the anisotropic analytical algorithm (AAA) was used for dose
calculations. With the latter, the prescribed doses for the 3- and 5- fraction regimens were
54 Gy and 55 Gy respectively, due to differences in dose calculation with the more
advanced algorithm. Follow-up was routinely conducted with a diagnostic CT scan
approximately 3, 6, and 12 months post treatment and every 6-12 months thereafter.

2.2.2

Contours
All pre-treatment and follow-up scans were manually contoured on every axial

slice using a lung window setting (window width of 1500 HU and window level of -600
HU). For tumours or fibrosis abutting the mediastinum, a mediastinal window setting
(window width of 350 HU and window level of 40 HU) was also used. All contours were
completed using ITK-SNAP [16] (Version 2.2.0). Two regions were contoured in the
follow-up scans based on the patterns of post-SABR CT changes which have been well
described [13, 15, 17]. The first, containing consolidative changes around the treatment
site, was defined as a region of increased density with no visibility of vessels. The
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second, containing ground glass opacities (GGO), was defined as an increase in normal
lung parenchyma density but with visibility of vessels [18]. Figure 2-1 shows an example
of the contours created for a single subject throughout the course of follow-up postSABR. All contours were completed by a single investigator (SAM) and subsequently
edited and approved by a thoracic radiation oncologist (DAP). Further details pertaining
to image acquisition and analysis are outlined in Appendix B.
Inter- and intra-observer variability has been reported in contouring of lung
tumours [19]. To simulate the effect of contouring variability, we implemented computer
software to expand and contract the contour borders by 1 mm in the axial plane, and
determined the effect of the expansion and contraction on the mean differences measured
between patients with RILI and recurrence. At the earliest significant time point for both
the consolidative and GGO regions, we expanded and contracted the borders by 1 mm
and recalculated our results.
0m

+4m

+8m

+14m

+24m

+27m

Figure 2-1: Manual contours throughout a course of follow-up for a patient whose cancer
recurred. The solid lines represent consolidative changes, and the dashed lines represent
ground-glass opacity (GGO).
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2.2.3

Data Analysis
Four measures were calculated for the contoured regions: (1) mean 3D volume,

(2) mean CT density, (3) standard deviation of CT density, and (4) mean RECIST
measurements. RECIST measurements were taken for only the solid consolidative areas
according to RECIST 1.1. MATLAB 7.13 (The MathWorks Inc., Natick, MA, USA) was
used in the calculation of the 3D volume and CT densities of the contoured regions. The
standard deviation (SD) of CT density was used as a basic texture metric, where larger
standard deviations correspond to more variegated image textures within the contoured
regions. Figure 2-2 shows an example of this image texture measure for three sample
image regions containing increasingly variegated texture, with the corresponding
standard deviations shown in HU.
(a)

(b)

(c)

Figure 2-2: The standard deviation (SD) of CT density was used as a basic texture
measure. Three examples from GGO regions of patients in this study, showing the
differences in texture with the varying SDs: a) 50.1 HU, b) 85.8 HU, c) 123.4 HU

For each lesion, the measures were analyzed cumulatively throughout the course
of follow-up up to a specified time point. This resulted in a mean RECIST size, mean 3D
volume, mean CT density, and standard deviation of CT density for each lesion over each
specified follow-up time interval. The time points we used for analysis were every 3
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months up to 2 years, then yearly thereafter. These time points were more frequent that
the regular follow-up scan intervals as there is occasionally some variability in CT scan
timing due to individual patient scheduling and potentially due to clinical indications.
The end date of treatment was considered day 0 of follow-up. Differences between
groups were assessed using an independent samples t-test with unequal variances in
MATLAB 7.13 (The MathWorks Inc., Natick, MA, USA). All statistical tests were twosided with p ≤ 0.05 indicative of statistical significance.

2.3

Results
A total of 136 CT scans were reviewed with a median imaging follow-up of 26

months (range: 6 - 44 months). The mean number of scans per patient was 6 (range 2-8);
patients with recurrence had a mean of 4 follow-up scans, and patients without recurrence
had a mean of 6 follow-up scans. Baseline patient and treatment variables are shown in
Table 2-1. We observed that over 50% of tumours were found in the upper lobe, which is
consistent with epidemiologic studies of lung cancer [20]. Three patients developed
clinical grade 3 pneumonitis, and no grade 4 or 5 thoracic clinical toxicity was observed
in this patient cohort. All patients without recurrence had a minimum follow-up of 2
years.
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Table 2-1: Baseline patient and treatment variables.
Total (n=22 patients, with 24 tumours)
Median (range) or Number (%)
69 (49-84)

Age (n=22)
Gender (n=22)
Male

14 (63.6%)

Female

8 (36.4%)
5 (1-10)

Charlson Score* (n=22)

20.4 cc (4.5-144.4 cc)

Planning target volume (n=24)
Fractionation schedule (n=24)
3 x 20 Gy

14 (58.3%)

5 x 11 Gy

1 (4.2%)

5 x 12 Gy

4 (16.7%)

8 x 7.5 Gy

5 (20.8%)

Treatment type (n=24)
Fixed beam

21 (87.5%)

RapidArc

3 (12.5%)

Tumour location (n=24)
Left upper lobe

4 (16.7%)

Left lower lobe

2 (8.3%)

Right upper lobe

10 (41.7%)

Right middle lobe

3 (12.5%)

Right lower lobe

5 (20.8%)

*age adjusted Charlson, current lung cancer not scored as comorbidity.
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2.3.1

Pre-treatment lesions
Table 2-2 shows the baseline pre-treatment imaging characteristics for patients

with recurrence and RILI. No significant differences were observed at baseline in mean
CT density, volume, or RECIST size, comparing lesions of patients whom would later
develop recurrence versus those with RILI. Since GGO was not contoured on the pretreatment scan, the standard deviation of CT density was not included in the
aforementioned table.
Table 2-2: Baseline pre-treatment imaging characteristics.

Pre-treatment CT Density
(p=.434)
Pre-treatment RECIST

Recurrence

Benign Fibrosis

Mean ± 95% CI

Mean ± 95% CI

-104.8 ± 34.40 HU

-124.6 ± 34.43 HU

3.55 ± 1.01 cm

2.36 ± 0.43 cm

22.29 ± 16.27 cc

6.67 ± 4.66 cc

(p=.052)
Pre-treatment 3D Volume
(p=.096)

2.3.2

Post-SABR Measures of Size
A significant difference in RECIST measurements was detected between patients

with recurrence vs. those with RILI as early as 15 months post-treatment (p=0.028).
Patients with recurrence had a mean cumulative RECIST [± 95% CI] of the consolidative
changes at 15 months of 4.34 ± 1.13 cm versus 2.63 ± 0.84 cm for patients with benign
RILI.
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Patients with recurrence had significantly larger solid consolidative changes as
measured with 3D volume, detected as early as 15 months post-treatment compared to
patients with RILI (mean at 15 months [± 95% CI] of 30.1 ± 19.3 cc vs. 5.1 ± 3.6 cc,
respectively; p=0.030). No significant difference was observed in the 3D volumes of the
GGO regions. Figure 2-3 shows the significant measures of size (both RECIST and 3D
volume measurements) of the consolidative regions for patients with recurrence and
RILI, during the course of follow-up post-SABR.
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Figure 2-3: Cumulative size measures of the consolidative regions throughout follow-up
post-SABR; all values are the mean ± 95 % CI. a) RECIST and b) 3D volume.
* Indicates statistical significance at p ≤ 0.05.
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2.3.3

Post-SABR Appearance Measures
Patients with recurrence had significantly denser mean [± 95% CI] solid

consolidative changes of -96.4 ± 32.7 HU versus -143.2 ± 28.4 HU for patients with
RILI, and this was detected as early as 9 months post-treatment (p=0.046). No significant
difference was observed in the CT density of the GGO at any point in follow-up.
Significantly increased variability of CT densities in the GGO areas was detected
at 9 months post-treatment (p=0.0078). Patients with recurrence had a standard deviation
of CT density at 9 months [± 95% CI] of 210.6 ± 14.5 HU vs. 175.1 ± 18.7 HU for
patients with RILI. This is indicative of larger variability in the HU of the GGO, or more
variegated texture, in patients with recurrence. No significant difference was observed in
the variation of CT densities within the consolidative regions. Figure 2-4 and Figure 2-5
show the cumulative appearance measures (CT density and standard deviation of CT
density), in the GGO and consolidative regions respectively, during post-SABR followup for patients with recurrence and RILI.
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Figure 2-4: Cumulative appearance measures of the ground glass opacity regions
throughout follow-up post-SABR; a) Mean [± 95% CI] CT density, and b) standard
deviation [± 95% CI] of CT density.
* Indicates statistical significance at p ≤ 0.05
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Figure 2-5: Cumulative appearance measures of the consolidative regions throughout
follow-up post-SABR; a) Mean [± 95% CI] CT density, and b) standard deviation [± 95%
CI] of CT density.
* Indicates statistical significance at p ≤ 0.05
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2.3.4

Contouring Variability
In the consolidative regions at 9 months, we expanded and contracted the borders

by 1 mm and recalculated our results. In all cases, including the original results, the
differences between the two groups remained between 36-59 HU, with the patients with
recurrence having higher HU density than patients with only RILI: [1 mm expansion:
RILI = -220.02 ± 35.70 HU, recurrence = -161.67 ± 36.26 HU; 1 mm contraction: RILI =
-95.43 ± 28.48 HU, recurrence = -59.58 ± 33.06 HU].
Similarly, for the GGO texture measure at 9 months, patients with recurrence had
a higher standard deviation of CT density compared to those with RILI, and the
difference between the two groups remained between 35-39 HU: [1 mm expansion: RILI
= 194.77 ± 14.99 HU, recurrence = 229.97 ± 10.85 HU; 1 mm contraction: RILI =
167.86± 21.71 HU, recurrence = 206.60 ± 17.16 HU].

2.4

Discussion
CT density changes are common after SABR and distinguishing recurrence from

RILI is becoming increasingly important. As SABR utilization increases, ambiguous CT
findings will become a more common clinical problem. A technique for early and
accurate diagnosis of post-SABR recurrence could allow for early salvage of recurrence,
and avoid unnecessary imaging and intervention in patients with RILI only. This study
suggests that changes in the cumulative mean density of consolidative regions and
textural analysis of the GGO have the potential to distinguish RILI from cancer
recurrence as early as 9 months post-SABR, compared to 3D volume and RECIST at 15
months. For RECIST of the consolidation and texture analysis of the GGO, we
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acknowledge the possibility that they may be inferior predictors as there does not appear
to be an increase in separation between the groups over time. To our knowledge, this is
the largest series of recurrences analysed for post-SABR radiological changes in the
literature.
We observed a significant difference in mean HU for the consolidative regions,
but not in the GGO regions, and conversely we observed a significant difference in the
standard deviation of HU in the GGO regions, but not in the consolidative regions. A
more detailed investigation is required in order to more fully understand the reasons
behind this observation. Since the consolidative regions are relatively opaque and
homogeneous in appearance on CT imaging, the standard deviation of HU in these
regions may be a less sensitive measure of difference between the groups, and the
significant difference in mean HU could potentially be due to changes in tissue
composition of the recurrent tumour (such as microvasculature and soft tissue) compared
to fibrotic tissue within radiation-induced lung injury.
The GGO regions contained a relatively greater amount of variation in the CT
densities as some areas have lower density lung tissue, and others have higher density
vessels; this may have rendered the standard deviation of HU measure a relatively more
sensitive measure of difference between the groups in the GGO regions. We surmise that
RILI results in a more uniform GGO density within these regions, whereas recurrences
seemed to have a more variegated appearance potentially representing tumour nodularity
or increased vascularity in areas of tumour recurrence. Further work is required to gain an
understanding of the exact reasons behind the association of our significant measures
with the consolidation or GGO regions for patients with recurrence and RILI.
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The findings of this study are consistent with previously published literature but
extend these previous findings in several important ways. Previous studies have shown
that an enlarging opaque region after 12 months is indicative of recurrence [21, 22],
consistent with the RECIST findings reported herein. We hypothesize that the decrease in
RECIST and volume of the consolidative regions for the recurrence groups at 3 months is
indicative of a partial response to treatment, and following this time point the rise we see
may possibly be a sign of progressive disease. However, an enlarging mass may not be
specific for recurrence: based on biopsy and further imaging, only a few patients with
enlarging masses are deemed to ultimately have recurrence [6]. Most previous studies of
radiological features of post-SABR recurrence are limited due to small sample size (of ≤5
recurrences) and mainly focused on the type and qualitative appearance of these changes
[6, 21, 22]. Our study extends these findings by quantifying changes in density, texture,
and 3D volume for patients, and suggests that these measurements may allow for the
earlier detection of recurrence.
A systematic review by Huang et al. identified several predictive factors of
recurrence [5]. Since the primary imaging modality for follow-up post-SABR is CT,
RECIST is traditionally used to determine a patient’s response to treatment. An enlarging
mass with 20% increase in size, or an absolute increase in size of at least 5 mm from
baseline, as described by RECIST 1.1, is suspicious for recurrence and warrants FDGPET for further investigation. Other high-risk features on CT include an enlarging masslike lesion, opacity enlargement after 12 months, bulging margin, disappearance of air
bronchograms, linear margin disappearance, ipsilateral pleural effusion, or lymph node
enlargement [5]. In terms of metabolic findings of recurrence, a SUVmax ≥ 5 using FDG-
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PET is highly suspicious of recurrence. In these cases, it is suggested a biopsy and/or
resection should occur if feasible. Validation of the findings presented herein may
improve this algorithm for imaging follow-up after SABR.
The conclusions of this study must be considered in the context of its strengths
and limitations. Although the number of recurrent lesions analyzed is more than in
previous studies, and the length of follow-up is long, the sample size remains small,
which may limit the power to detect small differences between groups. The patients
included are not completely reflective of the overall SABR population, in that both the
proportion of patients with recurrence, and the severity of benign RILI are higher than in
a general SABR population. This sample was selected in order to determine if image
feature analysis could differentiate recurrence from difficult RILI cases, but these
findings require validation in a large, separate dataset. Inter- and intra-observer
variability can exist in contouring of lung tumours [19], and further research is required
to refine these metrics so they are invariant to individual contouring practices. As a result,
it appears that even in the presence of contouring variability, the differences between the
RILI and recurrence group appear consistent. Furthermore, data analysis was completed
through cumulative analysis of measures up to a time point (0-3, 0-6, 0-9 months etc.),
rather than using smaller time ranges (0-3, 3-6, 6-9 months etc.). Future studies will
evaluate the relative benefits of using a cumulative analysis vs. using smaller time ranges.
Furthermore, lung density can vary with regional blood flow, respiration, as well as comorbid illnesses such as COPD [23, 24], and these factors were not considered in this
study. Further work must be completed on the effect of any co-morbidities on the
measures analysed in this study.
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In conclusion, our study suggests that the use of CT density of consolidative
changes as well as basic textural analysis of GGO may allow for early differentiation
between RILI and recurrence. With further validation of our results on a larger sample
size, and more detailed analysis of the features and changes observed throughout the
course of SABR follow-up, there is the potential for an earlier detection of recurrence
compared with traditional measures. This could potentially allow for earlier salvage of
patients with recurrence, and result in fewer investigations for patients exhibiting only
benign RILI.
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Chapter 3
Towards the goal of understanding if quantitative image features can predict local
recurrence in individual patients, we evaluated quantitative image feature analysis plus
machine learning techniques for predicting local recurrence in individual patients
following SABR.
The contents of this chapter were previously published in the journal Medical Physics:
SA Mattonen, DA Palma, CJ Haasbeek, S Senan, and AD Ward. Early prediction of
tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy
(SABR) for lung cancer. Med Phys 2014; 41(3): 033502. Permission to reproduce this
article was granted by the American Association of Physicists in Medicine and is
provided in Appendix A.4.

3

EARLY PREDICTION OF TUMOUR RECURRENCE
BASED ON CT TEXTURE CHANGES AFTER SABR FOR
LUNG CANCER

3.1

Introduction
Stereotactic ablative radiotherapy (SABR) is now a standard treatment option for

patients with early stage non-small cell lung cancer (NSCLC) who are medically
inoperable or refuse surgery [1, 2]. SABR uses advanced treatment planning and delivery
to treat the tumour to a high dose, while sparing surrounding normal tissue. Multiple
collimated radiation beams are used to achieve a dose distribution highly conformal to
the shape of the tumour with steep dose gradients at the tumour boundary. SABR
treatments are typically delivered with high doses per fraction with relatively fewer
fractions in the overall treatment (e.g. 7.5–18 Gy/fraction over 3–8 fractions for SABR,
compared to approximately 2 Gy/fraction over 20–30 fractions for conventional therapy)
[3].
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Currently, the standard imaging modality recommended and clinically used for
post-SABR follow up is computed tomography (CT) [2]. During follow-up assessment, a
key clinical decision is whether to provide further, possibly more invasive intervention
(e.g. surgery, chemotherapy) to treat or remove recurrent/residual disease. This decision
rests on the ability to assess the success of the SABR treatment; i.e. to determine whether
the patient’s cancer will recur. Since recurrent lung cancer typically progresses quickly, a
decision to proceed with further intervention is most valuable if made early, since
delayed detection of recurrence may reduce the options for salvage therapies. This
decision is complicated by the fact that following radiotherapy to the lung, radiationinduced lung injury (RILI) can occur as radiation pneumonitis and radiation fibrosis,
which appear as an increase in lung density on CT [4, 5]. Following treatment with
SABR, RILI can have similar size and morphology to a recurrent tumour [6, 7]. Several
studies have examined the radiologic appearance of recurrence on follow-up CT postSABR, and suggest that an enlarging opacity after 12 months is most suggestive of
recurrence; however, this criterion can only be met one year after treatment [8, 9]. A
systematic review of the literature also suggests that other imaging features, such as a
bulging margin and disappearance of air bronchograms, are also suggestive of recurrence
[10, 11].
Metabolic imaging modalities such as 18-fluorodeoxyglucose (FDG) positron
emission tomography (PET) imaging have been investigated for measuring treatment
response post-SABR. Standardized uptake values (SUVs) greater than 5, or greater than
the pre-treatment value, have been shown to be suggestive of recurrence; however,
optimal SUV thresholds have not been determined [11]. Adding to the challenge of
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interpreting FDG-PET images in the post-SABR context, hypermetabolic activity has
been observed in benign fibrotic tissues years following SABR, likely due to an
inflammatory response [12].
A means for predicting recurrence within 6 months of treatment based on routine
CT imaging would permit timely intervention for recurrence, which typically manifests
after 1 year [3], and would be ideally suited to tailoring clinical management. Image
texture analysis has been used for computer-aided diagnosis on lung CT, and secondorder texture statistics based on grey-level co-occurrence matrices (GLCMs) have been
shown to quantify lung abnormalities [13, 14]. Our previous work presented in Chapter 2,
demonstrated that a first-order texture feature [standard deviation (SD) of CT density]
within the ground-glass opacity (GGO) regions, as well as the density of the
consolidative regions, could statistically significantly differentiate recurrence and RILI
patient groups at 9 months post-SABR [15]. Our preliminary analysis showed that a
linear classifier could predict recurrence in individual patients at 9 months post-SABR
with error of 26% using first-order texture of the GGO [16]. To the best of our
knowledge, no previous work has demonstrated the ability to predict eventual cancer
recurrence based on images acquired within 6 months of SABR treatment.
Based on our observations of the utility of quantitative appearance measures of
the GGO in Chapter 2 [15], the primary objective of this study was to measure the
accuracy of second-order GGO texture features on CT images acquired within 6 months
of SABR treatment for prediction of recurrence, and to compare this with the accuracies
obtained using first-order appearance features and measures of size of the consolidation
regions. We analyzed texture features within GGO regions known to undergo
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radiographic changes post-SABR [17]. Based on our observation that contouring of the
consolidation regions is relatively straightforward in a clinical context, but GGO
contouring is highly time-consuming and requires more careful judgment, our secondary
objective was to measure the sensitivity of classification performance to perturbations of
the GGO boundaries. This study is intended to generate hypotheses regarding the relative
merit of GGO appearance features for predicting recurrence for further testing on a larger
data set.

3.2
3.2.1

Materials and Methods
Patient Selection and Imaging
A group of 22 patients with T1 or T2 N0 non-small cell lung cancer was selected

for this study, all of whom were treated with SABR at the VU University Medical Center
in the Netherlands. These patients had a total of 24 tumours; 13 developed benign RILI,
and 11 developed recurrence. Pathological evidence of recurrence was available in 8 of
the 11 tumour cases. Biopsy was not feasible in the remaining 3, and they were deemed
to be recurrences based on sequential imaging findings, multidisciplinary group
discussion, and eventual clinical outcome. All patients with benign RILI in this study had
at least 2 years of imaging follow-up and were selected based on moderate to severe
radiological findings [17], thus presenting a challenge to an algorithm designed to
distinguish the substantial CT changes in these RILI cases from true recurrences. Patient
characteristics and treatment variables are provided in Table 3-1.
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Table 3-1: Baseline patient characteristics and treatment variables.
Total (n=22 patients with 24 tumours)
Median (range) or Number (%)
Age (n=22)

69 (49-84)

Gender (n=22)
Male

14 (63.6%)

Female

8 (36.4%)

Charlson Score* (n=22)

5 (1-10)

Tumour location (n=24)
Left upper lobe

4 (16.7%)

Left lower lobe

2 (8.3%)

Right upper lobe

10 (41.7%)

Right middle lobe

3 (12.5%)

Planning target volume (n=24)

20.4 cc (4.5-144.4 cc)

Fractionation schedule (n=24)
3 x 20 Gy

14 (58.3%)

5 x 11 Gy

1 (4.2%)

5 x 12 Gy

4 (16.7%)

8 x 7.5 Gy

5 (20.8%)

Treatment type (n=24)
Fixed beam

21 (87.5%)

RapidArc

3 (12.5%)

*Age adjusted Charlson, current lung cancer not scored as comorbidity.

All of the post-SABR follow-up CT images were acquired at the VU Medical
Center in Amsterdam, Netherlands. Diagnostic CT scans were performed on one of three
scanners: Siemens Volume Zoom 4-slice, Siemens Sensations 64-slice (Siemens
Nederland N.V., Den Haag, Netherlands), or Philips Brilliance iCT 256-slice (Royal
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Philips Electronics, Inc., Amsterdam, Netherlands). Standard machine settings were 120
kVp, 100 mAs, spiral acquisition, 0.5 second rotation time, 2.5–5 mm slice thickness, and
images were acquired at inspiratory breath hold. Intravenous contrast (Ultravist-300;
Bayer Pharma AG, Berlin, Germany) was administered at a volume of 70 cc and a delay
of 25 seconds. Post-SABR diagnostic images were scheduled to be taken at
approximately 3, 6, and 12 months following treatment, then every 6 to 12 months
thereafter. However, due to practical considerations, the actual timing of follow-up scans
does not conform exactly to the above schedule. Figure 3-1 shows the recorded timing of
follow-up scans for the patients in our study, where the last date of treatment was
considered day 0 of follow-up. We observed clustering of the first and second follow-up
scans within the 2–5 and 5–8 month intervals post-treatment, respectively, and these were
therefore the two time intervals used for this study. A total of 46 scans were analyzed
within these two time intervals.

5 months

2 months

8 months

RILI
0
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300

Recurrence

Days Post-SABR

Figure 3-1: Distribution of post-SABR CT scan time points for the patients in this study.
Patients marked as recurrences on this plot experienced eventual cancer recurrence,
diagnosed later than the imaging time points indicated on this plot.
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3.2.2

Region of Interest Delineation
Manual segmentations of two regions of interest were obtained from the study

presented in Chapter 2 [15]. Two three-dimensional (3D) regions of common post-SABR
radiographic changes were manually contoured using the ITK-SNAP [18] (Version 2.2.0)
software package: consolidative and GGO regions. Segmentations were completed on
axial image slices using a lung window setting (window width of 1500 Hounsfield units
[HU] and window level of -600 HU). A mediastinal window (window width of 350 HU
and window level of 40 HU) was also used for delineation of any structures abutting the
mediastinum. All segmentations were completed by a single graduate student, reviewed
by a thoracic radiation oncologist with expertise in lung SABR, and approved after any
necessary editing. Consolidative regions were defined as having increased density with
respect to the surrounding region, with no visibility of blood vessels within. GGO regions
were defined by an increase in the normal lung parenchyma density with respect to the
surrounding region, with potential visibility of blood vessels within [19]. Figure 3-2
illustrates the consolidative and GGO delineations for a patient with benign RILI and one
with recurrence; note in this example the similarity of changes in the consolidative
regions throughout the course of follow-up for the two patients, as well as qualitative
differences between the recurrence and the RILI in the image textural qualities,
particularly in the GGO regions.
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A) Recurrence
0m

+3m

+6m

+12m

B) Benign radiation-induced lung injury
0m

+6m

+3m

+12m

Figure 3-2: Manual delineations of post-SABR consolidative and ground-glass opacity
findings throughout follow-up for a patient with recurrence (A) and radiation-induced
lung injury (B). The zero-month (0m) time point indicates the pre-treatment lesion. The
solid lines enclose consolidative regions and the dashed lines enclose ground-glass
opacity regions.

3.2.3

Measures of Size
Two measures of size were taken in the consolidative region: the one-dimensional

(1D) longest diameter as observed on any axial slice (henceforth referred to as the longest
axial diameter) and the 3D volume. The largest axial diameter was used to make a
Response Evaluation Criteria in Solid Tumours (RECIST) assessment for each
consolidative region, according to RECIST 1.1[20]. All images were imported into
ClearCanvas Workstation 2.0 (ClearCanvas Inc., Toronto, Canada) in anonymized form

90

and the longest axial diameter measurements were taken using the ClearCanvas
Workstation ruler. The 3D volumes of the consolidative regions were calculated using
MATLAB 7.13 (The MathWorks Inc., Natick, MA, USA) by multiplying the number of
voxels contained within each region by the voxel volume.

3.2.4 Measures of Imaging Appearance
Two first-order appearance measures were calculated within the GGO regions:
mean CT density, and standard deviation of CT density (the latter as a measure of image
texture, with higher standard deviation values indicative of more variegated textures).
MATLAB 7.13 was used to calculate these first-order measures.
Seven second-order appearance measures were calculated within the GGO
regions. Second-order image texture features measure, in various ways, the intensity
relationships between pairs of voxels in the image; typically, voxels forming a pair are
spatial neighbours. The first step in calculating such measures is to compute a gray-level
co-occurrence matrix (GLCM) [21]. This is a two-dimensional square matrix 𝑔 where the

rows and columns correspond to observable gray levels (or gray level ranges) within the

images, and where each matrix element 𝑔(𝑖, 𝑗) contains a non-negative integer indicating
the number of voxel pairs whose elements have gray levels 𝑖 and 𝑗. Our chosen seven

texture features were calculated based on the Conners, Trivedi, and Harlow feature set
[22-24]: energy, entropy, correlation, inverse difference moment (IDM), inertia, cluster
shade, and cluster prominence. Their definitions and equations are provided in Table 3-2,
where the weighted pixel average 𝜇 = ∑𝑖,𝑗 𝑖 ∙ 𝑔(𝑖, 𝑗) = ∑𝑖,𝑗 𝑗 ∙ 𝑔(𝑖, 𝑗) (due to symmetry

of 𝑔), and the weighted pixel variance 𝜎 = ∑𝑖,𝑗(𝑖 − 𝜇)2 ∙ 𝑔(𝑖, 𝑗) = ∑𝑖,𝑗(𝑗 − 𝜇)2 ∙ 𝑔(𝑖, 𝑗)
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(due to symmetry of 𝑔). These second-order texture features were calculated using the

Insight Segmentation and Registration Toolkit (ITK) 4.3.1, an open source image
processing software library available at www.itk.org [25].

Computation of second-order texture features requires the configuration of the
GLCM histogram bins and the spatial directions used to establish pairings of
neighbouring voxels. Histogram distributions of the CT densities within the GGO regions
were analyzed to determine the appropriate number and density ranges of the bins for the
GLCMs. Within the GGO, densities ranged from -1000 HU to 200 HU. The number of
density bins was set accordingly to 60 bins, yielding 20 HU bin widths for analysis. In
CT images there are thousands of possible greyscale values and therefore the allocation
of a GLCM bin to every possible greyscale value will result in a very large GLCM. This
can cause texture feature values to become very sensitive to the number of voxels in the
sample. Since we are analyzing a small region of interest, we wanted to reduce the
number of intensities per GLCM bin for analysis. Based on an inspection of one patient
image, a bin width of 20 HU was chosen as a balance that both sufficiently quantizes the
intensities while still having sufficient grey levels for discrimination of intensity
differences in the image. This bin width parameter was not precisely tuned to optimize
the results; improved results may be possible via optimization of this parameter in the
context of a larger samples size. Neighbouring voxels were paired in four spatial
directions within the 2D axial image planes [(-1, 0), (-1, -1), (0, -1), (1, -1)]. All secondorder texture measures were computed based on GLCMs calculated using each of these
four directions, and were averaged over all directions. When calculating a second-order
texture features a single direction for analysis results in a directional dependency of that
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feature. Therefore, calculating over multiple directions mitigates dependency on the
spatial orientation of the image (the image could be rotated in any direction in the axial
plane and the result would be similar). The four directions for analysis therefore include
all possible directions from a reference pixel: horizontal, vertical, and both diagonals. By
averaging across all directions we treat each direction of analysis equally and the result is
spatially invariant. Through-plane directions were not used in this study due to the
anisotropy of the voxels in our clinical images (5 mm slice thickness); such voxel
anisotropy is typical of clinical CT follow-up imaging post radiotherapy
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Table 3-2: Descriptions and equations of the second order texture features.
Equation

𝑖,𝑗

Entropy

− ∑𝑖,𝑗 𝑔(𝑖, 𝑗) log 2 𝑔(𝑖, 𝑗)

Describes the randomness of the
GLCM and is small for a constant
image (all pixel intensity pairs are the
same → high peak in the GLCM)

(𝑖 − 𝜇)(𝑗 − 𝜇)𝑔(𝑖, 𝑗)
𝜎2

Measures how correlated each pixel is
to its neighbour and is high for a
perfectly positively correlated image
(the pixel intensity pairs are highly
correlated in the GLCM)

1
𝑔(𝑖, 𝑗)
1 + (𝑖 − 𝑗)2

Measures the contrast in the image and
is high when there are large values on
the GLCM diagonal (pixel pairs have
equal intensities → peak along the
GLCM diagonal)

or 0 if 𝑔(𝑖, 𝑗) = 0

�

Correlation

𝑖,𝑗

Inverse
difference
moment

�
𝑖,𝑗

Cluster
prominence

Measures the contrast in the image and
is low when there are large values on
the GLCM diagonal (pixel pairs have
equal intensities → peak along the
GLCM diagonal)

�(𝑖 − 𝑗)2 𝑔(𝑖, 𝑗)

Inertia

shade

Describes the uniformity of the image
and is large for a constant image (all
pixel intensity pairs are the same →
high peak in the GLCM)

� 𝑔(𝑖, 𝑗)2

Energy

Cluster

Description

𝑖,𝑗

3

��(𝑖 − 𝜇) + (𝑗 − 𝜇)� 𝑔(𝑖, 𝑗)
𝑖,𝑗

4

��(𝑖 − 𝜇) + (𝑗 − 𝜇)� 𝑔(𝑖, 𝑗)
𝑖,𝑗
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Describes the skewness (lack of
symmetry) of the GLCM and is low
when the image is symmetric with
regard to its texture values (little
variation in intensities)
Describes the skewness (lack of
symmetry) of the GLCM and is low
when the image is symmetric with
regard to its texture values (little
variation in intensities and peak in the
GLCM around the mean intensity)

3.2.5

Data Analysis
Within the GGO regions, 9 features were computed: mean density, first-order

texture (standard deviation [SD] of density), and the seven second-order texture features
described previously (energy, entropy, correlation, IDM, inertia, cluster shade, and
cluster prominence). Within the consolidation regions, the longest axial diameter and 3D
volume were measured. Group differences were assessed using an independent samples ttest with unequal variances in SPSS Statistics Version 21.0 (IBM Corp., Armonk, NY,
USA) to test the null hypothesis that the means of the recurrence and RILI groups are
equal. A Kolmogorov-Smirnov test was also completed in SPSS to test for normality of
distribution for all the measures. All statistical tests were two-sided with p ≤ 0.05
indicative of statistical significance.
Figure 3-3 depicts the analysis performed on each of our features. To determine
the predictive capabilities of each of these measures individually, classification was
performed using the linear Bayes normal classifier [26-28] as implemented in the
PRTools 4.2.1 (Delft Pattern Recognition Research, Delft, The Netherlands) [29]
MATLAB toolbox. Each feature underwent 2-fold cross validation over 100 repetitions,
with all cross validations stratified to each fold. The means and standard deviations of the
classification errors, false negative rates (FNRs), and false positive rates (FPRs) were
measured over the 100 repetitions. These were compared between feature sets using a
Wilcoxon signed rank test for nonparametric data in SPSS. Receiver operating
characteristic (ROC) curve analysis was also used to determine the predictive capabilities
of each of these measures individually; specifically we calculated the area under the
receiver operating characteristic curve (AUC) for each measure. Spearman rank
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correlation coefficients were computed in SPSS to measure the correlations of all features
in our data set.

Size/Appearance Feature

2-Fold Cross Validation
Linear Classifier
100 repetitions

Receiver Operating
Characteristic Curve (ROC)
Linear Classifier

Spearman Rank Correlation

Mean Error
Mean False Positive Rate
Mean False Negative Rate

Area Under the ROC (AUC)

Correlation Coefficient

Figure 3-3: Flow diagram showing analysis performed on each of the 11 features. This
workflow was executed 11 times; once for each of the 11 features used in our study (2
size measures of the consolidation regions and 9 appearance measures of the GGO
regions).

3.2.6

RECIST Progressive Disease Criteria for Prediction
For this study, the longest axial diameter was used as an imaging-based size

measure for the consolidative regions. This measure forms the basis of the RECIST
response criteria which are used as the current clinical standard for determining disease
progression or response based on percentage change in the lesion diameter. To compare
the accuracy of RECIST for predicting recurrence post-SABR with the performance of
our imaging features, we classified as a recurrence each patient having a 20% increase in
the longest axial diameter, and classified all other patients as RILI, according to the
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current RECIST response guidelines. For each time period, the reference diameter was
taken as the smallest previously measured diameter (either pre-treatment or posttreatment) [20]. For the 2–5 month time period, the reference diameter was the pretreatment diameter. At the 5–8 month time period, the reference diameter was either the
2–5 month time diameter or the pre-treatment diameter, whichever was smaller.

3.2.7

Sensitivity of GGO Delineation
Although delineation of the consolidative regions is relatively straightforward for

the operator (and computer-assisted delineation tools have been developed for this
problem [30]), delineation of the GGO border requires more careful judgment and is
substantially more time consuming. Thus, we sought to determine the sensitivity of
classification performance to perturbations of the GGO boundaries. We performed a
simulation study wherein manual GGO delineations were concentrically expanded and
contracted in 1 mm increments, and classifier performance based on GGO features was
re-evaluated for each such modification of the GGO delineations. Expansion of the GGO
delineations was performed by varying a threshold on the distance transformation of the
manually-delineated GGO region. Thresholds were set between 1 mm to 5 mm, at 1 mm
increments. The expansion was performed such that the expanded GGO region did not
intersect with the manually delineated consolidative region, chest wall, or mediastinum.
Contraction was performed by thresholding the distance transformation of the binary
complement of the manual delineation. Contraction was performed at 1 mm and 2 mm
thresholds, as larger distances resulted in nearly complete volume loss of many small
GGO regions.
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3.3
3.3.1

Results
Group Differences
All samples passed a Kolmogorov-Smirnov normality test with p > 0.05. We

report as follows all significant differences found; significant differences were not
detected within either time period for all features not reported below. Within the 2–5
month follow-up time interval, the mean density within the GGO regions was
significantly different between the RILI and recurrence groups (p=.035). Patients with
recurrence had significantly denser GGO regions with a mean (±SD) density of -602.01 ±
59.54 HU compared to those with RILI of -659.16 ± 55.93 HU. The mean values of the
second-order texture features including energy (p=.036), entropy (p=.034), and inertia
(p=.036) were significantly different between the recurrence and RILI groups during this
time period. Patients with recurrence had significantly larger entropy (9.27 ± 0.65) and
inertia (54.59 ± 25.85) values, and significantly lower energy (0.0021 ± 0.0015) values
compared to patients with RILI (entropy = 8.66 ± 0.56, inertia = 33.42 ±15.84, and
energy = 0.0034 ± 0.0012); all p < 0.05.
Within the 5–8 month time interval, the mean first-order texture feature
(measured as the SD of CT densities) within the GGO regions was significantly different
between the RILI and recurrence groups (p=.0019). Patients with recurrence had a more
variegated first-order texture within the GGO with a mean (± SD) variability of 213.63 ±
21.79 HU compared to those with RILI of 173.52 ± 30.40 HU. An illustrative example is
shown in Figure 3-4, where a more variegated texture is demonstrated in (h) with a higher
SD, compared to a smoother texture in (e) which has a lower SD. Patients with
recurrence also had significantly denser consolidation regions (p=.021), mean density of -
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84.66 ± 72.34 HU compared to -158.28 ± 65.42 HU for those with RILI. The mean
values of the second-order texture features including energy (p=.031), entropy (p=.015),
inertia (p=.018), and correlation (p=.0025) were significantly different between the
groups at this time point. Patients with recurrence had significantly larger entropy (9.24 ±
0.55) and inertia (56.20 ± 17.24) values, and significantly lower energy (0.0020 ±
0.0012) and correlation (0.0069 ± 0.0012) values compared to those patients with RILI
(entropy = 8.69 ± 0.34, inertia = 38.50 ± 13.80, energy = 0.0031 ± 0.00081, and
correlation = 0.011 ± 0.0036).
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Figure 3-4: Sample texture images and their corresponding second-order energy,
entropy, and first-order (standard deviation [SD] of densities) texture values. Samples (ad) show artificial examples and (e-h) show images taken from lung tissue. The plots show
the change of each feature in the specified image relative to those in the leftmost image
(a) or (e).
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3.3.2

Classification Performance
Figure 3-5 shows the means and standard deviations of the overall errors, FNRs,

and FPRs for each of the measures using 2-fold CV. The top three predictors were all
second-order texture features within the GGO. GGO energy had the lowest prediction
error of 23% (corresponding to 77% prediction accuracy) on 2-fold CV followed by
GGO entropy and inertia with errors of 24-26%, compared to 40% and 42% error with
the longest axial diameter and 3D volume respectively. The first-order measure also
performed similarly with 27% 2-fold CV error, but had a larger standard deviation. The
longest axial diameter and volume size measures were outperformed by all of the
appearance measures, except for the cluster shade and cluster prominence second-order
texture features. Of our top performing texture features, GGO energy had the largest
FPRs but the lowest FNRs. GGO inertia had the most balanced FNR and FPR. Overall,
the two size measures had the lowest FPRs, but highest FNRs.
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Figure 3-5: (a) Cross validation errors, (b) false positive rates, and (c) false negative
rates for 2-fold cross validation. Glyphs indicate mean values, the error bars indicating
the standard deviation over the 100 repetitions.

In 2-fold cross validation, the errors, FPRs, and FNRs were compared for all
possible feature pairings using a Wilcoxon signed rank test for nonparametric data in
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SPSS (p ≤ 0.05 indicative of statistical significance) since not all of these samples passed
a Kolmogorov-Smirnov normality test with p < 0.05. The size measures of longest axial
diameter and volume had a significantly higher median 2-fold cross validation error
when compared to each of the appearance measures, except each with cluster
prominence. The longest axial diameter was also significantly different from the volume
measure. There was no significant difference between the median errors for energy and
entropy. First-order texture had a significantly different median error compared to all
second-order features, except correlation and inertia. All other pairings were significantly
different from one another. No significant difference was detected between the FPRs at 2fold cross validation for energy vs. entropy, first-order texture vs. inertia, and first-order
texture vs. longest axial diameter. There was also no significant difference detected
between the FNRs for IDM vs. entropy, correlation vs. entropy, and cluster shade vs.
cluster prominence. All other combinations were significantly different in terms of their
median FPRs and FNRs.
The top two features in terms of 2-fold classification error were: GGO energy and
GGO entropy. To explore these features in more detail and to compare them with size
measures, scatter plots of the recurrence and RILI patients in feature space, as well as
receiver operating characteristic (ROC) curves, are shown for GGO energy and entropy
(Figure 3-6) and solid volume and longest axial diameter (Figure 3-7). Figure 3-6 indicate
that the two classes are approximately equally separable in both feature spaces (by each
feature alone), with few outliers from both classes, whereas Figure 3-7 indicates
substantially poorer class separation by longest axial diameter and solid volume; the ROC
curves shown in the figures corroborate these observations. The AUCs for all measures at
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this 2–5 month time interval are shown in the first column of Table 3-3. GGO energy and
correlation produced the largest AUCs of 0.81 (energy is shown in Figure 3-6b), whereas
the size measures of longest axial diameter and volume produced AUCs of 0.716 and
0.652 respectively (shown in Figure 3-7c). GGO entropy and the first-order texture
feature also performed similarly to energy and correlation in terms of AUC. Overall,
energy was the best performer in terms of 2-fold cross-validation and AUC, with an error
of 22.7% and AUC of 0.81.
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Figure 3-6: (a) All lesions plotted by their energy and entropy values within the GGO at
2–5 months post treatment. Red circles indicate patients with recurrence and blue crosses
indicate those with benign injury. Qualitative example images of the patients indicated
by arrows are shown in Figure 3-9. (b,c) The corresponding ROC curves for the linear
classifier on each feature alone; AUC = 0.809 for energy and AUC = 0.800 for entropy.
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Figure 3-7: (a) All lesions plotted by their solid (consolidative volume) and longest axial
diameter at 2–5 months post treatment. Red circles indicate patients with recurrence and
blue crosses indicate those with benign injury. (b,c) The corresponding ROC curves for
the linear classifier on each feature alone; AUC = 0.716 for longest axial diameter and
AUC = 0.652 for 3D volume.
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Table 3-3: Areas under the receiver operating characteristic curve (AUC) for each
feature
AUC
Feature
2 to 5 Months

5 to 8 Months

Energy

0.809

0.875

Entropy

0.800

0.808

Inertia

0.782

0.800

First-order texture

0.791

0.867

Correlation

0.809

0.875

Density

0.764

0.667

Inverse difference moment

0.764

0.750

Cluster Prominence

0.709

0.758

Cluster Shade

0.618

0.675

Longest axial diameter

0.716

0.723

Volume

0.652

0.723

Due to the need to predict recurrence as early as possible after SABR treatment,
we were most interested in features providing useful performance during the earlier 2–5
month time interval. To evaluate the repeatability of these measures at a later time
interval on the same patients, we measured their performance during the 5–8 month time
interval. The mean 2-fold cross validation error of GGO energy and entropy performed
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within ±3% of the 2–5 month time interval. Longest axial diameter showed improvement
in error measurements of 3%. In terms of the AUCs at the 5–8 month time period (shown
in second column of Table 3-3), the top first and second-order texture features performed
similarly or better compared to the 2–5 month interval. Longest axial diameter and
volume also performed similarly to the 2–5 month interval.

3.3.3

Correlation of Measures
Spearman rank correlation coefficients were computed in SPSS to determine any

dependence or relationship among or between the first and second-order texture features
in our study. The correlations of GGO energy, entropy, and the first-order texture feature
are shown in Table 3-4. We also measured the correlation of these texture features with
the volume of the analyzed GGO region, as shown in Table 3-4. At 2–5 months postSABR, the highest correlation was observed with energy and entropy, with a coefficient
of -0.969; this correlation is apparent in Figure 3-6. In general, the second-order texture
features were better correlated with each other than they were with the first-order
measure. This pattern held at the 5–8 month time period, but overall all correlations
decreased at this time point. We observed no statistically significant correlations of the
texture features with the 3D volumes of the GGO regions.
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Table 3-4: Spearman rank correlation coefficients and significance values for features
within the ground-glass opacity
2 to 5 Months
Correlation
Coefficient

Significance

5 to 8 Months
Correlation
Coefficient

Significance

Energy vs. Entropy

-0.969*

< 0.001

-0.919*

< 0.001

Energy vs. First-Order

-0.936*

< 0.001

-0.687*

< 0.001

0.919*

< 0.001

0.583*

0.004

GGO Volume vs. Energy

-0.171

0.457

-0.302

0.172

GGO Volume vs. Entropy

0.062

0.788

0.064

0.778

GGO Volume vs. First-

0.243

0.289

0.382

0.079

Texture
Entropy vs. First-Order
Texture

Order Texture
* Correlation is significant at the 0.01 level

3.3.4

RECIST Progressive Disease Criteria for Prediction
The overall accuracy of RECIST for predicting tumour recurrence at 2–5 months

post-SABR was 52.2%, with a FNR of 25% and FPR of 72.7%. At 5–8 months postSABR, RECIST provided an accuracy of 65.2%, with a FNR of 45.5% and FPR of
27.3%. To measure whether a recurrence threshold other than the 20% increase given by
the current RECIST guidelines would provide better performance, we trained the linear
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classifier on our entire data set, using the percentage increase in longest axial diameter.
The classifier found optimal decision points higher than the RECIST guideline of 20%,
placing the decision boundary at 49% for 2–5 months and 77% at 5–8 months with
overall errors of 52.2% and 34.8%, respectively.

3.3.5

Sensitivity of GGO Delineation
Receiver operating characteristic curves were produced on the expanded and

contracted GGO regions for classification using each of the top feature sets at the 2–5
month time interval. Figure 3-8 shows the sensitivity of the AUC for prediction of
recurrence for our top first and second-order texture features based on these variations in
GGO delineation. After contraction of the regions by 1 or 2 mm, the first and secondorder texture features remained constant or decreased by 0.06 from their respective AUC
values in the manual GGO. This decrease is likely due to the fact that many of the lesions
had a small total volume of GGO, so a contraction of even 2 mm resulted in a large
volume loss and the remaining region may not have provided sufficient voxel samples for
a robust calculation of the texture features. With an expansion of the GGO up to 5 mm,
the AUC values for all texture features remained constant with slight fluctuations across
each level of expansion. First-order texture had fluctuations in its AUC up to 0.04,
whereas the AUC for energy remained constant, throughout all levels of expansion. The
AUCs for entropy were also stable, with a decrease of 0.06 at 3 mm, but returned to
baseline at 4–5 mm. By 5 mm, all features remained within 0.04 of their respective
baseline values from the manual GGO region. This demonstrates the robustness of the
AUC measure at each level after GGO boundary contractions and expansions, suggesting
robustness to variability in GGO delineation.
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Figure 3-8: Sensitivity of the area under the receiver operating characteristic curve
(AUC) for prediction of recurrence at 2-5 months post-SABR based on variations in
GGO delineation. The vertical dashed line indicates the AUC values for the manual
GGO delineation.

3.4

Discussion
Early detection of recurrence following SABR is critical to allow eligible patients

to undergo salvage therapies, including surgery, chemotherapy, or possibly additional
radiotherapy. Since CT scanning is the standard follow-up imaging modality, quantitative
analyses of these images that are predictive of recurrence in individual patients at an early
time point post-treatment could have great potential for translation to routine clinical use.
This study has demonstrated the ability, based on texture measures of the GGO in CT
images taken within 6 months of SABR treatment (within a 2–5 month interval following
treatment), to predict patients’ eventual cancer recurrence after SABR treatment of early111

stage non-small cell lung cancer. This study also demonstrated that appearance changes
in these regions precede changes in size of the consolidative/solid regions.
Previous studies have shown that current approaches to the interpretation of CT
imaging are insufficiently accurate for clinical use in detection of local recurrence [31,
32]; accurate prediction of eventual recurrence within 6 months of treatment is supportive
of salvage intervention. Although an increasing opacity on CT has shown to be
indicative of recurrence, this feature is accurately predictive based on imaging acquired
after 12 months post treatment [11]. FDG-PET alone or in combination with CT findings
has also demonstrated the ability to detect recurrences more than a year post-treatment
[33, 34]. However, one study has shown that residual FDG-PET uptake 12 weeks post
treatment, with an SUV greater than or equal to 5.0, signifies an increased risk of local
recurrence (sub hazard ratio for high SUV of 7.3) [35]. A recent study looked at texture
features of the gross tumour volume on pre-treatment diagnostic CT scans (in a PET/CT
context) of patients with stage IA–IV NSCLC being treated with SABR or conventional
radiotherapy treatment [36]. Although the study did not find significant correlation of
texture features with loco-regional recurrence, it was noted that motion artefact
mitigation may be important to the prediction of local recurrence. In the context of the
results of the Vaidya et al. study, our results suggest that assessment of the first follow-up
scan, motion artefact mitigation, and analysis of the GGO region may be important to
prediction of failure. To the best of our knowledge, this is the first study to show early
prediction (within 6 months of SABR treatment) of eventual cancer recurrence based on
measurements derived from CT imaging alone.
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Our decision to use second-order statistical texture measures was motivated by a
qualitative observation of differences between patient groups that appears to be related to
vascularity in the GGO regions, ranging from smooth to variegated appearance through
small numbers of larger vessels to larger numbers of small vessels. As these patterns
may vary in terms of the number and magnitude of transitions from low to high density as
one travels voxel-by-voxel through the image, we surmised that GLCM-based texture
measures could capture such neighbourhood relationships explicitly, giving a relatively
direct (and therefore understandable) quantification of this qualitative observation. In
addition, there is previous literature showing the utility of GLCM-based texture features
with lung pathologies [13, 14]. Thus, for this exploratory study, we limited our
investigation to this small number of more established texture features, leaving a more
comprehensive study of a larger number of texture features within the scope of future
work in the context of a larger sample size.
We observed that second-order texture features within the GGO were the most
accurate in predicting recurrence within the early 2–5 month time period. Measures of
size, and appearance measures within the consolidative regions, were not as accurately
predictive during the same time period. The most useful features in our study were
second-order energy and entropy which were shown to be highly correlated. The utility of
the first-order texture feature in differentiating recurrence from RILI also suggests the
importance of overall intensity variations within the GGO along with local, second-order
variations. The effectiveness of the second-order energy feature suggests that variations
in the spatial uniformity of densities within the GGO may be important for prediction.
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Energy and entropy are measures related to orderliness and how neighbouring
pixels are organized. An ordered image is one in which the same pixel intensity pairs
occur more frequently; this results in a few GLCM cells with higher values, compared to
an unordered image where neighbouring pixels have different intensities throughout the
image, resulting in more GLCM cells with lower values [37]. Energy increases with a
more ordered image and, as indicated in Table 3-2, is weighted by the sum of squared
elements in the GLCM. Entropy is weighted by the logarithm of the elements in the
GLCM, which is also known as a statistical measure of randomness in the GLCM,
decreases with a more ordered image, and is negatively related to energy. The difference
between energy and entropy is in the weights put on the GLCMs, with energy increasing
with orderliness and entropy increasing with disorder.
To illustrate the intuitive meanings of these features, Figure 3-4 shows sample
texture images; artificial examples and qualitatively corresponding CT image samples of
the lung. The resulting first-order texture, and second-order energy, and entropy values
are shown for each example. A more ordered or constant image, for example reflecting a
single vessel (Figure 3-4 a and e), results in relatively high energy and low entropy
values, as compared to the other sample images in Figure 3-4. As the number of vessels
increases, the first-order SD texture feature is either constant (Figure 3-4 a-c) or produces
non-monotonic changes (Figure 3-4 e-g) but second-order energy is monotonically
changing. In the lung image samples, as the number of vessels increases, energy
consistently decreases and entropy consistently increases. However, note that in Figure
3-4 g and h, the different patterns in the lung are better differentiated with the first-order
SD feature. Overall, we can observe that the first-order texture measure is sensitive to
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overall changes in contrast, but is less sensitive to the spatial arrangement of contrasting
elements (e.g. it does not differentiate well between one large vessel and multiple smaller
ones, such as depicted in Figure 3-4 a-c). The second-order measures are sensitive to the
spatial relationships of these contrasting elements, since they take pixel neighbourhoods
into account.
We observed that patients with recurrence have lower values of energy and higher
values of entropy, suggesting that GGO patterns closer to Figure 3-4 (c) and (g) within
the GGO are predictive of recurrence. To illustrate the qualitative meaning of varying
energy values in the context of the recurrences and RILI cases in our data set, Figure 3-9
shows four sample lesions from our study, sorted by increasing energy values in the GGO
from (a) to (d). The lesion locations in feature space can also be observed in Figure 3-6,
where Figure 3-9 (a) and (d) are at both extremes for energy values and thus easily
separated, but Figure 3-9 (b) and (c) are much similar and harder to classify. The
qualitative differences in GGO appearance between Figure 3-9 (a) and (d) are readily
apparent, with the recurrence case in (a) having substantially greater variegation of image
texture and contrast between the vasculature and the background, and (d) having an
overall smoother GGO appearance. By comparison, the recurrence in Figure 3-9 (b) and
the RILI in Figure 3-9 (c) are more difficult to qualitatively distinguish, and this is
reflected in their more similar GGO energy texture values. We speculate that these
observed differences (e.g. between Figure 3-9 (a) and (d)) may represent an increase in
vasculature within these regions in the recurrence cases (e.g. Figure 3-9 (a)), perhaps
indicating there are early vascular changes occurring which may eventually lead to a
recurring tumour. Patients with RILI had a more homogenous GGO with fewer evident
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vessels. At this early time point following treatment, this perhaps indicates the presence
of fibrotic tissue and other cells involved in the pathological response of radiation
pneumonitis following radiotherapy [38]. Future work including histological
examinations of these regions would be useful toward elucidating the tissue composition
of these regions and thus the meaning of our imaging observations.
(a)

(b)

(d)

(c)

Recurrence

Recurrence

RILI

RILI

Energy = 0.00086

Energy = 0.0023

Energy = 0.0026

Energy =0.0048

Figure 3-9: The 2–5 month scans for four lesions in our study. The solid curves enclose
consolidative regions and the dotted curves enclose ground-glass opacity (GGO) regions.
Images of patients who had eventual cancer recurrence are shown in (a) and (b), and
images of patients who developed RILI are shown in (c) and (d). The energy values in the
GGO for these lesions progressively increased from (a) through (d). Their locations in
feature space can be seen in Figure 3-6. (a) and (d) are at relative extremes in feature
space on the recurrence and RILI sides, respectively, and are qualitatively distinct. (b)
and (c) are examples of recurrence and RILI cases that are closer to the expected decision
boundary, and are more difficult to distinguish qualitatively.

The results of this study must be considered within the context of its strengths and
limitations. Although the sample size is small, this is one of the largest series of
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recurrences in a study determining treatment outcomes post-SABR. Even with the small
sample size, prediction accuracies remained robust using 2-fold cross validation;
however, validation of all results on a larger data set must be performed and this study
should be considered as hypothesis-generating. Intra and inter-observer variability in
region of interest delineation was also not directly measured in this study; however, the
robustness of our measures with expansion and contraction of the GGO suggests that
variability in delineation has minimal impact on these measures for predicting recurrence.
We also did not consider the effects of any co-morbidities, such as chronic obstructive
pulmonary disease (COPD), respiration, or variations in blood flow on lung density [39].
Any variations between scanners and reconstruction techniques which may affect density
measurements were also not considered [40]; however, all image acquisition parameters
were set consistently to minimize any variations. In terms of the texture analysis, it may
be valuable for future work to include a more extensive set of texture features and
classifiers for analysis.
In conclusion, we have demonstrated the ability of first and second-order image
texture features to predict eventual cancer recurrence based on CT images acquired
within 5 months of SABR treatment with accuracies greater than 77% using a linear
classifier. These appearance measures outperformed any measure of size during the same
time interval, where accuracies of approximately 60% could be achieved. However,
further validation of these results is needed on a larger sample size. We are also
investigating a faster and more reproducible delineation or sampling method of the GGO
regions to allow for clinical translation to a useful computer-aided diagnosis tool. The
impact of these early measures on a clinician’s diagnosis of RILI versus recurrence, as
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well as potential effects on clinical decision making must also be addressed in a user
study. This could eventually prevent unnecessary, invasive, and risky procedures for
patients with only benign disease and allow for the early salvage therapy for patients with
recurrence.
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Chapter 4
Towards the goal of understanding if semi-automated segmentation methods can be used
in this decision support system, we evaluated a semi-automated graph cuts based
approach to segment and sample regions of post-SABR radiological changes to be used
to predict local recurrence following SABR.
The contents of this chapter were previously published in the Journal of Medical
Imaging: SA Mattonen, S Tetar, DA Palma, AV Louie, S Senan, and AD Ward. Imaging
texture analysis for automated prediction of lung cancer recurrence after stereotactic
radiotherapy. J Med Imag 2015; 2(4):041010. Permission to reproduce this article was
granted by the SPIE and is provided in Appendix A.5.

4

IMAGING TEXTURE ANALYSIS FOR AUTOMATED
PREDICTION OF LUNG CANCER RECURRENCE
AFTER STEREOTACTIC RADIOTHERAPY

4.1

Introduction
Stereotactic ablative radiotherapy (SABR) (also known as stereotactic body

radiotherapy) is now the guideline-recommended treatment for patients with non-small
cell lung cancer (NSCLC) who are medically inoperable or refuse surgery [1, 2].
Compared with conventional radiotherapy techniques, SABR involves the treatment of
small lung tumours with higher doses per fraction in fewer fractions. Typically doses of
up to 18 Gy per fraction are delivered in between 3-8 fractions over 1–2 weeks, in
contrast to a dose of 2 Gy per day delivered over 4–6 weeks in conventional radiotherapy
techniques. The higher doses used in SABR has led to local control rates of up to 90% at
3 years post-treatment, similar to those reported after surgery [3, 4]. However, radiation
induced lung injury (RILI), such as radiation fibrosis, can occur after SABR. Some forms
of benign changes can appear with similar size and shape to a recurring tumour on
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computed tomography (CT) imaging, which is routinely acquired every three months as
part of follow-up care. This confounds the critical clinical decision to provide potentially
life-saving additional salvage therapies in cases where the cancer is recurring after
SABR.
Present guidelines recommend the use of serial CT scans for follow-up after
SABR, with the use of 18-fluorodeoxyglucose positron emission tomography (FDG-PET)
imaging used only when appropriate [5]. FDG-PET is recommended when recurrence is
suspected on CT; however, due to the high number of false positive findings on PET,
patients eligible for salvage treatment should undergo a biopsy if feasible [5]. Qualitative
image assessment has also been performed on CT images following SABR, and a highrisk feature set has been developed to discriminate benign fibrosis from recurrence [6, 7].
These features include an enlarging opacity, sequential enlargement from one scan to the
next, a bulging margin, loss of linear margin, and air bronchogram loss. However, these
features typically do not manifest until 1 year post-SABR [6].
Our overarching goal is to develop a fully automated system that will classify a
CT image as recurrence or RILI, supporting the decision to prescribe salvage therapy to
SABR patients with recurring tumours. This system will not require any manual
delineation other than that which is performed during the normal clinical workflow, and
will produce operator-independent, reproducible classification results. Quantitative
radiomic image analysis has been increasingly utilized on CT, magnetic resonance
imaging (MRI), and PET for differentiation of tumour types, grades, and for response
assessment across many disease sites [8, 9]. Texture analysis has been investigated in
predictive modeling of radiation pneumonitis after definitive lung radiotherapy [10]. It
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has also been described for predicting the development of radiation pneumonitis after
definitive radiotherapy for esophageal cancer [11, 12]. Cunliffe et al. compared
radiologist-defined severity of normal tissue damage with CT texture features [11]. In an
additional study, they demonstrated the ability to differentiate patients with and without
clinical radiation pneumonitis by measurements of dose-dependent texture change
between pre- and post-radiotherapy CT images [12]. To the best of our knowledge, these
are the only papers present in the literature measuring CT texture for benign radiation
induced lung injury. Our previous work presented in Chapters 3 evaluated quantitative
CT image texture analysis for early prediction of recurrence after SABR [13, 14]. We
have shown that second-order texture features based on grey-level co-occurrence
matrices (GLCM) calculated within manually delineated ground-glass opacity (GGO)
regions can predict recurrence within 6 months post-SABR. The regions of GGO refer to
hazy regions of increased attenuation in the lung within which vascular regions can still
be visualized, and these regions typically surround the consolidative mass. Texture
features within these regions showed 2-fold cross-validation (CV) errors of 23–30% and
areas under the receiver operating characteristic curve (AUC) of 0.78–0.81 [13]. As seen
in Figure 4-1, patients with benign injury tended to have a smooth GGO appearance
compared to a variegated appearance in patients with recurrence.
However, there are two main limitations to clinical translation of this technique.
First, although inter-operator variability in manual segmentations on radiographic images
is a well-known problem, little is known about predicting recurrence based on texture
feature analysis within GGO segmentations performed by different operators [15]. As
GGO boundaries are often barely discernible, it is reasonable to expect substantial inter-
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operator variability. Second, manual 3D segmentation of the GGO is time-consuming,
and automated GGO segmentation is extremely challenging due to the lack of any shape
regularity and difficulty, even for the human medical expert, in judging the locations of
the weak GGO boundaries. Inspired by our previous observation that a peri-consolidative
region (defined by a concentric expansion of the consolidative mass) intended to sample
GGO tissue yielded comparable classification performance to manually-delineated GGO
[14], we conjectured that accurate classification performance could be obtained using an
automatically-defined peri-consolidative region, rendering a complete GGO segmentation
unnecessary.
Based on these observations and challenges, our primary objectives in the current
study are as follows. First, we aim to measure the accuracy of texture features for
predicting recurrence based on the first 3 month follow-up scan, with a peri-consolidative
region derived from a semi-automatic segmentation of the consolidative region [16]. This
decision support system would eliminate the need for any time consuming manual
segmentations. Although the segmentation algorithm is semi-automatic, its only input is
the Response Evaluation Criteria in Solid Tumours (RECIST 1.1) line segment, which is
routinely obtained as part of the clinical imaging workflow; no additional user interaction
is required [17]. We also aim to determine the reproducibility of the system’s
segmentations recurrence predictions to inputs from different operators. Finally, we aim
to compare the classification performance to manually delineated segmentations.
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(B)

(A)

(C)

(D)

Figure 4-1: The 2–5 month follow-up image for four patients in our study. The solid
lines encompass consolidative changes and the dashed lines encompass regions of
ground-glass opacity, as delineated by a senior radiation oncology resident. The two
lesions which developed benign radiation induced lung injury are shown in (A) and (B),
and qualitatively the ground-glass opacity regions have a smooth appearance. (C) and (D)
show two lesions that eventually developed cancer recurrence and in these images a
variegated texture is visible in the ground-glass opacity regions.

4.2
4.2.1

Methods
Materials and Imaging

A total of 24 lesions from 22 patients treated for stage I NSCLC with SABR at the VU
University Medical Center, Netherlands between February 2004 and February 2010 were
used for this study. Of these 24 lesions, 11 were defined as local recurrences based on
biopsy confirmation (8/11) and/or ultimate clinical outcome (3/11). The remaining 13
lesions developed moderate to severe radiological RILI CT changes based on expert
assessment and had at least two years of imaging follow-up. These 13 RILI cases were
chosen because they were especially challenging to distinguish from recurrences based
on the first follow-up scan; for such cases computer-assisted decision support was
deemed to have greatest potential value in the clinical context. The proportion of
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recurrences is artificially inflated in this data set, and the true rate of local recurrence for
a typical stage I NSCLC cohort is around 10% [3, 4]. During follow-up, 46 posttreatment diagnostic CT scans were taken at the first two follow-up time periods (2–5 and
5–8 months) post-SABR on one of three scanners at the VU Medical Center: Siemens
Volume Zoom 4-slice, Siemens Sensations 64-slice (Siemens Nederland N.V., Den Haag,
Netherlands) or Philips Brilliance iCT 256-slice (Royal Philips Electronics, Inc.,
Amsterdam, Netherlands). To eliminate the effect of image acquisition parameters on
quantitative image analysis, all follow-up scans were acquired with the same acquisition
parameters at inspiratory breath hold, 120 kVp, 100 mAs, spiral acquisition, 0.5 second
rotation time, 2.5–5 mm slice thickness, with 70 cc of intravenous contrast (Ultravist300; Bayer Pharma AG, Berlin, Germany) administered with a 25 second delay. Iterative
reconstruction was not used in this imaging dataset and a standard sharp lung convolution
kernel was applied (B60f) with 0.5–0.9 mm isotropic in-plane voxel dimensions.

4.2.2

Region of Interest Segmentation

4.2.2.1

Lung Regions

The regions of the image containing normal lung parenchyma can be obtained for
the planning CT scan as part of the contouring normally performed during the radiation
therapy planning workflow and mapped by image registration onto follow-up scans, or
through the use of several automatic segmentation algorithms [18-21]. Although this step
is outside of the scope of our method, for the purposes of reproducibility, we are
providing the procedure that we followed to obtain this segmentation for each of our
scans. Normal lung parenchyma was automatically segmented in ITK-SNAP (Version
2.4.0) using region competition snakes [22]. For trachea-adjacent tumors, the trachea was
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separately segmented superior to the carina. A 3D rectilinear region of interest was
defined encompassing the segmentation target (the entire lung volume or the trachea) and
pre-processed using a sigmoid function, implemented as the intensity region filter in ITKSNAP, with the threshold set above -300 HU and smoothness of 1.00. One or more
spheres within the region of interest were used for initialization of the region competition
snakes and were evolved using a sparse field level set [14, 23]. Parameters for the
segmentation were set as follows: curvature velocity weight of 0.20, propagation force of
1.0, and 1500 and 250 iterations for the lung and trachea respectively. Post-processing
was performed in MATLAB 8.4 (The Mathworks Inc., Natick, MA, USA) by a slice-wise
morphological filling of small vessels or artifacts less than 10mm2 within plane. This
ensures larger vessels and any large consolidative components are not included in the
normal lung parenchyma. A whole-lung volume was achieved by manually filling in the
normal lung parenchyma to fill any abnormal consolidative regions.

4.2.2.2

Manual Segmentation of Consolidation and GGO

Segmentations were performed by a resident in radiation oncology (operator 1) on
all follow-up CT images in ITK-SNAP 3.0 [24]. A lung window setting (level/window 600/1500 HU) and the paintbrush tool or polygon outline were used. A mediastinal
window setting (level/window 50/450 HU) was also used for tumours or fibrosis abutting
the mediastinum. Consolidation changes were defined as an increased density with
respect to normal surrounding lung with no visibility of vasculature within. GGO was
defined as an increase in normal lung density with visibility of vasculature within. The
segmentations were randomly checked by a thoracic radiation oncologist. The time
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required to manually complete the consolidation and GGO segmentations was also
recorded on a subset of images.

4.2.2.3

Semi-Automatic Segmentation of Consolidation

An overview of our semi-automatic segmentation approach can be seen in Figure
4-2. In the current clinical workflow, a physician measures the lesion’s longest axial
diameter based on RECIST criteria to determine treatment response [17]. Since these
measurements are taken during the normal clinical workflow by the physician; we use
them as initializations for the segmentation algorithm. Specifically, the endpoints of the
RECIST segment on the CT image serve as the only operator inputs to the segmentation
algorithm. These line segments allow for localization of our post-SABR consolidative
regions of interest on the follow-up scan eliminating the need for any deformable
registration to localize the area from the planning scan.
The recently published OneCut graph cuts algorithm was used to segment the
consolidative regions [25, 26]. This algorithm finds the segmentation that minimizes the
L1 distance between unknown object and background appearance models. The variation
of this algorithm that uses seeds for initialization minimizes the energy function
𝐸(𝑆) = −𝛽�𝜃 𝑆 − 𝜃 𝑆̅ �𝐿1 + |𝜕𝜕|,

where 𝑆 is the segmentation, 𝜃 𝑆 and 𝜃 𝑆̅ are the distributions of object and background

intensities, respectively, and 𝛽 is a tuning parameter (0.05 in our experiments)

determining the relative contributions of the L1 intensity model difference and the
segmentation perimeter length to the overall energy. In practice, 𝜃 𝑆 and 𝜃 𝑆̅ are

represented as histograms with a specified number of bins (64 in our experiments). The
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(1)

tuning parameter was determined using a subset of 4 images (2 RILI and 2 recurrence)
spanning differences in size, shape, and appearance of the consolidative regions. The
input RECIST line segments used to tune the parameter was separate from the RECIST
line segments used to validate the algorithm. The OneCut approach globally minimizes
this energy function with a single graph cut and is particularly suited to our problem
given its speed, its natural incorporation of object and background seeds as input, and its
demonstrated superior performance to the closest competing GrabCut method [27] for
bin counts > 20, allowing for segmentation of objects having more subtle intensity
differences from background [25]. The foreground seeds were defined as voxels greater
than or equal to a threshold of -200 HU within a sphere 𝐴, centered at the midpoint of the
RECIST segment, with a diameter equal to the length of the RECIST segment plus 10

mm. The background seeds were defined as all voxels within normal lung parenchyma,
not within sphere 𝐴, and within a sphere 𝐵 centered at the midpoint of the RECIST

segment with a diameter equal to the length of the RECIST segment plus 20 mm. The
OneCut segmentation was performed on each slice (mapping the lung window/level
range of -1350 to 150 HU to an 8-bit range) within a region of interest (ROI) centered on
and enveloping the background seeds. Any parts of these segmentations lying outside of
the whole lungs (in cases where the consolidation abutted the lung boundary) were
removed and the 3D largest connected component closest to the RECIST line was taken.
Due to the inclusion of small adjacent vessels in the 3D volume, a subsequent slice-byslice 2D largest connected component was taken to remove these disconnected vessels in
plane. Finally, the 3D largest connected component was taken as the final consolidation
segmentation volume.
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Image with
Foreground and
Background Seeds

Automatic
Consolidation
with OneCut
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Figure 4-2: An overview of our semi-automatic segmentation approach and the methods
used in this chapter. On the original CT image, an operator places a RECIST line
segment to measure the longest axial diameter (taken in the normal clinical workflow).
This was used as initialization for the OneCut algorithm to automatically obtain the
consolidation segmentation (red). An expansion of this region defined the periconsolidative region (blue). On the original CT image manually delineated consolidation
and ground-glass opacity (GGO) regions were also obtained. Texture analysis was
performed in the GGO and semi-automatic peri-consolidative regions, and classification
results were compared using 2-fold cross validation errors, false positive rates (FPR),
false negative rates (FNR), and area under the receiver operating characteristic curve
(AUC).

To validate our algorithm and assess the impact of inter-operator variability on
segmentation and classification performance, three operators provided RECIST
measurements of the consolidative changes post-SABR. If the consolidation region was
split into more than one disconnected region, a separate measurement was taken for each
region. Validation was performed with typical users of the system, including a senior
radiation oncology resident (operator 1) and two thoracic radiation oncologists (operators
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2 and 3). To avoid biasing the results, none of the operators in this study contributed to
the design of the semi-automated segmentation algorithm.

4.2.2.4

Automatic Delineation of Peri-Consolidative Region

A peri-consolidative region within the lung parenchyma was derived
automatically by thresholding the 3D distance transform of the consolidation
segmentations. The threshold was set at 16 mm based on our previous observation that
classification performance does not differ substantially from that given by the
corresponding manually delineated GGO above this threshold [14]. The domain was also
restricted to a sphere, centered at the midpoint of the RECIST segment, with a diameter
equal to the length of the RECIST segment plus 32 mm (16 mm × 2). This is due to the
possible inclusion of connected vessels distant to the consolidative mass or extra
consolidative regions erroneously included in the semi-automatic segmentation. A sphere
defined by the RECIST line segment will, by definition, circumscribe the lesion; this
shape was chosen to enable concentric sampling of the tissue outside of the consolidative
mass. We want to ensure we are sampling the peri-consolidative region adjacent to the
treatment site and avoiding sampling additional normal lung distant to the consolidative
mass. The size of the sphere was chosen to encompass the entire RECIST line plus a 16
mm margin on each end, which was chosen for consistency with the 16 mm threshold
used for expansion from the consolidative mass. An example of a resulting periconsolidative region is seen in Figure 4-2.

4.2.3

Feature Extraction and Image Analysis
MATLAB 8.4 (The Mathworks, Natick, MA) was used to calculate first-order

texture as the standard deviation of the density within the GGO or peri-consolidative
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region. The Insight Segmentation and Registration Toolkit (ITK) 4.3.1 (www.itk.org)
was used to calculate four second-order texture features based on a gray level cooccurrence matrix (GLCM): energy, entropy, inertia and correlation [28-30]. The
equations for calculation of these texture features are
Energy = ∑𝑖,𝑗 𝑔(𝑖, 𝑗)2 ,

(2)

Entropy = − ∑𝑖,𝑗 𝑔(𝑖, 𝑗) log 2 𝑔(𝑖, 𝑗) or 0 if 𝑔(𝑖, 𝑗) = 0,
Correlation = ∑𝑖,𝑗

(𝑖−𝜇)(𝑗−𝜇)𝑔(𝑖,𝑗)
𝜎2

, and

Inertia = ∑𝑖,𝑗(𝑖 − 𝑗)2 𝑔(𝑖, 𝑗),

(3)
(4)
(5)

where 𝑔 is a two-dimensional matrix where each element 𝑔(𝑖, 𝑗) contains the number of
voxel pairs whose elements have gray levels 𝑖 and 𝑗, where 𝜇 is the weighted pixel
average

𝜇 = ∑𝑖,𝑗 𝑖 ∙ 𝑔(𝑖, 𝑗) = ∑𝑖,𝑗 𝑗 ∙ 𝑔(𝑖, 𝑗) (due to symmetry of 𝑔),

(6)

𝜎 = ∑𝑖,𝑗(𝑖 − 𝜇)2 ∙ 𝑔(𝑖, 𝑗) = ∑𝑖,𝑗(𝑗 − 𝜇)2 ∙ 𝑔(𝑖, 𝑗) (due to symmetry of 𝑔).

(7)

and 𝜎 is the weighted pixel variance

The number of bins and density ranges in the GLCM were set to yield 20 HU bin widths
between -1000 HU and 200 HU (60 bins), based on analysis of the histogram
distributions within manually delineated GGO regions. GLCMs were calculated within
four in-plane neighbouring voxel pair directions [(-1, 0, 0), (-1, -1, 0), (0, -1, 0), (1, -1, 0)]
for the entire 3D region of interest and texture features were averaged over all directions.
When calculating a GLCM, the neighbouring voxel to be analyzed must be specified by
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the distance and location (in the x, y, and z directions) from the reference voxel. An
example of the four in-plane neighbouring voxel relationships is shown in Figure 4-3.
Due to the voxel anisotropy typically seen in post-radiation follow-up lung CT images (5
mm slice thickness), we did not analyze through-plane directions in this study. Features
were analyzed within two discrete time periods: 2–5 and 5–8 months post-SABR. This
timing of images was chosen as the focus of our study is on the early prediction of
recurrence post-SABR. Within each time period, the images used for analysis spanned all
22 patients and 24 tumours available.
(-1, -1, 0)

(0, -1, 0)

(1, -1, 0)

(-1, 0, 0)

Figure 4-3: The four in-plane spatial relationships used for calculating the gray level cooccurrence matrix (GLCM). The dark central voxel is the reference voxel, and the
neighbouring voxels considered in the analysis are shown in gray.

4.2.4

Classification
PRTools 5.0 (Delft Pattern Recognition Research, Delft, The Netherlands) was

used for classification. For a stringent determination of classification performance, twofold CV over 1,000 repetitions was performed using a linear Bayes normal classifier. The
mean and standard deviation of the classification error, false negative rates (FNRs), false
positive rates (FPRs), and AUCs were measured, where recurrence is defined as positive.
Classification performance was measured for all five extracted texture features in both
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the automatically-defined peri-consolidative regions and the manually-delineated GGO
regions.

4.2.5

Comparison of the Semi-Automatic Segmentations
To compare the segmented regions between operators, similarity metrics were

calculated to measure segmentation differences. The symmetric mean absolute boundary
2 |𝑉𝐴 ⋂ 𝑉𝐵 |
�,
𝐴 | + |𝑉𝐵 |

difference (MAD), Dice similarity coefficient (DSC) � |𝑉
𝑇𝑇

𝑇𝑇

volume difference

(VD) (𝑉𝐵− 𝑉𝐴 ), recall �𝑇𝑇+𝐹𝐹�, and precision �𝑇𝑇+𝐹𝐹� were calculated, where 𝑉𝐴 and 𝑉𝐵

are the volumes of the segmentations by operator A and B, respectively, and 𝑇𝑇 = true

positive, 𝐹𝐹 = false positive, 𝑇𝑇 = true negative, and 𝐹𝐹 = false negative. Segmentation
metrics were calculated on all of the images used in this study. Each metric was
calculated on the same 3D image volume between operators. Calculation of
segmentations differences was completed between all operators for the semi-automated
consolidative regions. Due to the lack of a reference operator when comparing
segmentations between operators, the F1 score was calculated to eliminate the effect of
reference operator selection on precision and recall metrics. The F1 score is the harmonic
mean of the precision and recall and can be used to measure the segmentation
𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝∙𝑟𝑒𝑒𝑒𝑒𝑒

accuracy �2 ∙ �𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝+𝑟𝑟𝑟𝑟𝑟𝑟��. Additionally, the time to generate the manual and semiautomatic segmentations was measured and compared.

4.2.6

Statistical Analysis
All statistical analyses were completed in SPSS Statistics Version 22.0 (IBM

Corp., Armonk, NY, USA). To compare segmentation differences between operators, a
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Kolmogorov-Smirnov test was first completed to test for normality of distribution for all
the measures. A Wilcoxon signed rank test for nonparametric data was used to compare
differences between operators (two-sided with alpha ≤ 0.05). To compare classification
performance between operators, an independent samples t-test with unequal variances
was performed to test the null hypothesis that the mean classification performance
between operators was equal. Due to the repeated sampling in the cross-validation
metrics (1000 times), to correct for multiple testing a Bonferroni correction was applied
with alpha ≤ 0.05/1000. To determine non-inferiority of the semi-automated classification
results with respect to results obtained using the manual segmentations, the 95%
confidence interval of the difference in cross-validation metrics was assessed. An
inferiority margin of 5% was chosen as an acceptable clinical difference in crossvalidation metrics.

4.3
4.3.1

Results
Manual Segmentations
Classification performance at 2–5 months post-SABR using texture features

within manually delineated GGO regions is shown in Figure 4-4. We examined
classification results within this early time range, as we want to determine the ability to
predict recurrence as early as possible post-SABR. The top-performing feature in terms
of 2-fold CV error was entropy. At 2–5 months post-SABR, the mean 2-fold CV error
was 27.4%, with a mean FPR and FNR of 29.5% and 25.3% respectively, and an AUC of
0.64. For comparison, the AUC value at 5–8 months post-SABR was 0.67 and is shown
in Table 4-1. A 5–8 months post-SABR, the entropy feature demonstrated a 2-fold CV
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error of 30.0%, mean FPR of 25.2% and mean FNR of 36.2%. A qualitative
representation of the manually delineated regions of interest is provided in Figure 4-1.
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Error (%)

80%

*
*

*
*

0.9
0.8

70%

0.7

60%

0.6
*

50%
40%

*

*

*
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0.4
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(Manual)

AUC
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30%

0.3
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(Semi-auto)

20%

0.2

10%

0.1

Operator 3
(Semi-auto)

0%
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FPR

FNR

AUC

0

Entropy

Figure 4-4: Classification performance of the manual GGO and semi-automatic periconsolidative regions for the top-performing texture feature (entropy) at 2–5 months postSABR. The columns indicate the mean 2-fold cross-validation errors, mean false positive
rates (FPR), mean false negative rates (FNR), and the area under the receiver operating
characteristic curve (AUC). The whiskers indicated the standard deviation over 1,000
repetitions and each color represents a different operator. The asterisks indicate a
statistically significant difference between operators (p < 0.00005).
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Table 4-1: Area under the receiver operating characteristic curve for the top texture
feature (entropy) at both time points post-SABR
2–5 months

5–8 months

Operator 1 (Manual)

0.64 ± 0.04

0.67 ± 0.04

Operator 1 (Semi-auto)

0.73 ± 0.06

0.71 ± 0.05

Operator 2 (Semi-auto)

0.70 ± 0.04

0.67 ± 0.07

Operator 3 (Semi-auto)

0.71 ± 0.05

0.69 ± 0.07

4.3.2

Semi-Automated Segmentations

4.3.2.1

Segmentation Comparison

Similarity metrics for the semi-automatic consolidative segmentations are
summarized in Table 4-2. The majority of the metrics failed a Kolmogorov-Smirnov test
for normality, and therefore the median values are reported. A Wilcoxon signed rank test
for nonparametric data was performed to test the null hypothesis that the medians of each
group are equal. Overall, when using the semi-automatic approach, inter-operator
variability was low with values for the F1 score ranging from 0.87–0.93 and boundary
differences from 1.00–1.75 mm. Operator 3 showed the largest variability with
significant differences in all four metrics. However, the volume overlap (DSC)
measurements still showed high overall agreement in the segmentations, with values of
0.87–0.93. Qualitative examples for all of the operators’ semi-automatic segmentations
are shown in Figure 4-5.
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Table 4-2: Inter-operator variability in the semi-automatic consolidative segmentations;
all values are reported as the median [interquartile range].

Operator

1 vs 2

1 vs 3

2 vs 3
*#

MAD bilateral
(mm)

Volume
F1 Score

DSC

Difference
(cm3)

1.18

0.90

0.90

-1.66#

[0.31, 2.62]

[0.78, 0.98]

[0.78,0.98]

[-17.91, 0.33]

1.75*

0.87*

0.87*

-10.56*#

[0.60, 3.19]

[0.74, 0.97]

[0.74, 0.97]

[-22.86, -1.68]

1.00*

0.93*

0.93*

-3.57*

[0.45, 2.13]

[0.81, 0.97]

[0.81, 0.97]

[-13.58, 0.06]

Indicates significant differences between rows, p < 0.05

(1) Radiation-induced lung injury
Follow-Up
Planning

(2) Recurrence
Planning

Follow-Up

Operator 1

Operator 1

Operator 2

Operator 3

Operator 2

Operator 3

Figure 4-5: The pre-treatment lesion used for treatment planning and a 3-month followup scan showing the radiological changes post-SABR for a patient with radiation-induced
lung injury (1) and recurrence (2). Semi-automated segmentations of the consolidative
regions (red) and peri-consolidative regions (blue) surrounding them. Operators 1, 2 and
3 are shown for each case.
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4.3.2.2

Classification Performance

Classification performance at 2–5 months post-SABR within the automatically
derived peri-consolidative regions is shown in Figure 4-4 for the top feature (entropy).
Using these segmentations, entropy had mean 2-fold CV errors of 24.7-27.8% across all
three operators. Operator 1 had a significantly lower mean 2-fold error compared to
operators 2 and 3. There was no significant difference in mean errors between operators 2
and 3. Overall, the decision support system based on semi-automatic segmentations
produced balanced FPRs and FNRs of 25.8-30.6% and 23.5-25.3% respectively. There
was no significant difference in the mean FNRs between any of the operators. All three
operators had significantly different mean FPRs, however differences were all ≤ 5%. At
2–5 months post-SABR entropy had AUC values between 0.70-0.73 for all operators,
which was significantly different between all operators. For comparison, the AUC values
at 5–8 months post-SABR are shown in Table 4-1 and were between 0.67–0.71 for all
operators. At this time point, the entropy feature had 2-fold CV errors of 22.8-31.3%,
mean FPRs of 21.6-23.3% and mean FNRs of 22.8-43.9%.

4.3.3

Comparison of System Performance: Manual vs Semi-Automatic
Segmentations

4.3.3.1

Classification Performance

Comparison of classification performance at 2–5 months post-SABR using the
manual and semi-automatic decision support systems is shown in Figure 4-4.
Classification using the semi-automated method was compared to classification
performance using the manual delineations performed by the senior radiation oncology
resident. Using the semi-automatic segmentations, the entropy texture feature produced
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AUCs higher than the manual contours for all three operators. All AUC values using the
semi-automated approach were significantly different from reference manual contours. In
terms of mean 2-fold error, operator 1 demonstrated a significantly better performance
compared to their manual segmentations. There was no significant difference in
classification performance between the manual and the semi-automatic segmentations by
operators 2 and 3. There were also no significant differences with respect to the FNRs.
However, operators 1 and 3 produced significantly lower FPRs compared to the manual
segmentations, whereas no difference was observed with respect to operator 2. A noninferiority study was completed to determine if the semi-automated approach was noninferior to the manual approach. Figure 4-6 shows the 95% confidence intervals of the
differences between the semi-automated and manual classification metrics. Noninferiority was demonstrated for all metrics as the 95% confidence intervals fell within
clinically acceptable differences of 5%. At 5–8 months post-SABR the AUC and 2-fold
errors values were similar to 2–5 months. Results were also consistent between the
manual and semi-automated systems, with AUC values within 0.04 and 2-fold errors
within 7%. Overall, classification results showed robustness using the semi-automatic
approach and were comparable to or exceeded the results using manually delineated
regions. Individual feature values for the recurrence and injury groups, as well as all
classification metrics are summarized in Appendix C, Table C1 and C2.
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(A)
(i)
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-5%
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(B)
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Figure 4-6: Non-inferiority analysis for the difference between means (semi-automated –
manual) for the classification error metrics (A) and area under the receiver operating
characteristic curve (AUC) (B). The markers indicate the mean differences and the
whiskers represent the 95% confidence intervals. The vertical dashed lines represent an
acceptable clinical difference of 5% for all metrics.
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4.3.3.2

Timing

The average time (± SD) for operator 1 to manually delineate the consolidative
and GGO regions on each image (for a subset of 20 images) was 579 ± 472 seconds (i.e.
9.6 ± 7.9 minutes). The semi-automatic approach took 27 ± 25 seconds to obtain the
consolidative and peri-consolidative regions on each image. The increase in segmentation
speed was 20-fold, with an average savings of 9 minutes per image.

4.4

Discussion
The ability to distinguish benign fibrosis from tumor recurrence is crucial in

determining a patient’s care following SABR, and determine whether salvage surgery or
additional radiotherapy is required. Current clinical guidelines recommend the use of
serial CT imaging for follow-up assessment after treatment with SABR. Therefore, a
reliable measure for determining recurrence on CT imaging would be extremely valuable
as the utilization of SABR is rapidly increasing. The use of quantitative appearance
measures could provide an early assessment of response through quantifying subtle
patterns predictive of recurrence not typically considered by a radiologist or radiation
oncologist.
Our work in Chapter 3 has shown that the entropy texture feature calculated
within manually delineated regions of GGO could predict recurrence with 2-fold CV
errors of 24% at 2–5 months post-SABR [13]. The results presented in this study using
manual segmentations by a different operator were concordant, with an error of 27%.
There exist radiographic changes to the tissue surrounding the consolidative regions as a
result of SABR (as shown in Figure 4-1), which can cause a substantial loss of boundary
contrast. These observations provide important context for the evaluation of automatic
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segmentation algorithms for consolidation regions on post-SABR lung CT images by
quantifying the uncertainty inherent in the manual reference standard. GGO regions can
also have a highly variable appearance and an ill-defined border, rendering them very
challenging to delineate. This emphasizes the difficulties in delineating these regions and
lack of a single ground truth reference standard segmentation for this problem. To
eliminate the need for time consuming manual segmentations and any inherent variability
between them, the goal of this study was to produce an accurate and reproducible means
of recurrence prediction post-SABR using semi-automatic segmentations.
This work has shown the ability to predict recurrence post-SABR using texture
analysis in regions delineated by means of a semi-automated segmentation algorithm,
initialized using only the RECIST diameter measurement that is normally collected
during the clinical workflow. This diameter measure on post-SABR follow-up scans is
assessed according to the RECIST 1.1 criteria by comparing it to the pre-treatment scan
[17]. Consequently, it provides a quick and efficient means for initialization of our
decision support system. It will also guarantee localization of our post-SABR
consolidative regions of interest regardless of deformations and retractions from the pretreatment location. We also considered that in the typical clinical workflow, the RECIST
line segment would be taken by the radiologist reading the CT image and would be
external to our workflow. In other words, we would obtain this line segment when we
obtain the follow-up image, leading to a fully automatic overall system based on semiautomated segmentation.
We reported small differences between the semi-automated segmentations
obtained from each operator. This is due to variability in the placement of the RECIST
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line segment. It has been well described that substantial variability exists, both between
and within operators, in the measurement of response in lung cancer patients [31, 32].
This variation can be seen in the placement of line segments measuring longest axial
diameter according to RECIST guidelines. This can be particularly evident in the postSABR context due to the highly variable size and shape of the consolidative masses (they
are not typically spherical as is commonly the case for pre-treatment tumors) as shown in
Figure 4-1. Consequently, it can be difficult to determine the correct location on which to
place the line segment. However, the differences we observed in the physical placement
of the line segment had a minor impact on the graph cuts algorithm, since the foreground
and background samples (as shown in Figure 4-2) are likely to vary only slightly. The F1
scores were all greater than 0.85, suggesting high inter-operator agreement in the semiautomatic consolidative regions.
As mentioned previously, the GGO surrounding the consolidative regions on
follow-up images decreases the boundary contrast of the consolidation. Overcoming the
loss of contrast using smoothness and/or shape priors may not be straightforward, given
the non-smooth and highly variable shapes of the consolidative regions (as seen in Figure
4-1). Most importantly however, this semi-automatic segmentation provides basis for the
automatically-defined peri-consolidative region. As shown in Figure 4-5, the periconsolidative regions are in general dissimilar to the manual GGO regions seen in Figure
4-1. This is intentional, as our intention is to sample a region surrounding the
consolidative regions within which to calculate the texture features. Our previous work
demonstrated that sampling a region surrounding the consolidative region was sufficient
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for predicting recurrence, and that a complete segmentation of GGO was not required
[14].
Our system shows high predictive accuracy using the second-order entropy
texture feature with AUCs of 0.70–0.73 at 2–5 months post-SABR. It was also robust to
inter-operator variability in the initialization of the system by placement of the RECIST
diameter measurement. Although classification performance using the semi-automated
method was compared only against a single operator’s manual segmentations, noninferiority was demonstrated among all three operators. Robustness in classification
performance was also demonstrated among operators, suggesting a reproducible means
for delineating the consolidative regions even with variations in RECIST line segment
placement among operators. Our semi-automatic approach potentially eliminates the need
for manual segmentations and this provides an important avenue for future work on a
larger dataset as part of our ongoing work. Results at 5–8 months post-SABR were
comparable to the results at 2–5 months post-SABR. This demonstrates stability of
system performance through time, and also demonstrates that the appearance of
radiological changes at the two earliest clinically scheduled follow up time points
(approximately 3 and 6 months) could be important in predicting recurrence. As
previously demonstrated in patients with recurrence, these regions have a more
variegated texture, perhaps indicative of early vascular changes as seen in Figure 4-1.
Patients who develop only benign fibrosis seem to have a more homogenous appearance
to the GGO, or minimal appearance of GGO changes post-SABR. Our ongoing work is
examining these regions of post-SABR changes histologically, to determine their
composition and correlate this to observations on CT imaging.
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Previous studies using qualitative high-risk appearance features have shown the
utility of categorizing a patients risk of recurrence, however most of these features do not
typically appear until a year post-treatment [6]. Other imaging-based features such as size
or mass-like shape can be ineffective for early detection of local recurrence post-SABR
[33-35]. FDG-PET has also been investigated for distinguishing fibrosis from recurrence
post-SABR and it has been shown that maximum standardized uptake values (SUVmax)
can be predictive of recurrence, but not until a year post-SABR [36, 37]. A recent
approach using CT perfusion imaging for response assessment has been investigated for
pulmonary metastases undergoing SABR; however, further analysis is needed in a larger
cohort of patients [38]. The combination or addition of these techniques to our decision
support system may be useful for aiding in the assessment of difficult cases.
To the best of our knowledge, there has been no previous study on semi-automatic
segmentation of post-SABR consolidative changes on CT. An interesting avenue for
future work would be in refining these segmentations to enable quantification of shape
and size changes of these regions. Another interesting area of further study could look at
additional methods for segmentation. One such possibility is using the tumour delineation
on the planning scan and performing a deformable registration to the follow-up scan.
Such an approach would be fully automated but would require highly accurate
deformable registration capable of compensating for highly variable and localized postSABR radiological changes. This would also need to compensate for tissue retractions
that can occur in the lung post-SABR, displacing the consolidations from their original
locations in the planning scan. Nevertheless this would be an interesting future study and
would be considered a fully automated method, eliminating the impact of variability in
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RECIST line segment placement by different physicians. However, our initial work has
shown robustness of the decision support system to differences in line segment placement
by different operators.
We must consider our study in the context of its limitations, including the small
sample size of patients with significant benign fibrosis. Our ongoing work involves
validation on a larger sample set of patients matched based on patient and treatment
characteristics. This will allow for a more comprehensive analysis of post-SABR
changes. This study also focused solely on our previously published top five texture
features for recurrence prediction, and further work on a more compressive radiomic
feature set and machine learning platform may improve prediction results on a larger data
set. The focus of this study was on the early prediction of recurrence and images analyzed
at 3 and 6 months post-SABR. Further studies should be completed on additional time
points to determine the usefulness of image features for recurrence prediction as time
post-SABR increases and to determine the optimal time point for prediction. This study
also did not consider the effect of different scanners and reconstruction techniques in the
analysis; however, all images were taken with the same acquisition and reconstruction
parameters to minimize discrepancies [39]. Determining the effect of different acquisition
parameters on classification results is an interesting avenue for future study. Also,
reference manual contours for classification were completed by a single operator and the
validation of our semi-automated algorithm was completed with only 3 operators with
similar expertise. Further validation should be completed with additional operators with
different expertise (ex. radiologists or senior radiation oncologists) who would be
considered typical users of this time of algorithm. Another limitation of the current work
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is the use of the same imaging dataset as used in Chapters 2 and 3. Using the same small
dataset could potentially introduce bias into our results. To enable clinical translation, a
comprehensive validation and user study on a larger dataset is ongoing.

4.5

Conclusion
Second-order texture features calculated within GGO delineated from a semi-

automated algorithm, initialized using only the RECIST diameter measurement routinely
taken during the clinical workflow, have shown the potential to predict recurrence in
individual patients within 6 months of SABR. At 2–5 months post-SABR, second-order
entropy provided good recurrence prediction based on semi-automatic segmentations,
with AUCs of 0.70–0.73; the corresponding result using a manual segmentation was 0.64.
This system demonstrated consistent segmentations and prediction accuracies between
operators, which were concordant with prediction accuracies, based on a single reference
manual segmentations and obtained 20 times faster using the automated approach. The
next step of this study is to validate our algorithm on an additional 93 patients we have
obtained. This work has the potential to lead to a clinically useful computer-aided
diagnosis tool which can be easily integrated into a physician’s workstation and eliminate
the need for any manual segmentation. An automated decision support system can
improve the physician’s assessment of response following SABR to predict recurrences
as early as possible. This will allow patients to receive timely salvage therapies, and
reduce the risk of patients with only benign fibrosis undergoing risky biopsy procedures.

4.6
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Chapter 5
Towards the goal of understanding how physicians perform in response assessment postSABR, we evaluated and compared a radiomics decision support system to physician
assessment of response following SABR.
The contents of this chapter were previously published in the ernational Journal of
Radiation Oncology* Biology* Physics: SA Mattonen, DA Palma, C Johnson, AV Louie,
M Landis, G Rodrigues, I Chan, R Etemad-Rezai, TPC Yeung, S Senan, and AD Ward.
Detection of local cancer recurrence after stereotactic ablative radiotherapy (SABR) for
lung cancer: physician performance versus radiomic assessment. Int J Radiat Oncol Biol
Phys 2016;94(5):1121-28. Permission to reproduce this article was granted by Elsevier
and is provided in Appendix A.6.

5

DETECTION OF LOCAL CANCER RECURRENCE
AFTER SABR FOR LUNG CANCER: PHYSICIAN
PERFORMANCE VERSUS RADIOMIC ASSESSMENT

5.1

Introduction
Stereotactic ablative radiotherapy (SABR) is a guideline-recommended treatment

option for patients with early-stage lung cancer who are medically inoperable or refuse
surgery [1, 2]. SABR can achieve local control rates comparable to surgery of 90% at 3
years post-treatment [3]. However, following treatment with SABR, patients often
develop benign radiation-induced lung injury which can mimic recurrence. In some cases
this leads to resection for lesions ultimately proven to contain only fibrotic tissue [4-7].
Early detection of patients with local recurrence using standard follow-up computed
tomography (CT) images may allow for timely salvage surgery, which has been shown to
be feasible in such patients [8, 9]. Accurate recurrence detection may avoid unnecessary
scans and interventions in patients harboring only benign fibrosis.
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Local recurrences typically manifest at a median time of 15 months following
SABR, but may present up to 5 years later [10]. Qualitative high-risk CT features (HRFs)
have been validated as predictors of recurrence, and include the presence of an enlarging
opacity, enlargement after one year, sequential enlargement from one scan to the next,
bulging margin, linear margin disappearance, air bronchogram loss, and cranio-caudal
growth [11-13]. However, such HRFs are subject to inter-observer variability, and may
not be observable until beyond 1-year post treatment [12].
Radiomics is a developing area of research that aims to extract more complex
information from conventional medical images, including features not easily visible or
quantifiable with the naked eye. These features can be used to build models for clinical
outcomes, including diagnostic, prognostic, or predictive information [14, 15]. We
hypothesize that radiomic image features could improve prediction accuracies by
detecting subtle imaging changes not observed by a physician. In recent pilot studies, we
demonstrated the ability of quantitative CT image analysis for early prediction of
recurrence after SABR [16-18]. Texture features calculated within areas intended to
subsample post-SABR ground-glass opacity could predict recurrence at 3-months postSABR, with areas under the receiver operating characteristic curve (AUC) of 0.78–0.81.
However, a limitation to clinical translation of this technique was the small dataset and
limited set of radiomic features used.
To our knowledge, no prior studies have assessed either physician performance or
inter-physician variability and reliability in detecting recurrence after SABR. The goals
of this study were to determine the accuracy of expert radiologists and radiation

155

oncologists’ assessment of local recurrence versus non-recurrence on a series of followup CT images post-SABR, and to compare physician performance to a radiomics tool.

5.2

Methods and Materials

5.2.1

Materials and Imaging
The study population consists of patients with T1/T2N0 non-small cell lung

cancer (NSCLC) treated with SABR. 15 patients with local recurrence were matched 1:2
with patients without recurrence, but with radiological radiation-induced lung injury
(RILI), according to baseline factors including planning target volume (PTV) size,
tumour location, and fractionation as previously described [12]. These tumours were
treated to a dose of 54–60 Gy in 3–8 fractions, using a risk-adapted approach, as
described previously [19]. Of the 15 patients with local recurrence, seven recurrences
were confirmed with biopsy and the remaining eight were determined local recurrences
based on a combination of CT, FDG positron emission tomography (PET) findings and
subsequent clinical outcomes. The maximum inspiration phase of respiration was used
for analysis on the pre-treatment planning CT image. Standard follow-up practices were
to acquire diagnostic CT images at 3, 6, and 12 months post-SABR and every 6-12
months thereafter, although the actual timing of scans were subject to normal clinical
variability. Matched patients were required to have follow-up CT imaging at similar time
intervals and durations.
Pre-treatment CT scans used for treatment planning were acquired for each
patient using four-dimensional (4D) CT (Lightspeed 16; GE Medical Systems,
Waukesha, USA) at 140 kVp, 100–110 mAs, and 2.5 mm slice thickness. The maximum
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inspiration phase of respiration was used for analysis. Post-treatment diagnostic CT scans
were taken on one of three scanners: Siemens Volume Zoom 4-slice, Siemens Sensations
64-slice (Siemens Nederland N.V., Den Haag, Netherlands) or Philips Brilliance iCT
256-slice (Royal Philips Electronics, Inc., Amsterdam, Netherlands). Follow-up scans
were acquired at inspiratory breath hold with standard imaging parameters of 120 kVp,
100 mAs, spiral acquisition, 0.5 second rotation time, 2.5–5 mm slice thickness, and 70
cc of intravenous contrast (Ultravist-300; Bayer Pharma AG, Berlin, Germany)
administered with a 25 second delay.

5.2.2

Observer Performance
Three thoracic radiation oncologists specializing in treatment of NSCLC with

SABR (observers 1–3) and three board-certified thoracic radiologists (observers 4–6), all
of whom were blinded to outcomes, were asked to score all follow-up images as either
benign injury/no recurrence or local recurrence. Data collection was completed using an
in-house developed user interface in ClearCanvas Workstation 2.0 (Synaptive Medical,
Toronto, Canada), as shown in Figure 5-1. All images were anonymized and randomized
for each observer.

157

Figure 5-1: In-house developed user interface in ClearCanvas Workstation 2.0
(Synaptive Medical, Toronto, Canada) for data collection in observer study.

The custom-made interface in ClearCanvas was developed to mimic the clinical
assessment of sequential scans over time. The interface first provided the physician with
the planning CT scan to localize the pre-treatment lesion. After reviewing the planning
scan, the first follow-up image was displayed. The physician was required to then provide
an assessment (no recurrence vs. recurrence), and indicate the certainty level of the
assessment on an ordinal scale (none, somewhat, moderately, very, or completely
certain). Physicians were then asked to recommend the immediate next step for this
patient (ignoring any non-local signs of disease); options included ongoing CT follow-up
at standard or shorter time interval, biopsy, PET, or immediate salvage therapy. After
entering these data, the responses were locked and the next follow-up image was shown.
Assessments were made sequentially on all follow-up images available for each patient.
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Observers were able to return to earlier scans in order to assess sequential changes, but
could not modify responses. They also had full control over the interface to view and
assess images at their own speed and adjust the window/level settings as needed.
Observers were also provided written and verbal instruction prior to the reading session
informing them of the task required, number of cases to be read and expected duration.
To mitigate the assumption of a clinical prevalence of 10% local recurrences, observers
were informed that the series of 45 patients contained 30–40% local recurrences. Of note,
the term recurrence has been used throughout the chapter, although early assessment
could indicate persistent disease.
At the first time point post-SABR, overall accuracy, false positive rate (FPR), and
false negative rate (FNR) for physician assessment was measured. Sensitivity and
specificity for assessing recurrence was also measured across all time points and
available images. Fleiss' kappa was used to measure the reliability of agreement in all
observations, across all six raters [20, 21]. Fleiss kappa is a measure of agreement
between more than two raters giving categorical ratings, where agreement due to chance
is factored out. A kappa less than or equal to 0 indicates poor agreement with agreement
increasing as kappa approaches 1 (slight agreement=0.01-0.20, fair=0.21-0.40,
moderate=0.41-0.60, substantial=0.61-0.80, and almost perfect agreement=0.81-1.00)
[21]. Statistical analyses were completed in MATLAB 8.4 (The Mathworks, Natick, MA)
with statistical testing at the 0.05 significance level.
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5.2.3

Radiomic Analysis
Consolidative and peri-consolidative regions were delineated based on our semi-

automated method, previously described in Chapter 4 [17, 18]. Briefly, on all follow-up
CT images the tumour’s longest axial diameter based on Response Evaluation Criteria in
Solid Tumours (RECIST 1.1) is measured during the normal clinical workflow and this is
used to initialize the segmentation algorithm [22-24]. Further details pertaining to the
region of interest delineation are outlined in Chapter 4. Examples of segmented
consolidative and peri-consolidative regions are shown in Figure 5-2.
A custom radiomics and machine learning platform developed in-house was used
to extract features from the consolidative and peri-consolidative regions using MATLAB
8.4. In total, 22 first-order features and 22 second-order grey-level co-occurrence matrix
(GLCM) textures were calculated in both regions. The number of bins and density ranges
for the GLCMs were set to yield 20 HU bin widths with densities between -1000 HU and
200 HU (60 bins) for the peri-consolidative regions and -600 HU and 200 HU (40 bins)
for the consolidative regions. Due to the voxel anisotropy in post-SABR follow-up
images, GLCMs were calculated within four in-plane neighbouring voxel directions [(1,1,0), (-1,0,0), (0,1,0), (-1,-1,0)] within the 3D segmented volume, and texture features
were averaged over all directions. Additionally, in the consolidative regions, 16 size- and
shape-based features were calculated. These features were not calculated in the periconsolidative regions as these regions’ sizes and shapes are defined according to the size
and shape of the consolidation region and therefore would not be independent
measurements. In total, 44 features were extracted from the peri-consolidative regions
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and 60 features from the consolidative regions, for a total of 104 features per image
volume.

(1) Local recurrence
(A)

(B)

(2) Benign radiation induced lung injury
(C)

(D)

Figure 5-2: The 3-month post-SABR follow-up image for two patients who developed
local recurrence (A and B) and two patients who developed only benign injury (C and D).
The corresponding semi-automated consolidative (red) and peri-consolidative (green)
segmentations are also shown.
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Features were analyzed within the earliest follow-up time point post-SABR at 2–5
months, corresponding to the clinically scheduled 3-month follow-up scan. PRTools 5.0
(Delft Pattern Recognition Research, Delft, The Netherlands) was used for feature
selection and classification [25]. Leave-one-out cross validation (LOOCV) was used for
feature selection. At each fold of cross validation (CV), forward feature selection was
performed on the training dataset only to select the optimal feature set, using the 1nearest neighbour leave-one-out classification performance. A support vector machine
(nu algorithm, linear kernel) was used to evaluate classification performance [26]. Nu is
the regularization parameter which is the expected fraction of support vectors estimated
by the leave-one-out-error of the 1-nearest neighbour rule. For a direct comparison to
physician performance at 2–5 months post-SABR, classification error, FNRs and FPRs,
where recurrence is defined as positive, were calculated. Across all folds of cross
validation, a voting scheme was used to determine the most frequently selected features.
These features were chosen as the radiomic signature. Evaluation on the entire dataset
was completed by leave-one-out, 10-fold, 5-fold, and 3-fold CV to determine the impact
of different training and testing set sizes on classification performance. The AUC was
also determined for this dataset.

5.3
5.3.1

Results
Patient Baseline Characteristics
Baseline characteristics for all 45 patients are presented in Table 5-1. In total, 182

follow-up images were available for analysis with a median imaging follow-up of 20
months. The recurrence and non-recurrence patient groups were well matched, with a
median age of diagnosis of 70 years (range 59–84) and median PTV size of 38 cm3
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(range 4–158 cm3). The fractionation scheme, and proportion of patients with central
versus peripheral tumours, was also consistent across the groups.
Table 5-1: Baseline patient characteristics.
All Patients

Recurrence

No-Recurrence

(n = 45)

(n = 15)

(n = 30)

70 (59−84)

71 (60−84)

70 (59−84)

Tumour size (mm) – mean (SD)

34 (15)

35 (14)

33 (15)

Male – N (%)

32 (71)

11 (73)

21 (70)

Charlson score – mean (SD)

2.7 (1.8)

2.9 (1.3)

2.7 (2.0)

LUL

15 (33)

4 (27)

11 (37)

LLL

11 (24)

4 (27)

7 (23)

RUL

11 (24)

3 (20)

8 (27)

RML

2 (4)

2 (13)

0 (0)

RLL

6 (13)

2 (13)

4 (13)

Central

6 (13)

2 (13)

4 (13)

Peripheral

39 (87)

13 (87)

26 (87)

38 (4, 158)

38 (5, 144)

40 (4, 158)

Fixed Beam

37 (82)

12 (80)

25 (83)

Rapid Arc

8 (18)

3 (20)

5 (17)

3

12 (27)

4 (27)

8 (27)

5

21 (47)

7 (47)

14 (47)

8

12 (27)

4 (27)

8 (27)

Characteristic
Age – median (range)

Involved lobe – N (%)

Location – N (%)

PTV (cm3) – median (min, max)
RT technique – N (%)

Fractionation – N (%)
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5.3.2

Observer Performance
To determine the physicians’ ability to assess response over the entire course of

follow-up, the sensitivity and specificity for identifying a recurrence at any time point
during follow-up was assessed. Physicians had varying sensitivities and specificities for
making a diagnosis of recurrence as observed in Table 5-2. The median sensitivity for
physician assessment was 83.8% (range 67–100%) and median specificity was 75.0%
(range 67–87%) across all observers. There was only a moderate level of agreement
among all 6 observers, with a kappa value of 0.54 for all 182 assessments of recurrence
vs. no recurrence. In all cases, radiologists (observers 4–6) had lower specificity
compared to radiation oncologists (observers 1–3), but on average radiologists had higher
sensitivity in detecting recurrence. The average time for each physician to first detect a
local recurrence correctly post-SABR was greater than one-year post-SABR. However,
radiologists were typically able to detect the recurrence earlier (mean of 13.4 months)
than the radiation oncologists (mean of 18.2 months).
Although observers were informed that the dataset contained 30–40% local
recurrences, the actual percentages of patients identified as recurrences varied among the
observers. All three radiation oncologists assessed 38% of the patients as having a
recurrence, consistent with the true percentage they were provided. However, all three
radiologists assessed 49–53% patients as having a recurrence; a higher percentage than
what was provided as truth.
The physicians’ certainty levels in their assessment varied substantially, with
almost no agreement between observers (Table 5-2). One radiation oncologist (observer
2) and the three radiologists (observer 4-6) tended to score the majority of images as very
164

or completely certain. Across all images, physicians’ certainty of assessment had a Fleiss
kappa of 0.06, indicating only slight agreement.
Table 5-2: Physician assessment of response post-SABR based on all follow-up images.
Radiation Oncologists

Radiologists

Observer Observer Observer Observer Observer Observer
1

2

3

4

5

6

Sensitivity

86.7%

80.0%

66.7%

80.0%

100%

100%

Specificity

86.7%

83.3%

76.7%

66.7%

70.0%

73.3%

Average Time to
Correctly Identify
Recurrences*, Months
(SD)

16.8
(10.6)

19.4
(9.9)

18.4
(10.8)

13.7
(5.7)

14.2
(7.0)

12.4
(7.0)

None

7
(3.8)

7
(3.8)

0
(0)

0
(0)

2
(1.1)

0
(0)

Somewhat

34
(18.7)

19
(10.4)

49
(26.9)

1
(0.5)

26
(14.3)

12
(6.6)

Moderately

63
(34.6)

23
(12.6)

50
(27.5)

32
(17.6)

50
(27.5)

33
(18.1)

Very

70
(38.4)

43
(23.6)

52
(28.6)

56
(30.8)

84
(46.2)

76
(41.8)

Completely

8
(4.4)

90
(49.5)

31
(17.0)

93
(51.1)

20
(11.0)

61
(33.5)

Certainty Level,
Number of Images (%)

*For each observer, the average time across all patients to first detect a true local
recurrence correctly. Abbreviations: SD: standard deviation.
Figure 5-3 depicts the recommendations made for the next clinical intervention
for each image dataset. Approximately 5% of all non-recurrence images (17 of 30
patients) were recommended for additional intervention with PET imaging. There were
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also 8 patients in which at least one observer recommended more invasive interventions
including biopsy or immediate salvage for patients with only benign injury. The interobserver agreement in terms of recommendation across all images had fair agreement
with a Fleiss kappa of 0.31.
100

Percent of Images (%)

90
80
70

Observer 1

60

Observer 2

50

Observer 3

40

Observer 4

30

Observer 5

20

Observer 6

10
0

NOREC

REC

NOREC

Biopsy

REC

CT Shorter

NOREC

REC

CT Standard

NOREC
PET

REC

NOREC

REC

Salvage

Figure 5-3: Inter-observer variability in follow-up recommendations across all follow-up
image for patients with (REC) and without (NOREC) local recurrence.

The ability of physicians to predict recurrence within six months of SABR (using
the 2–5 month follow-up scans) is shown in Table 5-3. At 2–5 months post-SABR, 38 of
45 patients had a CT image available for analysis. Physicians assessed the majority of
images this time point as benign injury/no recurrence, with a false negative rate of 100%
for five of six physicians. In 5 instances during this time period (of 228 total
assessments), a PET scan was recommended. In no scenarios was a biopsy or surgical
salvage recommended.
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Table 5-3: Leave-one-out cross-validation results of the radiomic signature compared to
physician assessment at 2–5 months post-SABR.
Radiation Oncologists
Radiomic Observer
signature
1

Radiologists

Observer

Observer

Observer

Observer

Observer

2

3

4

5

6

Error

23.7%

34.2%

34.2%

36.8%

34.2%

36.8%

31.6%

FPR

24.0%

0%

0%

4.0%

0%

4.0%

0%

FNR

23.1%

100%

100%

100%

100%

100%

92.3%

Percent
Very or
Completely
Certain

-

50%

100%

68%

100%

55%

95%

5.3.3

Radiomics Performance
To determine the final radiomic feature set for validation, the top features which

had votes in at least 80% of the feature selection folds (i.e. at least 30 votes) were chosen.
The top five most-selected features over CV folds were four features in the periconsolidative region (minimum grey-level, GLCM homogeneity, GLCM correlation, and
GLCM energy) and one feature in the consolidative region (grey-level uniformity) as
shown in Table 5-4. This left a total of five features in the radiomic signature.
Interestingly, nine of the top ten features were all appearance features within the periconsolidative region.
To assess the predictive power of this five-feature radiomic signature, folded CV
was performed. Leave-one-out CV produced an error of 23.7%, FPR of 24.0%, and FNR
of 23.1%. The results of leave-one-out, 10-fold, 5-fold, and 3-fold cross validation are
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shown in Figure 5-4. The radiomic signature demonstrated robustness to differences in
training and testing dataset size, with classification error increasing by only 8% from
leave-one-out to 3-fold CV. It also demonstrated balanced FPRs and FNRs, with the
exception of 3-fold CV. The AUC for this radiomic signature on this dataset was 0.85.
Examples of six correctly classified recurrence and injury cases in the LOOCV are shown
in Figure 5-5. A false positive and false negative case are also shown for comparison.
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Table 5-4: Top selected features at 2–5 months post-SABR based on leave-one-out
feature selection (38 folds).
Features

Equation

Region of Interest

Number
of votes

Minimum greylevel

The minimum intensity value of
the region of interest.

Peri-consolidative

32

Peri-consolidative

31

Peri-consolidative

31

Peri-consolidative

30

Consolidative

30

GLCM
homogeneity
GLCM
correlation

𝑁𝑔 𝑁𝑔

𝑃(𝑖, 𝑗)
��
1 + |𝑖 − 𝑗|
𝑖=1 𝑗=1

𝑁𝑔 𝑁𝑔

(𝑖 − 𝜇𝑖 )�𝑗 − 𝜇𝑗 �𝑃(𝑖, 𝑗)
��
𝜎𝑖 𝜎𝑗
𝑖=1 𝑗=1

Where:

𝑁𝑔 𝑁𝑔

𝜇𝑖 = � � 𝑖𝑖(𝑖, 𝑗)
𝑖=1 𝑗=1
𝑁𝑔 𝑁𝑔

𝜇𝑗 = � � 𝑗𝑗(𝑖, 𝑗)
𝑖=1 𝑗=1

𝜎𝑖2

𝑁𝑔

= �(𝑖 − 𝜇𝑖 )2 𝑃(𝑖, 𝑗)
𝑖=1
𝑁𝑔

2

𝜎𝑗2 = ��𝑗 − 𝜇𝑗 � 𝑃(𝑖, 𝑗)
GLCM energy

Grey-level
uniformity

𝑗=1

𝑁𝑔 𝑁𝑔

2

� � 𝑃(𝑖, 𝑗)
𝑖=1 𝑗=1
𝑁𝑙

2

� 𝑃(𝑥)

𝑥=1
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*Grey-level co-occurrence matrix (GLCM) features: 𝑃(𝑖, 𝑗, ) is the GLCM, 𝑁𝑔 is the

number of discrete grey level intensities, 𝑖 is the ith row of the GLCM, 𝑗 is the jth column

of the GLCM.

First-order features: P(x) is the intensity value of voxel x within the region of interest; x =

Error (%)

1, 2, 3, …, N, where N is the number of voxels within the region of interest.

50%
45%
40%
35%
30%
25%
20%
15%
10%
5%
0%

Leave-one-out
10-fold
5-fold
3-fold

Error

FPR

FNR

Figure 5-4: Results of folded cross-validation at 2–5 months post-SABR using the fivefeature radiomic signature.
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(1) Local recurrence
(C)

(D)

(2) Benign radiation induced lung injury
(E)
(F)
(G)

(H)

(A)

(B)

Figure 5-5: Example 2–5 month post-SABR scans for four patients who developed local
recurrence (A-D) and four who developed only benign injury (E-H). Correctly classified
recurrence (A-C) and injury patients (E-G) in LOOCV by the radiomic signature are
shown. A false negative (D) and false positive (H) patient are also shown.

5.4

Discussion
Surveillance following SABR for lung cancer is a major clinical challenge as

radiographic fibrosis can mimic local recurrence. Recent reports of patients undergoing
‘salvage resection’ for benign disease [4-6] underscore the difficulty in accurately
distinguishing recurrence from fibrosis. To our knowledge, this is the first study assessing
physician performance and accuracy in detecting local recurrence post-SABR. Overall,
physicians demonstrated high sensitivity (83%) and moderate specificity (75%) for
detecting recurrences, but the median time to detection of recurrence was 15.5 months. In
addition, 9.4% of scans in patients with only benign changes resulted in a
recommendation for further intervention with PET, biopsy, or immediate salvage
treatment. Physicians were generally unable to detect recurrences within 6 months of
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SABR. In contrast, radiomics assessment was able to correctly classify 76% of patients
using scans done <6 months post-SABR.
In our study, scans performed within 6 months post-SABR did not often result in
suspicion of local recurrence by physicians, and this finding is consistent with the
published literature on early post-SABR imaging. In a study examining the impact of
early post-SABR imaging within 6-months post-treatment in 62 patients, only 3% of
patients had changes on those scans that ultimately led to a diagnosis of early recurrence
[27]. Overall, we demonstrated the ability of physicians to detect recurrences at a later
time point, typically when the HRF’s become more salient on imaging. Agreement
between observers in terms of assessments of recurrence was only moderate and the
certainly level of assessments varied across all images and physicians. This suggests the
importance of a multi-disciplinary group discussion when assessing responses postSABR.
The appearances detected by radiomics may be early indicators of the disease
persistence and progression to local recurrence, which were not typically considered by
physicians. Radiomics could augment a physician’s assessment of response post-SABR
to potentially allow for earlier detection of recurrence post-SABR and fewer
investigations of only benign fibrosis. Future work includes measuring the performance
of the physician when provided with the output of the radiomics system. The importance
of radiomic appearance features in the peri-consolidative region supports the work
presented in Chapters 2-4 on the importance of features surrounding the consolidative
regions for recurrence prediction [16-18]. As seen in Figure 5-5, patients with recurrence
tend to have increased presence of ground-glass opacity surrounding consolidative
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changes compared to patients with benign injury. The false negative cases predicted by
radiomics tended to have minimal ground-glass opacity as seen in Figure 5-5(D) and
false positives tended to have a larger presence of ground-glass opacity as seen in Figure
5-5(H). These appearances were similar to those cases correctly classified by the
radiomics signature. Previous studies have also demonstrated the ability of CT texture
analysis for predicting the development of radiation pneumonitis [28]. Radiomic
signatures may identify patients in whom more frequent imaging, and regular reviews by
multidisciplinary tumour boards are warranted.
This study must be considered within the context of its strengths and limitations.
We used actual clinical cases with standard-of-care imaging follow-up, assessors were
blinded, and we used a large number (six) of expert observers. We used solely CT
imaging for physician assessment, however in clinical practice the patient’s clinical
information would be available and may be considered in their assessment, and additional
investigations, such as PET, could be ordered before proceeding to the next time point. In
this study, although physicians were able to assess images on their own time with their
preferred reading and room conditions, they were unable to obtain multidisciplinary
input. In addition, not all patients with recurrence had pathologic confirmation, as
pathologic confirmation of recurrence may not be possible in patients who are ill due to
comorbidities, or may not be pursued if no treatment options are available. Also, since
histologic patterns of recurrence post-SABR are still unknown, validation of our radiomic
signature with histology is needed. Future work includes the assessment of physician and
radiomic performance in the context of pathologic specimens for lung SABR patients
planned for surgical resection within 10 weeks of radiotherapy (MISSILE clinical trial,
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NCT02136355). This will involve correlating post-SABR CT changes with histologic
findings.
Regarding the radiomic signature, analysis was only performed at the early 2–5
month time point. Future studies should be completed on how radiomic performance
changes as time post-SABR increases. Although this is one of the largest series of
recurrences post-SABR, further validation of the radiomics signatures is needed on a
larger dataset. Another limitation of the current study is the use of a pre-validated
radiomic signature for comparison to physicians’. Future work includes measuring
radiomic performance on a separate validation set as well as prospective studies.

5.5

Conclusions
Physician assessment of post-SABR CT images shows high sensitivity and good

specificity, but median time to detection of recurrence is long, inter-observer agreement
is moderate, and unnecessary interventions are sometimes recommended for patients with
only benign changes. Although physicians generally perform poorly in detecting
recurrences within 6 months post-treatment, radiomic assessment demonstrates excellent
classification ability during that time point, with an AUC of 0.85. This suggests that there
are CT features predictive of recurrence that are not salient to the human expert at this
early, clinically-important time point. This radiomic tool has the potential to lead to a
clinically useful computer-aided decision support tool based on routinely-acquired CT
imaging, which could lead to earlier salvage opportunities and fewer unnecessary
invasive investigations of patients with only benign injury.
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Chapter 6
6

Conclusions and Future Directions

The final chapter of this thesis reexamines the research objectives and provides a
summary of the key findings and conclusions of Chapters 2-5.This chapter will also
address limitations of the current study and potential solutions. Finally, future directions
for response assessment following SABR are presented.

6.1

Overview of Rationale and Research Objectives
Stereotactic ablative radiotherapy (SABR) is now a guideline recommended

treatment option for patients with early-stage NSCLC [1]. SABR has demonstrated local
control rate similar to surgery of over 90% at 3 years follow-up [2, 3]. However, the
presence of substantial post-radiotherapy radiological changes are found on CT followup, which can appear with similar shape and size to a recurring tumour [4].
Misclassification of benign fibrosis as local tumour recurrence has been reported,
resulting in patients undergoing unnecessary and invasive surgical procedures to remove
only scar tissue [5]. Current approaches to aid in response assessment have focused on
qualitative high-risk features on CT imaging or metabolic imaging with FDG-PET, which
do not typically detect recurrence until after a year following treatment. There is currently
an unmet clinical need to provide timely and accurate assessment of response following
SABR for early stage NSCLC.
The recent introduction of radiomics, has demonstrated the ability to quantify
tumour phenotypes based on quantitative image features [6, 7]. This has the potential to
personalize patient care based on predicted responses to therapy and has the ability to
detect treatment failure at an earlier time point following treatment. In response to this
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unmet clinical need, we aim to develop a radiomics decision support tool to aid in
response assessment following SABR for early stage NSCLC. A means for predicting
recurrence on routine CT imaging within 6 months of treatment would allow for timely
intervention of recurrence, which typically manifests after 1 year [8]. Accordingly, the
overarching objective of this thesis was to develop a radiomic software system to aid in
treatment response assessment on follow-up CT after SABR.

6.2

Summary and Conclusions
In this thesis the overarching objective was evaluated by testing the following

central hypothesis: a radiomic software system will outperform physicians in the early
assessment of response post-SABR. Radiomics demonstrated the ability to predict local
recurrence with higher accuracy than physicians within 6 months of treatment. This thesis
has advanced knowledge and technology towards the improvement of response
assessment following SABR for early stage NSCLC. Prior to this work, there was no
study assessing a physician’s performance in distinguishing fibrosis from recurrence
following SABR for lung cancer. The use of quantitative image appearance features to
detect recurrence following SABR had also never been investigated.
Prior to the work presented in this thesis, physicians relied on qualitative image
characteristics of an enlarging opacity and the RECIST guidelines for basic quantitative
measurements on CT imaging, to assess response after SABR. PET imaging is also used
to detect recurrence after SABR; however most of these tools do not typically detect
recurrence until a year after treatment. The use of biopsy to confirm recurrence is also
used, but can be risky and may not be feasible in all patients. The work completed in this
thesis has advanced knowledge and technology, suggesting the possibility for integration
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of quantitative radiomic features to assist physicians in early detection of recurrence
following SABR. Quantitative image features can be easily acquired on routine follow-up
CT imaging after SABR. These features also have the ability to obtain much richer
information from the CT image compared to a single measurement which is typically
done with RECIST. Compared to response assessment on PET imaging, CT is more
accessible, is inexpensive, does not require a radiotracer or additional imaging session,
and standardization is less complex. An automated decision support system may also be
more reproducible and consistent compared to qualitative image assessment, which can
be subject to operator variability. CT is also less invasive and risky compared to a biopsy.
This decision support system outperformed physicians for the early assessment of
response and has the potential to improve response assessment following SABR by
providing more accurate and timely prediction of recurrence compared to standard
techniques in the current clinical workflow.
In Chapter 2, we evaluated the potential of quantitative image feature analysis for
distinguishing recurrence and benign fibrosis patient groups. In this hypothesis
generating study, regions of common post-SABR consolidative and ground-glass opacity
changes were manually delineated on all follow-up CT images for 24 lesions treated with
SABR. Quantitative size and appearance image features were extracted from both regions
and analyzed according to time post-SABR. Traditional size measurements including
longest axial diameter and 3D volume could not distinguish patient groups until 15
months post-SABR. Appearance features including density of consolidative changes and
first-order texture of ground-glass opacity regions could distinguish patient groups at 9
months post-SABR. These findings suggest that advanced appearance measures may
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provide an earlier detection of recurrence compared to traditional measure of size. Thus,
the thesis advanced knowledge in SABR response assessment by demonstrating that
quantitative appearance features of post-SABR CT changes were able to significantly
distinguish local recurrence and benign injury patient groups.
In Chapter 3, we examined the ability of radiomic features to predict recurrence in
individual patients. Second-order texture features were evaluated for their ability to
predict local recurrence within 6 months post-SABR and compared to traditional
measures of size. Once again, manual delineation of post-SABR consolidation and
ground-glass opacity was performed. We demonstrated the ability of second-order texture
features within regions of ground-glass opacity to predict recurrence within 6 months
post-SABR with accuracies greater than 75%. Traditional size measures at the same time
point produced accuracies less than 60%. Classification based on the clinical standard
response evaluation criteria in solid tumours (RECIST) progressive disease guidelines,
demonstrated accuracies of 52%. These findings suggest that CT texture features on posttreatment images taken within 6 months post-SABR has the potential to predict eventual
local recurrence. Thus, the thesis advanced knowledge in SABR response assessment by
demonstrating that texture features within post-SABR regions of GGO can predict
eventual cancer recurrence in individual patients within 6 months post-SABR with higher
accuracies than standard measures of size and response criteria measures.
In Chapter 3, we also examined the impact of perturbations on the borders of the
manually segmented regions of post-SABR changes. We demonstrated minimal changes
in classification performance with perturbations of the manual GGO boundaries,
signifying that perhaps a complete and accurate delineation of the GGO may not be
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necessary for prediction of recurrence with radiomic features. Thus, the thesis advanced
knowledge in SABR response assessment by demonstrating that complete delineations of
the GGO regions are not needed for recurrence prediction, suggesting the use of a
sampling method could allow for a faster segmentation and clinical translation of a
radiomics decision support tool to aid in assessing response.
In Chapter 4, we developed and evaluated the use of a graph cuts based semiautomated segmentation system to predict local recurrence following SABR. For clinical
translation of our system to a useful computer-aided diagnosis system, the use of a faster
and more reproducible delineation or sampling method of the GGO regions is needed. A
semi-automated segmentation system was developed using the clinical standard longest
axial diameter measurement taken as part of the RECIST guidelines. This system
segmented the consolidative changes and performed a 3D concentric expansion to create
a peri-consolidative region, intended to sample regions of GGO surrounding the
consolidative mass. Radiomic features could then be extracted for classification. This
system was evaluated with three expert observers to examine consistency and
reproducibility of segmentations and classification performance. We found that our semiautomated system produced more reproducible segmentations and could predict
recurrence with non-inferiority to manual segmentations. Thus, the thesis advanced
knowledge in SABR response assessment by demonstrating a semi-automated decision
support system could predict recurrence with similar accuracies to a manual approach.
This system is an advance in technology that was 20 times faster than manual
delineations and could be integrated into the clinical workflow to aid in response
assessment post-SABR.
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In Chapter 5, to provide a basis of comparison for our radiomics system, an
observer study to measure expert physician performance in response assessment was
completed. Three radiation oncologists and three radiologists scored all follow-up images
after SABR and classified the images as recurrence or no recurrence. Physicians had high
sensitivity (median of 83%) and specificity (median of 75%) for detecting recurrence at
any time point during follow-up. However, the median time to detect local recurrences
was 16 months following treatment. Radiologists tended to have higher sensitivity but
lower specificity for detecting recurrence compared to radiation oncologists. Within 6
months of treatment, physicians tended to assess all image as no recurrence, suggesting
there are not suspicious of recurrence at this early time point and tend to wait until an
enlarging mass is evident on CT to assess patients as a local recurrence. Thus, the thesis
advanced knowledge in SABR response assessment by demonstrating a physician’s
ability to detect local recurrence on follow-up CT imaging and provides for a base level
of performance to assess the incremental value of a decision support system.
Also in Chapter 5, a multi-feature radiomic signature was developed on a larger
dataset of 45 patients to predict recurrence within 6 months of treatment. We identified
five radiomic appearance features within regions of post-SABR consolidative and periconsolidative regions which could predict recurrence with a leave-one-out cross
validation error of 23%. Texture features within the peri-consolidative regions were the
top performing features, demonstrating that appearance measures within these regions are
more predictive of recurrence compared to size, shape, or appearance features in the
consolidative regions. Patients with recurrence tended to have increased presence of
GGO surrounding the consolidative changes. The appearances in the GGO also tended to
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be spiculated and were emerging from the consolidative mass, compared to a smoother
appearance in patients with only benign fibrosis. Radiomics outperformed physicians at
this early follow-up time point, where physician assessed almost all images as no
recurrence. These appearances picked up by radiomics may be early indicators of either
disease persistence following treatment or progression to local recurrence. Thus, the
thesis advanced knowledge in SABR response assessment by demonstrating the ability of
radiomic appearance features of post-SABR radiological changes to predict eventual
cancer recurrence earlier than expert physicians. This demonstrates the possible role of
radiomic features to provide additional information for physicians by means of a decision
support tool to assist in response assessment post-SABR.
In summary, we have provided: (1) evidence that quantitative image appearance
features of post-SABR radiological changes can distinguish recurrence and benign patient
groups earlier than traditional measures of size; (2) evidence that radiomic texture
features within post-SABR ground-glass opacity changes can predict recurrence in
individual patients within 6 months of treatment; (3) evidence that a new semi-automated
segmentation system could delineate regions of common post-SABR changes based on
the clinically acquired longest axial diameter measurement, extract radiomic features, and
predict recurrence with non-inferiority to manual segmentations; and (4) evidence that
radiomics can detect early changes within 6 months of SABR treatment that may be
associate with disease persistence or progression to local recurrence which are typically
not picked up by expert physicians.
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6.3

Limitations
The contents of this thesis must be considered within the context of its limitations.

Specific limitations for Chapters 2-5 are presented in the discussion section of the
respective Chapters. However, there are general limitations of this thesis that should be
addressed. One limitation to all studies was that a relatively small dataset of patients was
analyzed. All patients analyzed throughout this thesis were treated and followed at the
same institution. Therefore all follow-up imaging was performed at the same centre, with
a standard acquisition and reconstruction protocol. Although images were from a single
institution with set scanning parameters, variation may exist between scanners [9]. This
system should be evaluated with a larger dataset of patients from multiple institutions, to
account for any variability image acquisition or reconstruction. Another limitation of this
work is that not all patients with recurrence had pathologic confirmation. However, to
avoid imaging-based definitions of recurrence which may introduce substantial bias, in
these studies, patients with recurrence were assessed based on multidisciplinary group
discussion, a combination of PET and CT findings and eventual clinical outcomes.

6.4

Future Directions
The methods developed in this thesis support research initiatives in several future

directions. This section will address remaining gaps in knowledge that exist and potential
applications of this system on future research directions.

6.4.1

External Validation and Evaluation of Additional Imaging
Radiomics has shown the potential to outperform expert physicians in the early

assessment of response following SABR treatment. However, prior to clinical validation,
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radiomic features must be validated on multiple large independent datasets. We have
shown the potential of radiomics to predict local cancer recurrence within 6 months of
treatment. However, further investigation on radiomics at later follow-up time points is
warranted and may provide supplemental information to the early time points. Delta
radiomics is an emerging area of study which refers to analyzing the change in radiomic
features over time. The use of delta radiomics to assess changes in radiomic features over
the course of post-SABR follow-up may provide additional information in longitudinal
image analysis [10]. A thorough investigation of pre-treatment tumour characteristics
may also yield insight into factors associated with recurrence [11]. This could result in
personalized management of lung cancer patients to inform treatment decision making or
risk stratification. The combination of these approaches may provide additional
information to improve response assessment following SABR and provide personalized
patient care and follow-up assessment.

6.4.2

Incorporation of High-Level Domain Knowledge
This thesis has made significant contributions to improve timely and accurate

assessment of response following SABR for early stage NSCLC. However, there remains
room for improvement in SABR response assessment. To date our decision support
system to aid in treatment response assessment has focused on analysis of the treatment
area on follow-up CT. Our analysis has focused on evaluating regions of post-SABR
consolidative and ground-glass opacity changes. Therefore, we have been focusing on
solely the quantitative characteristics of the lesion on CT imaging. However, more
information may be available regarding the lesion or patient as a whole. Therefore, the
utility of additional features in combination with radiomics should be evaluated.
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Qualitative high risk CT features have been independently validated and could provide
useful information at later follow-up time points [12, 13].
The use of FDG-PET imaging has been shown to distinguish local recurrence
from benign RILI on pre- and post-treatment imaging. Previous work has also
demonstrated that abnormal texture of pre-treatment SUV uptake was associated with
nonresponse and poorer prognosis following chemo-radiotherapy for NSCLC [14]. The
combination of PET and CT features has also been shown to predict response in lung
cancer [15]. The addition of quantitative SUV values on PET may provide additional
metabolic information to complement the radiomic features seen on CT, and allow for a
more comprehensive view of the tumour. Although there are limitations with using postSABR SUV values for response assessment, the use of radiomic analysis on posttreatment PET imaging may provide a measure of regional heterogeneity of SUV uptake
values within the tumour or reveal changes from pre-treatment values. This information
may play a role in response following SABR and warrants further investigation. The
combination of radiomic information on CT and PET can provide phenotypic and
metabolic information regarding the tumor. However, the addition of genomic or
molecular markers may provide associations of outcomes or radiomic features with gene
expression patterns [6].
Although all patients in our study were early stage (T1/T2, N0) lung cancer, there
can exist substantial variability in patient history and clinical characteristics of the
disease. Tumour size has been shown to be an important predictor of local control
following treatment for NSCLC [16]. Therefore, characteristics of the patients’ disease,
including T stage, may augment the decision support system. Additional clinical
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information and prognostic factors related to the patients’ history, including age, gender,
past smoking history, lung function, and performance status could also be useful [17].
This thesis did also not consider the effects of co-morbidities and the potential impact on
the normal lung tissue on CT. Future work analyzing the impact of these co-morbidities
on normal lung appearances and radiomic features warrants further investigation.
Pathological features including tumour grade and histological cell type, as well as other
genomic or biological marker may also play a role in lung cancer prognosis and should
be considered in a decision support system [18]. These clinical prognostic factors may
augment radiomic image features to improve prediction of local recurrence following
SABR.
All patients in our study were treated with a risk-adapted approach with one of
three fractionation regimens: 60 Gy in 3, 5, or 8 fractions. The impact of different dose
fractionation regimes has not been considered in any of our studies and may provide
additional information for predicting recurrence. Other dosimetric factors of both the
tumour (e.g. maximum PTV dose) and normal tissue (e.g. V20, percent of the lung
volume receiving 20 Gy or more) may be useful for predicting outcomes. The doseresponse relationships may also provide additional information regarding the radiological
changes seen post-SABR [19]. Registration of pre-treatment dose distributions to followup images may allow for the association of radiomic features with dose levels. This could
provide insight into changes associated with high or low dose regions and the location of
the local recurrence with respect to dose received.
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6.4.3

Use in Clinical Decision Support
Currently assessment of response following SABR relies on expert qualitative

assessment [20]. A combination of metabolic imaging with FDG-PET and/or biopsy may
augment and confirm a physician’s assessment of response. The radiomic decision
support tool developed in this thesis has the potential to aid in this clinical decision.
Therefore, the impact of a radiomic decision support system on clinical management
must also be determined in an additional observer study. First, effective presentation of
this information from the decision support system must be investigated. The decision
support tool could provide information on the regions of interest being analyzed or a
confidence value of the classifier. Providing information regarding the radiomics
confidence or decision could be presented in a continuous or discrete manner.
Consultation with radiation oncologist and radiologist users should be performed to
determine preferences and suggestions for decision support tools.
The integration of computer aided detection and diagnosis tools in lung cancer has
demonstrated the ability to improve radiologists performance in detecting and diagnosing
lung nodules [21]. The work completed in this thesis was the first-ever study to determine
physician ability to assess response post-SABR. Effects of this decision support tool on
physician assessment of response post-SABR must be assessed to determine the
incremental value of performance without any decision support. Training of the operators
may also have an impact on the effect of the decision support tool, and selection of
physicians for this study must be considered [22]. Integration into the clinical workflow
could allow for earlier detection of local recurrence following SABR to allow for timely
salvage interventions. If this tool demonstrates success by improving a physician’s
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assessment of response, a prospective clinical trial evaluating its impact on clinical
decision making and patient outcomes could be determined.
Finally, the correlation of radiomic features with post-SABR histology would also
be extremely valuable. This would allow for evaluation of tissue components within
different regions of post-SABR changes. This could provide insight into the biological
properties associated with certain radiomic features. This information may be important
to provide to physician users to allow for the interpretation of what the radiomic features
mean biologically.
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APPENDIX B – Supplementary Material to Chapter 2
Scan Parameters
Planning scans used for treatment planning were acquired using four dimensional (4D)
CT (Lightspeed 16; GE Medical Systems, Waukesha, USA) at 140 kVp , 100-110 mAs,
and a 2.5 mm slice thickness. 4D CT was completed using free breathing with binning by
respiratory phase. Pre-treatment 4D-CTs used for image analysis were maximum
inspiration of each patient.
For the purposes of this analysis, diagnostic CT scans taken post-treatment were used. All
diagnostic CT scans done at the treating center were performed on one of three scanners
[Siemens Volume Zoom 4-slice, Siemens Sensations 64-slice (Siemens Nederland N.V.,
Den Haag, Netherlands) or Philips Brilliance iCT 256-slice (Royal Philips Electronics,
Inc., Amsterdam, Netherlands)]. Standard machine settings for post-treatment scans were
120 kVp, 100 mAs, spiral acquisition, 0.5 second rotation time, and 2.5-5 mm slice
thickness. Scans were acquired at inspiratory breath hold and 70 cc of intravenous
contrast [Ultravist-300; Bayer Pharma AG, Berlin, Germany] was administered with a
delay of 25 seconds.
Importing and Contouring
All images were received in an anonymized form and imported into ClearCanvas
Workstation 2.0 (ClearCanvas Inc., Toronto, Canada). Contouring was completed in
ITK-SNAP (Version 2.2.0) (15) using a lung window setting (window width of 1500 HU
and window level of -600 HU), and a mediastinal window setting (window width of 350
HU and window level of 40 HU) for tumours or fibrosis abutting the mediastinum.
Contours were manually segmented slice-by-slice using a polygon tool and/or paintbrush
tool.
Calculation of Measures
Response Evaluation Criteria in Solid Tumours (RECIST) measures were taken using the
ClearCanvas Workstation ruler, for the consolidative areas on the pre- and post-treatment
images, according to RECIST 1.1. MATLAB 7.13 (The MathWorks Inc., Natick, MA,
USA) was used in the calculation of three dimensional (3D) volume and CT density
measures for both the consolidative and ground glass opacity contours. 3D volume was
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calculated by determining the voxel volume encompassed by the contours, based on the
voxel dimensions. The number of voxels contained within each contoured region was
determined and then multiplied by the voxel volume to determine 3D volume of each
contoured region. CT density was determined based on the mean intensity values (HU) of
all voxels in each contoured region of interest.
Analysis of Measures
The measures were analysed cumulatively from the treatment end date until a specific
follow-up time point. The follow-up time points used in this study included 3, 6, 9, 12,
15, 18, 21, 24, 36, and 42 months post treatment. For a given time point, all images up to
that time point were used in the analysis. For a given lesion, the following cumulative
measures were calculated:
1)

RECIST – Mean of all RECIST measures per scan

2)

CT density – Mean of all voxels’ intensities (HU)

3)

Standard deviation of CT density – Standard deviation of all voxel intensities
(HU)

4)

3D volume – Mean of all 3D volume measures per scan

Differences between groups were assessed using an independent samples t-test with
unequal variances in MATLAB 7.13 (The MathWorks Inc., Natick, MA, USA). All
statistical tests were two-sided with p ≤ 0.05 indicative of statistical significance.
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APPENDIX C – Supplementary Material to Chapter 4
Table C1: Individual texture feature values and classification metrics including error,
false positive rate (FPR), false negative rate (FNR), and area under the receiver operating
characteristic curve (AUC) at 2–5 months post-SABR. All values are reported as the
mean ± the standard deviation.

Observer

Correlation

Operator 1
(Manual)
Operator 1
(Semiauto)
Operator 2
(Semiauto)
Operator 3
(Semiauto)

Energy

Operator 1
(Manual)
Operator 1
(Semiauto)
Operator 2
(Semiauto)
Operator 3
(Semiauto)

Feature

Feature

Value -

Value -

Recurrence

Injury

0.006 ±

0.01 ±

0.002

0.007

0.008 ±

0.014 ±

0.001

0.01

0.009 ±

0.014 ±

0.001

0.010

0.009 ±

0.014 ±

0.001

0.010

0.002 ±

0.004 ±

0.001

0.003

0.003 ±

0.007 ±

0.001

0.010

0.003 ±

0.007 ±

0.001

0.010

0.003 ±

0.008 ±

0.001

0.010

p-value

Error

FPR

FNR

AUC

0.098

33.6 ± 10.9

37.8 ± 12.9

29.0 ± 12.8

0.61 ± 0.06

0.082

28.3 ± 7.4

43.8 ± 7.0

11.3 ± 10.8

0.67 ± 0.06

0.077

25.8 ± 7.4

39.0 ± 7.8

11.4 ± 9.4

0.69 ± 0.06

0.079

26.5 ± 7.1

38.1 ± 7.6

13.9 ± 9.1

0.72 ± 0.06

0.032*

27.2 ± 4.7

37.8 ± 6.5

15.8 ± 5.4

0.70 ± 0.05

0.131

27.3 ± 6.3

45.3 ± 7.8

7.7 ± 9.0

0.77 ± 0.05

0.142

30.9 ± 5.4

49.1 ± 7.5

11.0 ± 8.5

0.72 ± 0.05

0.138

30.9 ± 5.8

48.1 ± 8.0

12.2 ± 8.9

0.73 ± 0.06
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Entropy

Operator 1
(Manual)

9.35 ± 0.51

8.62 ± 0.91

0.030*

27.5 ± 8.5

29.5 ± 8.1

25.3 ± 11.5

0.64 ± 0.04

8.68 ± 0.31

8.05 ± 0.86

0.032*

24.7 ± 8.3

25.9 ± 7.9

23.5 ± 11.1

0.73 ± 0.06

8.64 ± 0.29

8.02 ± 0.87

0.036*

27.8 ± 6.0

30.6 ± 7.0

24.7 ± 8.0

0.70 ± 0.04

8.58 ± 0.29

7.96 ± 0.86

0.035*

26.7 ± 7.3

28.0 ± 7.1

25.3 ± 9.9

0.71 ± 0.05

56.82 ±

47.90 ±

23.84

46.02

0.563

48.5 ± 12.1

33.4 ± 22.7

65.1 ± 12.2

0.54 ± 0.05

44.06 ±

32.65 ±

16.49

17.24

0.120

34.2 ± 9.9

21.9 ± 10.6

47.5 ± 14.2

0.64 ± 0.06

42.70 ±

32.64 ±

16.19

17.44

0.166

37.8 ± 11.1

27.8 ± 13.7

48.8 ± 14.7

0.60 ± 0.05

42.10 ±

31.71 ±

16.04

16.96

0.146

34.0 ± 10.1

21.8 ± 10.4

47.4 ± 15.1

0.63 ± 0.06

240.46 ±

205.48 ±

37.10

62.16

0.115

36.1 ± 9.1

27.6 ± 10.4

45.5 ± 12.4

0.59 ± 0.06

197.79 ±

171.15 ±

15.92

38.56

0.044*

36.2 ± 5.4

36.5 ± 6.8

35.8 ± 7.9

0.58 ± 0.04

196.73 ±

169.50 ±

14.81

37.89

0.036*

31.0 ± 4.7

31.3 ± 4.6

30.6 ± 8.9

0.64 ± 0.04

191.18 ±

165.59 ±

16.69

36.13

0.042

33.6 ± 5.6

29.6 ± 6.8

38.0 ± 7.9

0.62 ± 0.04

Operator 1
(Semiauto)
Operator 2
(Semiauto)
Operator 3
(Semiauto)
Inertia

Operator 1
(Manual)
Operator 1
(Semiauto)
Operator 2
(Semiauto)
Operator 3
(Semiauto)

Standard

Operator 1

Deviation

(Manual)
Operator 1
(Semiauto)
Operator 2
(Semiauto)
Operator 3
(Semiauto)

* Feature values are significant between recurrence and injury groups at the 0.05 level.
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Table C2: Individual texture feature values and classification metrics including error,
false positive rate (FPR), false negative rate (FNR), and area under the receiver operating
characteristic curve (AUC) at 5–8 months post-SABR. All values are reported as the
mean ± the standard deviation.

Observer

Correlation

Operator 1
(Manual)
Operator 1
(Semiauto)
Operator 2
(Semiauto)
Operator 3
(Semiauto)

Energy

Operator 1
(Manual)
Operator 1
(Semiauto)
Operator 2
(Semiauto)
Operator 3
(Semiauto)

Entropy

Operator 1
(Manual)

Feature

Feature

Value

Value

Recurrence

Injury

0.006 ±

0.009 ±

0.001

0.004

0.008 ±

0.012 ±

0.001

0.009

0.008 ±

0.012 ±

0.001

0.009

0.008 ±

0.013 ±

0.001

0.009

0.002 ±

0.004 ±

0.001

0.003

0.003 ±

0.007 ±

0.001

0.012

0.003 ±

0.007 ±

0.001

0.012

0.003 ±

0.008 ±

0.001

0.012

9.29 ± 0.46

8.48 ± 0.76

p-value

Error

FPR

FNR

AUC

0.030*

31.9 ± 5.5

22.7 ± 8.8

43.9 ± 8.1

0.67 ± 0.05

0.086

34.3 ± 5.8

26.1 ± 6.0

44.8 ± 10.1

0.65 ± 0.06

0.110

41.3 ± 5.6

31.1 ± 6.9

54.7 ± 10.4

0.60 ± 0.06

0.086

33.4 ± 5.2

27.4 ± 5.8

41.3 ± 9.6

0.66 ± 0.06

0.014*

27.9 ± 4.8

32.2 ± 6.2

22.4 ± 6.8

0.68 ± 0.04

0.192

31.3 ± 5.0

10.2 ± 6.1

58.7 ± 10.3

0.70 ± 0.06

0.212

36.5 ± 5.3

11.6 ± 6.7

68.8 ± 12.7

0.66 ± 0.06

0.205

35.2 ± 5.1

11.7 ± 6.2

65.8 ± 13.1

0.68 ± 0.07

0.005*

30.0 ± 4.5

25.2 ± 5.4

36.2 ± 7.4

0.67 ± 0.04
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Operator 1
(Semi-

8.87 ± 0.44

8.13 ± 0.89

0.019*

22.8 ± 4.8

22.8 ± 2.7

22.8 ± 10.8

0.71 ± 0.05

8.73 ± 0.37

8.15 ± 0.93

0.057

31.3 ± 5.0

21.6 ± 4.6

43.9 ± 10.8

0.67 ± 0.07

8.68 ± 0.32

8.1 ± 0.92

0.050

28.3 ± 5.7

23.3 ± 3.0

34.7 ± 12.3

0.69 ± 0.07

55.14 ±

52.35 ±

19.08

53.76

0.864

43.5 ± 6.4

16.7 ± 9.2

78.4 ± 9.8

0.48 ± 0.06

47.77 ±

34.19 ±

15.93

12.88

0.042*

32.8 ± 5.2

16.6 ± 6.1

53.8 ± 10.0

0.60 ± 0.05

46.15 ±

34.46 ±

15.27

13.33

0.070

34.9 ± 6.9

20.8 ± 8.0

53.3 ± 12.3

0.58 ± 0.05

45.45 ±

33.52 ±

13.79

13.05

0.049*

32.3 ± 7.6

21.1 ± 6.8

46.9 ± 13.5

0.61 ± 0.05

240.75 ±

206.39 ±

22.24

39.28

0.016*

33.3 ± 4.8

22.3 ± 7.4

47.5 ± 8.7

0.61 ± 0.04

206.57 ±

175.84 ±

24.53

35.26

0.023*

36.8 ± 4.9

24.9 ± 6.8

52.2 ± 9.1

0.61 ± 0.05

200.56 ±

176.56 ±

17.47

36.26

0.051

44.0 ± 5.7

31.8 ± 6.8

59.9 ± 11.4

0.55 ± 0.05

198.40 ±

171.94 ±

16.76

33.53

0.023*

37.3 ± 4.4

30.0 ± 5.2

46.7 ± 7.9

0.60 ± 0.04

auto)
Operator 2
(Semiauto)
Operator 3
(Semiauto)
Inertia

Operator 1
(Manual)
Operator 1
(Semiauto)
Operator 2
(Semiauto)
Operator 3
(Semiauto)

Standard

Operator 1

Deviation

(Manual)
Operator 1
(Semiauto)
Operator 2
(Semiauto)
Operator 3
(Semiauto)

* Feature values are significant between recurrence and injury groups at the 0.05 level.”
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Bachelor of Science (with Honours) – Medical Radiation Sciences
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Sept. 2011 – present

Sept. 2008 – Apr. 2011

Western University, London, ON
Sept. 2004 – Apr. 2008
Honours Bachelor of Medical Sciences
• Double major in Medical Sciences and Microbiology & Immunology

RESEARCH
Prediction of tumour recurrence after stereotactic ablative radiotherapy
Sept. 2011 – present
(SABR) for lung cancer
•
MSc/PhD project, Western University
•
Supervisors: Dr. Aaron Ward & Dr. David Palma
•
Determine differences in quantitative measures of post-SABR radiological
changes on CT between patients with recurrence and radiation fibrosis
•
Image analysis and machine learning using MATLAB
•
Feature extraction using Insight Segmentation and Registration Toolkit
(ITK) in C++
•
Statistical analyses in SPSS and MATLAB
•
Observer study design and implementation for evaluating decision
support systems
An interprofessional approach to establishing image guided radiotherapy
(IGRT) registration guidelines in gynaecological sites
•
Radiation therapy research methods course
•
Supervisors: Ms. Caitlin Gillan & Dr. Michael Milosevic
•
Princess Margaret Hospital, Toronto, ON
•
Determine inter and intraobserver variability in manual soft tissue image
matching in the gynecological site group
•
Determine the reproducibility and consistency of patient specific matching
strategies in IGRT practice
Quantifying tumour microvasculature
•
Medical Biophysics 6-week research project, Western University
•
Supervisor: Dr. Ian MacDonald
•
Assisted in analyzing tumour microvasculature images
•
Compared quantitative results using statistical analysis
•
First-hand experience with image analysis through MATLAB
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Refereed journal articles
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Mattonen, S., Palma, D., Johnson, C., Louie, A., Landis, M., Rodrigues, G., Chan, I., Etemad-Rezai,
R., Yeung, T.P.C., Senan, S., & Ward, A.D. Detection of local cancer recurrence after stereotactic
ablative radiotherapy (SABR) for lung cancer: physician performance versus radiomic assessment.
International Journal of Radiation Oncology, Biology, Physics, 2016; 94(5):1121-28.
Mattonen, S., Tetar, S., Palma, D., Louie, A., Senan, S., and Ward, A.D. Imaging texture analysis for
automated prediction of lung cancer recurrence after stereotactic radiotherapy. Journal of Medical
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Mattonen, S., Palma, D., Haasbeek, C.J.A., Senan, S., and Ward, A.D. Early prediction of tumor
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fibrosis from tumor recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a
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Letters to the editor
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Yeung, T.P.C.*, Rodrigues, G., Mattonen, S., Warner, A., Johnson, C., Lagerwaard, F., Palacios, M.,
Bohoudi, O., & Ward, A.D. Magnetic resonance imaging radiomics to personalize brain metastases
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Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Early prediction of lung
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Bohoudi, O., & Ward, A.D. Personalized treatment selection for brain metastases using MRI
radiomics. Imaging Network Ontario Symposium (ImNO). London, ON. Mar. 30-31, 2015. (podium
& poster presentations)
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Early prediction of lung
cancer recurrence after stereotactic radiotherapy using texture analysis of automatic graph cuts
segmentations. OICR Scientific Meeting, Toronto, ON. March 12-13, 2015. (poster presentation
and 2 minute poster teaser presentation).
Johnson, C.*, Mattonen, S., Yeung, T.P.C., &. Ward, A.D. Translation of medical image analysis
tools to a clinical trial. OICR Scientific Meeting, Toronto, ON. March 12-13, 2015. (poster
presentation)
Yeung, T.P.C.*, Rodrigues, G., Mattonen, S., Warner, A., Johnson, C., Lagerwaard, F., Palacios, M.,
Bohoudi, O., & Ward, A.D. Treatment selection for brain metastases using magnetic resonance
imaging radiomics. OICR Scientific Meeting, Toronto, ON. March 12-13, 2015. (poster
presentation)
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Early prediction of lung
cancer recurrence after stereotactic radiotherapy using second-order texture statistics. London
Imaging Discovery, London, ON. June 26, 2014. (poster presentation, awarded 2nd prize)
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Early prediction of lung
cancer recurrence after stereotactic radiotherapy using second-order texture statistics. Oncology
Research & Education Day, London, ON. June 20, 2014. (poster presentation)
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Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Early prediction of lung
cancer recurrence after stereotactic radiotherapy using second-order texture statistics. Canadian
Student Health Research Forum. Winnipeg, MB. Jun. 10-12, 2014. (Selected to attend and present a
poster by Dr. Andy Watson, the Associate Dean of Graduate and Postdoctoral Studies as one of
the top ranked PhD students in the Schulich School of Medicine & Dentistry, received an award
of excellence, gold category)
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Early prediction of lung
cancer recurrence after stereotactic radiotherapy using second-order texture statistics. Imaging
Network Ontario Symposium (ImNO). Toronto, ON. Mar. 24-25, 2014. (podium & poster
presentations, awarded 2nd prize)
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Early prediction of lung
cancer recurrence after stereotactic radiotherapy using second-order texture statistics. London Health
Research Day, London, ON. March 18, 2014. (podium presentation, awarded 2nd prize)
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Assessment of response after
stereotactic ablative radiotherapy (SABR) for lung cancer: can advanced CT image feature analysis
predict recurrence? Canadian Cancer Research Conference (CCRC). Toronto, Ontario. Nov. 3-6,
2013. (poster presentation)
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Assessment of response after
stereotactic ablative radiotherapy (SABR) for lung cancer: can advanced CT image feature analysis
predict recurrence? American Society for Radiation Oncology (ASTRO) Annual Meeting. Atlanta,
Georgia, USA. Sept. 22-25, 2013. (podium presentation)
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., & Ward, A.D. Assessment of response after
stereotactic ablative radiotherapy (SABR) for lung cancer: can advanced CT image feature analysis
predict recurrence? Canadian Association of Radiation Oncology (CARO)/Canadian Organization of
Medical Physicists (COMP) Joint Scientific Meeting, Montreal, QC. Sept. 18-21, 2013. (podium
presentation, COMP Young Investigators Award Finalist)
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Assessment of response after
stereotactic ablative radiotherapy (SABR) for lung cancer: can advanced CT image feature analysis
predict recurrence? Oncology Research & Education Day, London, ON. June 21, 2013. (poster
presentation, awarded poster award)
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Distinguishing radiation
fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a
study of CT image feature analysis. International Stereotactic Radiosurgery Society (ISRS) Congress.
Toronto, ON. June 16-20, 2013. (podium presentation)
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Assessment of response after
stereotactic ablative radiotherapy (SABR) for lung cancer: can advanced CT image feature analysis
predict recurrence? London Imaging Discovery, London, ON. June 13, 2013. (poster presentation)
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. Prediction of cancer
recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer using CT image feature
analysis. London Health Research Day, London, ON. Mar. 19, 2013. (podium presentation)
Mattonen, S.*, Palma, D., Haasbeek, C.J.A., Senan, S., &. Ward, A.D. CT image feature analysis in
distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy
(SABR) for stage I non-small cell lung cancer: a preliminary study. Imaging Network Ontario
Symposium (ImNO). Toronto, ON. Feb. 4-5, 2013. (podium & poster presentations, awarded 2nd
prize)
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Mattonen, S.*, Ward, A.D., Haasbeek, C.J.A., Senan, S., & Palma, D. Differentiating radiation
fibrosis from tumor recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: the
impact of CT-based image texture analysis. Canadian Association of Radiation Oncology (CARO)
Annual Scientific Meeting, Ottawa, ON. Sept. 12-15, 2012. (podium presentation)
Mattonen, S.*, Ward, A.D., Haasbeek, C.J.A., Senan, S., & Palma, D. Differentiating radiation
fibrosis from tumor recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: the
impact of CT-based image texture analysis. London Imaging Discovery, London, ON. June 27, 2012.
(podium & poster presentation)
Mattonen, S.*, Ward, A.D., Haasbeek, C.J.A., Senan, S., & Palma, D. Differentiating radiation
fibrosis from tumor recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: the
impact of CT-based image texture analysis. Oncology Research & Education Day, London, ON. June
22, 2012. (podium presentation)
Mattonen, S.*, Ward, A.D., Senan, S., & Palma, D. Lung density changes of radiation-induced lung
injury vs. cancer recurrence following stereotactic radiation therapy of early stage non-small cell lung
carcinoma. London Health Research Day, London, ON. March 20, 2012. (podium presentation,
awarded 1st prize)
Mattonen, S.*, Gillan, C., Li, W., & Milosevic, M. Communicating clinical information in IGRT
practice to facilitate an individualized approach to online image matching guidelines in gynecological
sites. RTi3: Radiation Therapy Conference, Toronto, ON. March 4-5, 2011. (podium presentation)
Invited presentations
Mattonen, S. Radiomics for the early prediction of recurrence after stereotactic ablative radiotherapy
for lung cancer. Sunnybrook Medical Image Analysis Laboratories Seminar Series, Sunnybrook
Research Institute, Toronto, ON. May 16, 2016.
Mattonen, S. Radiomics for the early prediction of recurrence after stereotactic ablative radiotherapy
for lung cancer. Department of Radiation Oncology, Harvard Medical School. Boston, MA. Apr. 25,
2016.
Mattonen, S. Radiomics for the early prediction of recurrence after stereotactic ablative radiotherapy
for lung cancer. Department of Radiology, Stanford University. Stanford, CA. Apr. 22, 2016.
Mattonen, S. Radiomics for the early prediction of recurrence after stereotactic ablative radiotherapy
for lung cancer. Department of Radiology, University of Chicago. Chicago, IL. Apr. 19, 2016.
Mattonen, S & Huang, K. Assessing response after SABR for lung cancer: from clinic to lab and
back again. Citywide Cancer Imaging Seminar. London, ON. Sept. 24, 2014.
Mattonen, S. & Ward, A.D. Assessment of response after stereotactic ablative radiotherapy (SABR)
for lung cancer: can advanced CT image feature analysis predict recurrence? Techna Institute Medical Image Processing Seminar. Toronto, ON. Oct. 21, 2013.
Mattonen, S. Prediction of cancer recurrence after stereotactic ablative radiotherapy (SABR) for lung
cancer using CT image feature analysis. Department of Medical Biophysics Annual A.C. Burton Day.
London, ON. Mar. 21, 2013. (one of two invited graduate speakers)
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PATENTS
United States Patent Application No. 61/896349: Method and Apparatus for
Analyzing Three-Dimensional Image Data to Classify a Region of Interest

Oct. 2014

HONOURS AND AWARDS
Natural Sciences and Engineering Council of Canada (NSERC) [$90,000]
Postdoctoral Fellowship
$45,000/year for 2 years
Ranked 2/55 in the Computing Sciences Committee

2016 – 2018

Natural Sciences and Engineering Council of Canada (NSERC) [$105,000]
Alexander Graham Bell Canada Graduate Scholarship – Doctoral
$35,000/year for 3 years
Ranked 14/121 in the Computing Sciences Committee

2013 – 2016

American Society for Radiation Oncology (ASTRO) Annual Meeting Abstract
Award [$1,000]
Basic/Translational Science - Junior Investigator Radiation Physics

2015

Dr. Alfred Jay Medical Biophysics Award for Translational Research [$2000]

2016

Imaging Network Ontario Symposium (ImNO) Magna cum Laude Abstract Award
Top rated abstract - Imaging Translation Program

2016

London Health Research Day Top Abstract by Category [$100]
Medical Physics, Engineering and Imaging

2016

Centre for Translational Cancer Research Trainee Travel Award [$1000]
Schulich School of Medicine & Dentistry, Western University

2016

Canadian Cancer Society Research Institute (CCSRI) Travel Award [$1850]

2016

International Conference on the use of Computers in Radiation Therapy (ICCR) Young Investigator prize shortlist

2016

SPIE Medical Imaging Robert F. Wagner All-Conference Best Student
Paper Conference Finalist
Computer-Aided Diagnosis Conference

2016

Western Graduate Research Scholarship, Western University [$2,900/term]

2011 – 2016

Canadian Cancer Society Research Institute (CCSRI) Travel Award [$2000]

2015

Nellie Farthing Fellowship, Western University [$3,000]
Recognizing excellence in research to a full-time doctoral student in
the Medical Sciences at Western University

2015

American Society for Radiation Oncology (ASTRO) Annual Meeting Abstract
Award [$1,000]
Annual Meeting Travel Award in the Physics category

2015

London Imaging Discovery 2nd Place Poster Award [$150]

2014
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Canadian Institute of Health Research (CIHR) National Research Poster
Competition Award [$500]
Award of Excellence (Gold category) - Canadian Student Health Research Forum
1 of 12 Gold category winners out of approx. 120

2014

Canadian Institute of Health Research (CIHR) Travel Award [$833.33]
Canadian Student Health Research Forum - CIHR Poster Presentation

2014

Imaging Network Ontario Symposium (ImNO) Poster Award [$200]
2nd Place Poster - Imaging Translation Program

2014

2013-2014 National Volunteer Award Nomination, Let’s Talk Science Outreach

2014

London Health Research Day Platform Award [$600]
2nd place for podium presentation in platform competition – Theatre

2014

Ontario Graduate Scholarship (OGS) [$15,000]
Declined

2013 – 2014

The Canadian Organization of Medical Physicists (COMP) Young Investigators
Award Finalist [$250]

2013

Oncology Research and Education Day Poster Award [$100]

2013

Let’s Talk Science – Volunteer of the Month (March)

2013

Imaging Network Ontario Symposium (ImNO) Poster Award [$200]
2nd Place Poster - Imaging Translation Program

2013

Natural Sciences and Engineering Council of Canada (NSERC) [$17,500]
Alexander Graham Bell Canada Graduate Scholarship – Master’s

2012 – 2013

Ontario Graduate Scholarship (OGS) [$15,000]
Declined

2012 – 2013

London Health Research Day Platform Award [$700]
1st place for podium presentation in platform competition – Salon B

2012

University of Toronto/
The Michener Institute for Applied Health Sciences, Toronto, ON
Graduated with Honours
Faculty Nominated: Excellence in Clinical Preparation Scholarship
• For consistently exhibiting professional behavior and the ability to work
effectively both as an individual and in an inter-professional team in the
clinical preparation semester
Graduation Award: Outstanding Achievement in Research Methods [$100]
• Excellence in research by a final year Medical Radiation Sciences
student

2011

Western University, London, ON
Dean’s Honours List
Dean’s Honours List
Western Scholarship of Excellence [$2,000]
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2005 – 2006
2004 – 2005
2004

EMPLOYMENT HISTORY
Graduate Research Assistant, London, ON
MSc/PhD Student
Supervisors: Dr. Aaron Ward & Dr. David Palma
Let’s Talk Science Outreach Senior Coordinator, London, ON
Western University

2011 – present

Jul. 2015 – present

Teaching Assistant: Medical Biophysics 9520B – Practical Medical Imaging
Supervising weekly labs using the desktop imaging systems
Marking lab reports
Let’s Talk Science Teacher Partnership Coordinator, London, ON
Western University

Jan – Apr. 2015

Jul. 2014 – Jul. 2015

Ontario Women’s Hockey Association (OWHA) Level II Official, Aurora, ON
Central York Girls Hockey Association

2001 – 2004
2008 – 2010

Wright Dental (WD) Canada, Richmond Hill, ON
Summer Student

2007 – 2008

Vertex Outsourcing, Markham, ON
Summer Student, Human Resources/Application Support

2005 – 2006

SPECIAL TRAINING
Graduate Recruitment Committee
• Discuss and prepare/plan for recruitment of new graduate trainees
• Participate in graduate student recruitment fairs
• Departmental contact with potential graduate students
Design of Medical Imaging Labs - Medical Biophysics Course
• Gained experience on principles of good teaching and curriculum
design
• Designed 10 hours of lab material for the DeskCAT optical CT system
• These materials were used for course “Medical Biophysics 9520B –
Practical Medical Imaging” beginning in Winter 2015

2014 – 2015

2014

VOLUNTEER EXPERIENCE
Let’s Talk Science, Western University
2011 – present
• Organized and demonstrated hands-on science activities, and lead
children (preschool through teen) through their completion
• Partnered with a science class at Robarts School for the Deaf
• Planning committee co-chair for Let’s Talk Cancer high school symposium
• Medical Biophysics department representative
• Nomination for National Volunteer Award, Let’s Talk Science
Outreach
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Canadian Cancer Society
• Sold daffodil pins during Daffodil Month

2015 – 2016

Thames Valley Science and Engineering Fair Judge
• Judged grade 6-8 students science fair projects in the physical
sciences category
• Team lead for final judging

2015

Community Outreach – Homecoming Medical Biophysics Demonstration
• Provided an explanation and demonstration of the DeskCAT system
• Provided an overview of my thesis to Schulich Medicine alumni

2014

Community Outreach – London Regional Cancer Program Lab Tour
• Provided an explanation and demonstration of the DeskCAT system
• Provided a tour of the Baines Imaging Research Lab

2014

March Break Open House, Western University
• Provided an explanation and demonstration of the DeskCAT system

2014

Consult the Experts, Western University
• Provided support and feedback to graduate/undergraduate students on their
research proposals for national and provincial scholarship competitions

2013

Central York Girls Hockey Association Annual House League and
Silverstick Tournaments
• Organized team registration, scheduling, and fundraising for the
tournament
• Communicated information regarding schedules, registration,
and provided directions to players and families

2012, 2008 – 2010
2000 – 2004

Peer Tutor, The Michener Institute for Applied Health Sciences
• Communicated fundamental and practical concepts of physics
and treatment planning to radiation therapy students (three
students on a regular basis throughout the two-year period, plus
several others on a one-time basis)

2009 – 2011

Doors Open Toronto, The Michener Institute for Applied Health Sciences
• Provided approx. 25 tours of the computed tomography suites
during this one-day event to the general public, and
communicated information regarding the equipment and
education of technologists using an approach suitable for a lay
audience

2009

REVIEWER
International Journal of Radiation Oncology • Biology • Physics (IJROBP)
Journal of Medical Imaging

2016
2016

CERTIFICATION
Canadian Association of Medical Radiation Technologists
Registered Radiation Therapist (RTT)
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Jun. 2011

